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This retrospective cohort study uses 2013 Marketscan® claims data to quantify
healthcare resource utilization and national healthcare costs attributable to using potentially
inappropriate medications represented in 2012 Beers Criteria. We compare hospital
admissions, days spent in the hospital, and total healthcare costs generated from inpatient and
outpatient visits and prescription medication use for community-dwelling Medicare patients
that received medications in Beers Criteria compared to a well-matched group of patients that
received medications not included in Beers Criteria. Using Beers Criteria medications is
associated with greater odds of hospital admission. Of those that are hospitalized, patients using
Beers Criteria medications experience a greater number of hospital admissions and spend more
days in the hospital compared to patients treated with medications not in Beers Criteria. We
found total inpatient, outpatient, and prescription drug costs to be higher on average for patients
that received Beers Criteria medications, and these patients were responsible for significantly
higher annual healthcare costs in 2013. This study suggests the importance reducing the risk
of unnecessary hospitalizations attributed to using inappropriate medications to minimize the
burden the elderly population will have on our national healthcare system in the future.
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I.

INTRODUCTION
Over the last century, the human life span in the United States has increased from

47 years to more than 75 years, and this number will continue to rise through the year 2050
(Anderson, 1999). The increase in the number of adults over the age of 65 is a major public
health concern, with healthcare spending expected to increase 25% by the year 2030 due
largely to the aging population (Centers for Disease Control and Prevention, 2013). Factors
that contribute to the high cost of healthcare in the elderly population include deterioration
of health and increased use of medications to treat a growing number of health problems
as they age.
More than 90% of non-institutionalized adults aged 65 and older use at least one
medication per week, and more than 40% use five or more different medications each week
(Field et al., 2004). Many of these medications are not medically necessary, thus making
polypharmacy a major issue of concern that is associated with prescription drug use in the
elderly population. Consequences of polypharmacy are associated with rising healthcare
costs, an increase in hospitalization rates (which also, in turn, impact growing costs), and
a negative impact on functional status and quality of life (Maher, Hanlon, & Hajjar, 2013).
It was estimated that over $7 billion in annual incremental healthcare expenditures
in 2001 were related to inappropriate medication use in community dwelling individuals
over the age of 65 (Fu et al., 2007). The term inappropriate medication is generally used to
describe those medications in which the risk of experiencing an adverse drug event (ADE)
is greater than the potential benefit of that medication (Beers et al., 1991). As the elderly
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population continues to grow, and as people continue to live longer, this population will
require more medications to manage a growing list of multiple health problems, indicating
that polypharmacy will continue to be an issue in the years to come.
As the number of medications consumed by the elderly increases, there is a greater
risk of experiencing an ADE compared to those patients taking fewer medications (Maher
et al., 2013). ADEs are a leading cause of poor health and death in the U.S. (Center for
Drug Evaluation and Research, 2016). ADEs require preventable hospitalizations or may
require patients to live out their remaining years in a long-term care (LTC) facility.
Unfortunately, these consequences do not allow patients to maintain healthy, independent
lives as they age.
One strategy that will address increasing healthcare costs prevalent in older adults
is to reduce unnecessary healthcare utilization associated with PIMs included in Beers
Criteria. This criteria includes PIMs or medication classes in which the increased risks of
experiencing a negative health outcome outweigh potential benefits for adults over the age
of 65 (American Geriatrics Society, 2012). The criteria are intended to be used by
prescribing clinicians and pharmacists, and, if used appropriately, can help minimize
polypharmacy and unnecessary negative health events in the elderly (American Geriatrics
Society, 2015). At its initial development, the list was intended to serve as a tool to enable
clinicians to identify those medications that should be avoided specifically in nursing home
patients (Beers et al., 1991). Beers Criteria was updated in 1997 (Beers, 1997), 2003 (Fick
et al., 2003), 2012 (American Geriatrics Society, 2012), and most recently in 2015
(American Geriatrics Society, 2015). These updates now encompass PIMs for all patients
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over the age of 65 regardless of where they reside or receive care. A detailed history of the
development and iterations of Beers Criteria is included in chapter two.
Despite the adoption of Beers Criteria among a variety of healthcare professionals
and settings associated with geriatric care, PIM prescribing in the elderly remains prevalent
(Page, Linnebur, Bryant, & Ruscin, 2010). Previous research of PIMs has focused on the
prevalence, potential risk factors, and health outcomes associated with PIM use in the
elderly. Few studies have included an economic outcome measure related to PIM use. Risk
of hospitalization, hospitalization rates, days admitted to the hospital, and total costs
associated with using PIMs listed in Beers Criteria have not been previously quantified.
Previous studies of retrospective claims data have included only a select number of PIMs
in Beers Criteria or have failed to address cost implications associated with healthcare
resource utilization while accounting for all Beers Criteria medications classified as
potentially inappropriate in older adults.
The goal of this study was to quantify healthcare resource utilization and national
healthcare costs attributable to Beers Criteria medication use. This retrospective cohort
study used research strategies not previously included in cost analyses of medication
classes represented in 2012 Beers Criteria. We compared hospital admissions, days spent
in the hospital, and total healthcare costs for patients that received medications in Beers
Criteria compared to a well-matched group of patients that received medications not
included in Beers Criteria.

Community-dwelling Medicare patients with private

supplementary insurance were included in the study, and healthcare utilization and costs
were analyzed using 2013 Truven Health Marketscan® Commercial Claims and
Encounters Database (Truven Health Analytics, 2017). Marketscan® is a nationally
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representative database that consists of de-identified, standardized medical and
pharmaceutical claims data (Truven Health Analytics, 2017). We identified inpatient visits,
outpatient visits, and prescription medication costs for patients that received medications
included in Beers Criteria as well as patients that received medications not included in
Beers Criteria. Total healthcare costs were compared. Patients that received medications
that are contraindicated due to Beers Criteria were matched to patients that received
medications not included in Beers Criteria. This was the first study to analyze healthcare
utilization and total healthcare costs for patients that were prescribed medications that
adhere to Beers Criteria versus patients with similar health conditions that were prescribed
medications that do not adhere to Beers Criteria.
Findings from this study will be of assistance to clinicians (i.e. primary care
providers, psychiatrists, and other specialists), pharmacists that work with the elderly
population, the elderly, and payers. Healthcare administrators and policy makers are also
important stakeholders. Considering the consequences that PIM use has on healthcare
spending, and considering the likelihood for increased healthcare costs in the near future
due to an aging population, this group will be influential in guiding policy changes
necessary to influence clinical practice to reduce unnecessary hospitalizations attributed to
inappropriate prescribing behaviors in this population. Before we can expect a clinical
change in medication management in the elderly population, we first needed to understand
the hospitalization rates and cost implications of using PIMs listed in Beers Criteria
(compared to using alternative medications not listed in Beers Criteria) and the overall
impact on annual healthcare costs. It is critical that clinicians prescribe the right medication
to the right patient at the right time. Beers Criteria may help with that. Elderly patients and
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their caregivers need to be engaged and aware of the risks of Beers Criteria medications so
they can become actively involved in the care they receive. Minimizing unnecessary
hospitalizations will allow patients to maintain healthy, independent lives as they age and
help alleviate rising healthcare costs.

Aim 1
To examine the healthcare resource utilization for Medicare patients who receive
medications included in Beers Criteria compared to a well-matched group of Medicare
patients who do not receive medications included in Beers Criteria.
Hypotheses
H1: The odds of hospital admission in a group of patients who receive Beers Criteria
medications is greater than the odds of hospital admission in a group of patients who do
not receive Beers Criteria medications.
H0: OR Hospital Admissions (Beers Criteria group) = OR Hospital Admissions
(Control group)
Ha: OR Hospital Admissions (Beers Criteria group) ≥ OR Hospital Admissions
(Control group)
H2: Among patients who had a hospitalization, the mean number of days admitted to the
hospital is greater in patients who receive Beers Criteria medications compared to patients
who do not receive Beers Criteria medications.
H0: µ Hospital Days (Beers Criteria group) = µ Hospital Days (Control group)
Ha: µ Hospital Days (Beers Criteria group) ≥ µ Hospital Days (Control group)
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Aim 2
To determine the total healthcare costs for Medicare patients who receive medications
included in Beers Criteria compared to a well-matched group of Medicare patients who do
not receive medications included in Beers Criteria.
Hypothesis
H1: Total healthcare costs are greater in patients who receive Beers Criteria medications
compared to patients who do not receive Beers Criteria medications.
H0: µ Healthcare Cost (Beers Criteria group) = µ Healthcare Cost (Control group)
Ha: µ Healthcare Cost (Beers Criteria group) ≥ µ Healthcare Cost (Control group)
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II.

REVIEW OF THE LITERATURE
In 1972, the U.S. life expectancy at age 65 was 15 years, compared to a life

expectancy of 19 years in 2010 (Ortman, Velkoff, & Hogan, 2014). Americans are living
longer, and, as a result, the elderly population continues to increase dramatically. As
depicted in Figure 2.1, there will be over 83 million Americans over the age of 65 by the
year 2050, nearly double the size of the population in 2012 (Ortman et al., 2014). More
than 20% of the total U.S. population will be represented by adults over the age of 65 by
2050. For comparison, in 1970 the elderly population represented less than 10% of the total
U.S. population (Ortman et al., 2014).

Figure 2.1: Population Aged 65 and Older for the United States: 2012 to 2050 (Ortman
et al., 2014)

The growing elderly population is a burden to the U.S. healthcare system and a
public health concern. The cost of providing health care for one person over the age of 65
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is nearly five times greater than the cost of providing care to someone under the age of 65
(Centers for Disease Control and Prevention, 2013). As the aging population continues to
grow, healthcare costs are expected to increase as much as 25% by the year 2030 (Centers
for Disease Control and Prevention, 2013).
Factors that contribute to the high cost of healthcare in the elderly population
include deterioration of health as people age and increased use of medications to treat a
growing number of health problems. Older adults are often prescribed medications that are
not medically necessary, thus making consequences of polypharmacy a major concern.
Older people have more health problems, take more medications than younger people, and,
as a result, are seven times more likely to experience negative health outcomes that require
an emergency room visit and/or hospitalization (Budnitz, Lovegrove, Shehab, & Richards,
2011). ADEs in particular are a common cause of hospital admission. One in six elderly
hospital admissions is attributed to an ADE, and one in three adults over the age of 75
experience at least one ADE every year (Pretorius, Gataric, Swedlund, & Miller, 2013).
There are classes of medications that are especially inappropriate for use in adults
aged 65 and older. The American Geriatric Society created a medication evaluation tool,
referred to as Beers Criteria, that contains lists of PIMs in which the risks outweigh
potential benefits for adults over the age of 65 (American Geriatrics Society, 2012). The
criteria are used to evaluate the appropriateness of medications and are intended to serve
as a guideline in geriatric care. Experts suggest there is a relationship between ADEs, poor
patient outcomes, and medications listed in Beers Criteria (American Geriatrics Society,
2012).
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Considering that the life expectancy of this population is expected to increase,
prescription drug coverage through Medicare has improved, and more medications are
available on the U.S. market each year, it is expected that the rate of medication use in the
elderly population will continue to rise in the years ahead (Page et al., 2010). It was
estimated that over $7 billion in annual incremental healthcare expenditures in 2001 were
related to inappropriate medication use in community dwelling individuals over the age of
65 (Fu et al., 2007), and novel strategies are needed to minimize the burden the elderly
population has on the healthcare system.
In the following sections, the consequences of polypharmacy in the elderly and the
medication evaluation tools available to minimize PIM use in the aging population are
discussed. The most commonly used medication evaluation tool currently used in practice
is Beers Criteria. What started as a tool specifically for nursing home residents, Beers
Criteria has been revised several times since its creation in 1991, increasing from 23 PIMs
to over 50 medications and medication classes that can be potentially detrimental to the
health of elderly patients using these medications. A history of Beers Criteria is provided
which highlights the primary changes in medications included on or removed from Beers
Criteria since its creation. The limitations of Beers Criteria are also discussed.
Also included in this section is a review of previous research that has included
Beers Criteria. The studies selected for this review included Beers Criteria as the primary,
or one of the primary, medication evaluation tools of elderly adults. Beers Criteria has been
used in previous studies primarily to describe the prevalence of PIM use in the elderly.
Previous research has also evaluated health outcomes associated with PIMs included in
Beers Criteria. Although Beers Criteria was developed in the U.S., interestingly, Beers
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Criteria has also been incorporated in a number of studies outside of the U.S. Included in
this review are international studies of Beers Criteria that were conducted in Europe,
Africa, Asia, Australia, and South America. Technology-based interventions to minimize
PIM use in the elderly are beginning to incorporate Beers Criteria, and previous studies of
these interventions are highlighted in this section. Reviews of the few studies that have
used Beers Criteria to quantify the impact of PIM use on healthcare costs are also discussed
in this section. To conclude this review of the literature, an overview of propensity score
matching (PSM) and a review of how this technique has been used in previous studies of
Beers Criteria is provided. Measures of baseline health conditions that will be used in PSM
in this dissertation are also addressed in this chapter.
2.1

Polypharmacy
As they age, older adults experience a greater number of health problems, and these

conditions usually require treatment with multiple medications (Hajjar, Cafiero, & Hanlon,
2007). The use of multiple medications concurrently by the same patient to treat one or
more health conditions is referred to as polypharmacy. Polypharmacy also represents “the
use of more medications than are medically necessary” (Maher et al., 2013) and has been
associated with PIM prescribing (Cahir et al., 2010). Polypharmacy is a concern for
community-dwelling individuals as well as patients in ambulatory care settings, those that
are hospitalized, and patients residing in nursing homes (Maher et al., 2013).
Approximately half of hospitalized patients, ambulatory care patients, and nursing home
residents receive at least one drug that is deemed unnecessary (Tjia, Velten, Parsons,
Valluri, & Briesacher, 2013).
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Although the elderly population represents only 15% of the total population, this
group is the largest consumer of medications (Page et al., 2010). Results from the National
Health and Nutrition Examination Survey indicate that 90% of adults over the age of 65
take at least one prescription medication (Kantor, Rehm, Haas, Chan, & Giovannucci,
2015). National trends in prescription drug use among all adults are on the rise. Fifty one
percent of U.S. adults reported using at least one prescription medication in the 1999-2000
survey, while 59% of US adults reported using at least one prescription in the 2011-2012
survey (Kantor et al., 2015). A comparison of survey results from 1999-2000 and 20112012 indicate that rates of polypharmacy (represented by the use of five of more
medications) in older adults has increased over time as well. In the 2011-2012 survey 39%
of adults over the age of 65 were taking five or more medications, compared to 24% in the
1999-2000 survey (Kantor et al., 2015).
There are a number of negative health consequences of polypharmacy, including
drug-drug interactions, medication non-adherence, decline in functional status, and ADEs.
The use of multiple medications puts the elderly at an increased risk for interactions
between drugs (Hajjar, Cafiero, & Hanlon, 2007). In a study of community-dwelling older
adults living in six different countries, nearly 50% of the participants experienced at least
one significant drug-drug interaction (Bjorkman et al., 2002). The risk for drug-drug
interactions increases with the number of medications consumed, and these interactions
cause unnecessary adverse events and preventable hospitalizations (Maher et al., 2013).
Medication non-adherence is associated with poor clinical outcomes and has
significant clinical and economic implications. Poorly treated health conditions require
additional medical treatment and often hospitalization, which in turn negatively impact the
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patient’s quality of life (Hughes, 2004). An estimated 10% of hospitalizations and nearly
25% of LTC facility admissions are attributed to medication compliance issues, and
roughly 125,000 deaths occur each year as a result of non-adherence (Peterson, Takiya, &
Finley, 2003). Non-adherence is also economically burdensome. The direct and indirect
costs of medication non-adherence is estimated to be anywhere from $100 to nearly $290
billion each year (Viswanathan et al., 2012).
Functional status is frequently used to measure overall well-being within the older
adults. Polypharmacy can threaten functional status, and any limitations to functional status
can negatively impact the use of healthcare resources, quality of life, independence, and
risk of mortality (Peron, Gray, & Hanlon, 2011). Additionally, poor functional status is a
predictor of LTC facility admissions (Hilmer & Gnjidic, 2008). Previous studies have
demonstrated how polypharmacy can negatively impact functional status. A study of
elderly adults found that as the number of prescriptions consumed increased, the patient’s
ability to perform basic and instrumental activities of daily living declined (Magaziner,
Cadigan, Fedder, Hebel, 1989). A study of community-dwelling, disabled women
demonstrated that participants receiving polypharmacy (more than five medications in this
study) experienced increased difficulty performing instrumental activities of daily living
(Crentsil, Ricks, Xue, & Fried, 2010). Another study evaluated the relationship between
PIMs included on 2003 Beers Criteria and functional status among the very old (older than
80 years), and results indicated a correlation between PIM use and impaired functioning
(Landi et al., 2007).
Another consequence of polypharmacy is an increased risk of experiencing an
ADE. ADEs are defined as harm caused by a medication or use of an inappropriate
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medication (Nebeker, Barach, & Samore, 2004). Adverse events that are common in adults
over the age of 65 include mental decline, delirium, falls, fractures, and car accidents
(American Geriatrics Society, 2012). Falls are especially detrimental to this population as
they are attributed to increased morbidity and mortality (Maher et al., 2013). Results from
a study of elderly ED admissions indicates that the risk of experiencing an ADE is
significantly higher as the number of medications consumed by this population increases.
Patients that consumed two medications had nearly a 15% increased risk of experiencing
an ADE, and that risk increased to almost a 40% likelihood of having an ADE when using
five medications. Those using seven or more medications had over an 80% risk of
experiencing an ADE requiring an ED visit (Goldberg, Mabee, Chan, & Wong, 1996). An
11-year study using outpatient and ED visit data from the National Center for Health
Statistics estimates that over 4 million older adults experience an ADE requiring medical
attention annually (Bourgeois, Shannon, Valim, & Mandl, 2010). A meta-analysis of 39
prospective studies conducted in the U.S. revealed that over 2 million hospitalized patients
experienced an ADE and over 100,000 patients died as a result of an ADE in one year alone
(Lazarou, Pomeranz, & Corey, 1998). Based on these calculations, ADEs could be as high
as the fourth leading cause of death in the U.S. (Center for Drug Evaluation and Research,
2016).
Consequences of polypharmacy and inappropriate medication use directly affect
elderly patients, however, caregivers, hospitals, and LTC facilities are indirectly affected
by these consequences as well. Caregivers must face the burden of caring for loved ones
that are directly impacted by the consequences of polypharmacy. They often are faced with
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insurmountable hospital and/or LTC expenses to ensure their loved ones receive the level
of care required to treat ADEs and functional consequences of polypharmacy.
Hospitals and LTC facilities face an increased burden of caring for patients that
experience unnecessary drug events associated with using too many medications or using
inappropriate medications that increase the risk for adverse events. These events are a
common cause of hospital admission. The elderly population represents over 35% of
annual hospital admissions (Page et al., 2010), and one in six hospital admissions of older
adults can be attributed to an ADE (Beijer & De Blaey, 2002). These events are not only
costly to initially address in these institutions, but there is also a risk of increased hospital
readmission rates as a result of negative drug outcomes (Sehgal et al., 2013). Polypharmacy
is associated with an increase in outpatient and hospital visits, and it is responsible for
nearly a 30% increase in medical expenses (Maher et al., 2013). ADEs can also have longterm consequences that impair a patient’s functioning in such a way that they require
institutionalization in LTC facilities for treatment or prevention of future negative drug
outcomes. Not only do consequences of polypharmacy and ADEs immediately impact
healthcare costs, but readmissions and the need for long-standing treatment continue to
drive up costs in the long-term as well.
2.2

Medication Evaluation Tools
Geriatric clinicians can minimize consequences of polypharmacy by using

appropriate medication evaluation tools to help guide clinical decision making when
prescribing medications to elderly patients. ADEs and other consequences of
polypharmacy associated with PIM use can be minimized if clinicians perform frequent
medication reviews and adhere to prescribing guidelines (Ryan et al., 2009). While there
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is not one globally accepted medication evaluation tool, several explicit (criterion-based)
and implicit (judgment-based) criteria have been developed to help guide medication
decisions and ensure clinicians are adhering to quality prescribing practices (Levy, Marcus,
& Christen, 2010). Beers and colleagues (1991) were the pioneers of explicit medication
criteria, not only within the U.S. but internationally as well. Explicit criteria are more
efficient to use and allow for consistency when performing medication reviews, compared
to implicit criteria which tend to require more time to use given the clinical interpretation
that is required (Levy et al., 2010). Beers Criteria was the first objective tool to benchmark
the use of inappropriate medications within the elderly population (Levy et al., 2010).
Following the initial development of Beers Criteria in 1991, several medication evaluation
tools have emerged.
2.2.1

Medication Appropriateness Index
The Medication Appropriateness Index (MAI) was developed by Hanlon and

colleagues (1992) during the same time period that colleagues were developing the 1991
version of Beers Criteria. The goal of this implicit tool is to identify several elements of
prescribing practices that are relevant to a variety of medications and clinical settings
(Hanlon et al., 1992). The team conducted an initial literature review to identify articles
that included medication evaluation measures or scales. Those studies that specifically
addressed drug-related problems were evaluated by a pharmacists and geriatrician. Using
the literature and their own clinical judgment these individuals “independently identified
key elements of desirable medication use” (Hanlon et al., 1992, p. 1046) to create the MAI.
The MAI, as shown in Appendix A, is a set of 10 questions that addresses drug
indication, medication effectiveness, dosing, correct and practical directions, drug-drug
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interactions, drug-disease interactions, duplication with other drugs, duration, and cost
(Hanlon et al., 1992). This tool differs from Beers Criteria and other explicit criteria
discussed in sections 2.2.2 and 2.2.3 in that specific medications deemed inappropriate are
not specifically listed on the MAI. As is the case with implicit criteria, the MAI requires
clinical judgment to answer the 10 medication-related questions represented in the tool.
Hanlon and colleagues (1992) standardized the rating process by including definitions of
each criteria and detailed instructions to guide clinicians on how to answer each of the 10
questions. Clinicians rate each item as appropriate, marginally appropriate, or
inappropriate medication use (Hanlon et al., 1992). The MAI has also been used to identify
and define inappropriate drug use in patients receiving at least one medication rated as
inappropriate on three of the 10 MAI criteria: indication, efficacy, and therapeutic
duplication (Hajjar et al., 2005).
Hanlon and colleagues (1992) evaluated the reliability of the MAI in a randomly
selected sample of 10 elderly patients regularly using five or more medications and
receiving care at a Veterans Affairs Medical Center. Medication use and medical history
was obtained from each patient chart. A pharmacist and a geriatrician applied the MAI and
evaluated each patient’s medication use at baseline and again two to four months later
(Hanlon et al., 1992). To evaluate generalizability of the MAI, a second chart review of 10
randomly selected sample of patients regularly using five or more medications was
conducted by a separate pharmacist and geriatrician. Inter-rater and intra-rater reliability
was achieved, and the authors present the MAI as a valid and reliable tool (Hanlon et al.,
1992).
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Despite the reliability and validity of the MAI, this evaluation tool is not without
its limitations. The MAI requires considerable clinician time to complete compared to other
medication evaluation tools. The tool takes on average about 10 minutes for a clinician to
complete an evaluation for each individual drug (Samsa et al., 1994). While the MAI
addresses many elements of prescribing appropriateness, it does not take into account
consequences of polypharmacy. The tool does not offer guidance to help clinicians
prioritize specific drugs that should be avoided or changed, and the MAI is not a useful
tool to help clinicians evaluate those specific medications that are attributable to
unnecessary ADEs (Hanlon & Schmader, 2013).
2.2.2

Improved Prescribing in the Elderly Tool
The Improved Prescribing in the Elderly Tool (IPET) was developed in Canada by

Naugler and colleagues (2000) to identify inappropriate prescribing in adults over the age
of 65. This tool was developed using criteria previously established by McLeod et al.
(1997). In the McLeod study, a 32-member panel comprised of pharmacologists,
geriatricians, family practitioners, and pharmacists from academic medical centers across
Canada rated the clinical significance (not significant to highly significant) of 71
prescribing practices in the elderly population. The panel also offered alternative
treatments for each prescribing practice. A final list of 38 inappropriate prescribing
practices were agreed upon by the panel and were categorized into three groups:
medications contraindicated for the elderly (based on the 1991 version of Beers Criteria),
medications with drug-drug interactions, and medications that can cause drug-disease
interactions (McLeod, Huang, Tamblyn, & Gayton, 1997).
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Naugler and colleagues (2000) used McLeod et al.’s (1997) list of 38 inappropriate
prescribing practices as the basis for the IPET. The goal of the study conducted by Naugler
and colleagues was to apply the McLeod et al. (1997) guidelines to inpatient hospital
records to develop a brief and valid screening tool to enable clinicians to screen for PIMs
in the elderly (Naugler, Brymer, Stolle, & Arcese, 2000). Records of 361 consecutive
inpatient discharges of elderly patients over the age of 70 that occurred in 1997 were
reviewed. Medications and medical conditions that were included in the McLeod et al.
(1997) guidelines that were identified in the charts were recorded.

Inappropriate

prescriptions were identified in 12.5% of the inpatient charts (45 of the 361 charts included
at least one PIM) (Naugler et al., 2000). The IPET, represented in Appendix B, consists of
14 questions based on the specific PIMs detected in the review. To confirm the validity
and reliability of the tool, the IPET was applied to a new set of 100 consecutive discharge
charts from the same hospital that occurred over a six-month period in 1998 (Naugler et
al., 2000).
Compared to Beers Criteria, the IPET is not as widely used in clinical practice or
research (Ryan et al., 2009). It also has not had the international success as Beers Criteria.
The primary criticism of the IPET is its narrow scope and inclusion of obsolete criteria
(Levy et al., 2010). The IPET includes a select number of medications. There are only three
medication classes found on both Beers Criteria and the IPET (long-acting
benzodiazepines, nonsteroidal anti-inflammatory drugs [NSAIDs] in peptic ulcer disease,
and the use of b-blockers in Chronic Obstructive Pulmonary Disease) (Barry, O'Keefe,
O'Connor, & O'Mahony, 2006). Many commonly used classes of medications that are
attributed to specific problems in the elderly population are excluded. The limited number
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of medications represented in the IPET does make it an easier tool for the user (Barry et
al., 2006), but there are concerns about the validity of the tool given the number of well
recognized PIMs that are omitted from the list. Previous research conducted by Barry et al.
(2006) compared Beers Criteria and the IPET. In this study, Barry and colleagues measured
the frequency of PIM prescribing among 350 elderly patients hospitalized in Ireland and
compared the efficacy of 2003 Beers Criteria and the IPET in detecting PIM prescribing in
this population. Beers Criteria identified 34% of patients were prescribed at least one PIM
compared to 22% of patients that were prescribed at least one PIM as identified by the
IPET (Barry et al., 2006). Results from this study indicate that Beers Criteria has greater
sensitivity than the IPET mainly due to the fact that Beers Criteria includes a vastly greater
list of medications, the majority of which are not represented in the IPET (Barry et al.,
2006).
2.2.3

STOPP and START Criteria
Earlier versions of Beers Criteria have been criticized for their applicability in

Europe, primarily because some drugs included in Beers Criteria were not approved in
most European countries (Dalleur, Boland, & Spinewine, 2012). As a result, an 18member panel comprised of geriatricians, pharmacists, pharmacologists, and primary care
clinicians from academic centers in Ireland and the United Kingdom developed the
Screening Tool of Older Persons’ Prescriptions (STOPP) and Screening Tool to Alert
doctors to Right Treatment (START) criteria.

Initially published in 2008, the

STOPP/START criteria have been well-received internationally and have been used to
evaluate medication use in community-dwelling, hospitalized, and institutionalized elderly
patients in countries across the world (Hill-Taylor et al., 2013). The criteria were developed
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after careful consideration of Beers Criteria (1991, 1997, and 2003 versions), the MAI, and
the IPET. The goal in developing STOPP/START criteria was to create a comprehensive
list of PIMs that were (a) valid, (b) based on consensus from an expert panel, (c) based on
current clinical practice (at the time of development), and (d) easy and time-efficient for
clinicians (Gallagher, Ryan, Byrne, Kennedy, & O'Mahony, 2008). Another characteristic
that distinguished STOPP/START criteria from previously developed medication
evaluation tools was the inclusion of medications associated with drug-drug and drugdisease interactions as well as drugs unlikely to be prescribed despite clear evidence that
the drug is likely to benefit the elderly patient (Gallagher et al., 2008).
A two round Delphi validation process was used to evaluate 68 STOPP criteria and
22 START criteria. Consensus was established on all 22 START criteria and 65 of the 68
STOPP criteria (Gallagher et al., 2008). The final list of agreed upon STOPP criteria,
shown in Appendix C, and START criteria, shown in Appendix D, were organized in a
way to allow for clinicians to screen medication regimens easily in busy practices. The 65
PIMs included on STOPP are organized into 10 categories based on physiological systems,
and a specific explanation as to why each individual PIM may be inappropriate in the
elderly is also included. The 22 PIMs included on START are organized by physiological
systems into 4 categories (Gallagher et al., 2008).
The STOPP/START criteria were recently updated in 2014 (O'Mahony et al.,
2015). A 19-member panel consisting of geriatric experts from 13 European countries
executed a two-round Delphi validation process to generate the current version. The current
list includes 80 STOPP criteria and 34 START criteria organized by physiological systems.
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Fifteen medications previously included in STOPP/START were removed from the second
version (O'Mahony et al., 2015).
It is important to note the similarities and differences in the specific medications
included on STOPP and Beers Criteria. Similar recommendations between the two lists
include avoiding “benzodiazepines in individuals with history of falls or fractures, calcium
channel blockers in individuals with chronic constipation, and long-duration
sulfonylureas” (Dalleur, Boland, & Spinewine, 2012, p. 2188). Considering the two
medication evaluation tools were developed in separate countries, and it is not surprising
that there is variability in the specific PIMs included in the individual tools given the
differences in medications available in each country. There are 33 PIMs included on
STOPP are not represented in 2003 Beers Criteria. There are 27 medications represented
in 2003 Beers Criteria that were rarely used in European healthcare settings at the time
STOPP was developed (Gallagher et al., 2008), however, 14 of those medications were
removed in recent revisions to Beers Criteria (American Geriatrics Society, 2012;
American Geriatrics Society, 2015). A comparison of 2012 Beers Criteria to STOPP
revealed that the two lists share only a minority of the criteria. About 55% of medications
addressed through STOPP are not included in 2012 Beers Criteria (Dalleur, Boland, &
Spinewine, 2012). The 2012 Beers Criteria includes delirium and dementia, which are
prevalent medical concerns in the elderly population, among the health conditions of
concern included in the list (American Geriatrics Society, 2012). Alternatively, STOPP
addresses the use of warfarin and opiates which are often associated with ADEs in the
elderly (Budnitz, Lovegrove, Shehab, & Richards, 2011). Warfarin and opioids have since
been added to the 2015 version of Beers Criteria (American Geriatrics Society, 2015).
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Additionally, the 2012 Beers Criteria also addresses risks of using anticholinergics in a
more explicit way compared to STOPP (Dalleur, Boland, & Spinewine, 2012).
Recent studies have identified Beers Criteria to be more successful in identifying
PIM use in the elderly compared to STOPP/START. Using three years of managed care
administrative claims data, Brown et al. (2016) compared 2003 Beers Criteria, 2012 Beers
Criteria, and STOPP criteria to determine the prevalence of PIM prescribing among
174,275 commercially insured patients in the U.S. The 2003 version of Beers Criteria
identified PIM use in 32% of patients, 2012 Beers Criteria identified PIM use in 34% of
patients, and STOPP criteria identified PIM use in 27% of the cohort (Brown et al., 2016).
Fadare and colleagues (2015) used 2012 Beers Criteria and STOPP criteria to estimate the
incidence of PIM use among 358 elderly Nigerian outpatients. Beers Criteria identified
30% of the patients were prescribed at least one PIM, and STOPP criteria identified 15%
of the study participants were using at least one PIM (Fadare et al., 2015). Oliveira et al.
(2015) applied the 2012 Beers Criteria and STOPP criteria to 142 patients included in the
study to identify the prevalence of PIM use among the elderly in primary care settings in
Brazil. The prevalence of PIM use in this group was over 51% according to Beers Criteria,
compared to 33% of PIMs used according to the STOPP criteria (Oliveira et al., 2015). A
cross-sectional study of community-dwelling elderly patients residing in Spain was
designed to evaluate the prevalence of PIM use. 2003 Beers Criteria, 2012 Beers Criteria,
and STOPP Criteria were compared. Although 2003 Beers Criteria did not perform as well
in detecting PIM use in this population compared to STOPP criteria, 2012 Beers Criteria
was successful in identifying the largest number of PIMs prescribed to this population. The
2012 version of Beers Criteria was able to detect 44% of participants using PIMs compared
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to 35% identified with the STOPP criteria (Blanco-Reina, Ariza-Zafra, Ocaña-Riola, &
León-Ortiz, 2014). Grace and colleagues (2014) used the 2012 Beers Criteria and STOPP
criteria to evaluate the prevalence of PIM use among 165 Irish elderly nursing home
residents that were admitted to the ED. There were 242 different medications prescribed in
this cohort, and 91 of those medications were defined as a PIM according to 2012 Beers
Criteria or STOPP. Beers Criteria had greater success in identifying PIM use. Over 89%
of patients were using PIMs according to Beers Criteria compared to 84% of patients were
using PIMs according to STOPP (Grace et al., 2014). Results from these studies indicate
that despite the international use of STOPP/START, Beers Criteria remains a reliable and
valid tool to minimize PIM use in the elderly.

It is unlikely that a universally accepted medication evaluation tool will become
available in the years ahead. The majority of research evaluating PIM use in the elderly has
used Beers Criteria over any other evaluation tool. Intervention studies aimed to improve
the quality of geriatric prescribing practices have also used Beers Criteria more frequently
than any other medication evaluation tool (Levy et al., 2010). Clinicians must consider
several factors when selecting a tool among the available medication evaluation criteria,
including ease of use, accuracy of the tool, drug availability, and clinician preference (Levy
et al., 2010). Although a variety of medication evaluation tools are available, Beers Criteria
remains the most commonly used tool among healthcare providers treating the elderly
population (Griebling et al., 2016).
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2.3

History of Beers Criteria
Dr. Mark Beers and a group of 13 geriatric clinicians created the first Beers Criteria

in 1991 (Appendix E) (Beers et al., 1991). The panel completed a literature review of the
appropriateness of medication use in the elderly and a review of published medication
prescribing guidelines used in the elderly in general or for nursing home residents
specifically. A survey was developed based on the guidelines identified and completed by
the 13-member panel. A two-round, modified Delphi technique was used to process the
responses of each individual panel member to establish a group consensus on the guidelines
derived from the literature. The original list was comprised of 30 medications, including
commonly prescribed antidepressants, antipsychotics, and sedative-hypnotics, and was
intended to serve as a tool to assist clinicians in identifying those medications that should
be avoided specifically in nursing home patients regardless of clinical diagnosis, dose, and
frequency of use. At that time, nursing home patients were specifically targeted because
patients residing in nursing homes were particularly at risk for suffering from medicationrelated negative outcomes (Beers et al., 1991).
Beers Criteria was modified and republished in 1997 to expand the applicability of
prescribing patterns to include non-institutionalized elderly individuals (Appendix F)
(Beers, 1997). This expansion identified specific medications that should be avoided all
together in this population, medication dose or frequency that should not be exceeded, and
medications that should be avoided in elderly patients with specific co-morbidities.
Following a similar modified Delphi process, a six-member panel of geriatric experts
established consensus on 28 medications or classes to avoid all together in the elderly
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population and 35 medications or classes considered to be potentially inappropriate when
taking medical condition into consideration (Beers, 1997).
A 12-member panel employed the modified Delphi method to develop the 2003
Beers Criteria revision (Appendix G) (Fick et al., 2003). Fifteen medications included in
the 1997 Beers Criteria were removed during the 2003 revision. The panel identified 48
medications or classes to avoid regardless of medical condition, and they identified
medications considered inappropriate for use with 20 specific medical conditions. Another
notable addition to the 2003 version is the use of a high or low rating that was assigned to
each medication to reflect the level of severity of ADEs for each medication included on
the list (Fick et al., 2003).
An 11-member panel, led by the American Geriatric Society, followed the Institute
of Medicine standards to conduct a systematic review of over 2,000 high-quality research
studies of medications prescribed for older adults to generate the 2012 update (Appendix
H) (American Geriatrics Society, 2012). The 2012 list includes 53 PIMs or classes in which
the increased risks of experiencing an ADE outweigh potential benefits for adults over the
age of 65. One notable change to the criteria was the addition of a third category, compared
to the two categories in which medications were classified in previous versions of Beers
Criteria. The 53 medications or classes are classified as (a) medications to avoid all together
in this population, (b) medications to avoid in adults with certain medical conditions, and
(c) medications to be used with caution in the elderly population (American Geriatrics
Society, 2012).
The most current version of Beers Criteria was published in 2015 (Appendix I)
(American Geriatrics Society, 2015). Thirteen panelists reviewed close to 7,000 clinical
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trials and research studies that were published since the last Beers Criteria update in 2012.
Changes are not as extensive as previous revisions, and medications are still classified
under one of the three categories. New to this list are medications that should be avoided
or have their dose adjusted in patients with poor kidney function and medications that may
be inappropriate when prescribed at the same time (American Geriatrics Society, 2015).
A combined graphical representation of all five versions of Beers Criteria is
presented in Appendices J, K, and L. These figures provide a comparison of medications
that have been added or removed through the various revisions to Beers Criteria. Appendix
J includes all PIMs included on all five versions that were classified as those medications
to avoid in older adults. Appendix K includes PIMs to avoid in older adults due to drug–
disease or drug–syndrome interactions that may exacerbate the disease. This separate
classification was added in the 1997 revision, thus medications represented in 1991 Beers
Criteria do not apply to this category. Lastly, Appendix L represents the new category of
PIMs be used with caution that was added in 2012 and updated in 2015.
2.4

Medication Classes Included in Beers Criteria
Beers Criteria is an explicit medication evaluation tool comprised of three separate

categories of inappropriate medications: (a) PIMs that should be avoided all together in
older adults, (b) PIMs to avoid in older adults due to drug–disease or drug–syndrome
interactions that may exacerbate the disease, and (c) PIMs to be used with caution in older
adults (American Geriatrics Society, 2012; American Geriatrics Society, 2015). Beers
Criteria is intended to be applied to all adults over the age of 65 with the exception of those
adults receiving palliative and hospice care. Individuals receiving palliative and hospice
care were excluded from the criteria given that risk-to-benefit of medication use and end-
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of-life clinical decision making is vastly different compared to individuals not receiving
palliative and hospice care. Controlling symptoms through end-of-life care is usually more
imperative than avoiding PIMs (American Geriatrics Society, 2012; American Geriatrics
Society, 2015).
The PIMs included in Beers Criteria that should be avoided all together in older
adults

include

Anticholinergics,

Antithrombotics,

Anti-infective

medications,

cardiovascular medications, pain medications, and medications targeting the central
nervous system, endocrine system, and gastrointestinal system (American Geriatrics
Society, 2015). These medications should be avoided all together and safer medications or
non-medication treatments are preferable to these PIMs (American Geriatrics Society,
2012).
Anticholinergics

represented

in

Beers

Criteria

include

first-generation

antihistamines (Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine,
Cyproheptadine, Dexbrompheniramine, Dexchlorpheniramine, Dimenhydrinate, oral
Diphenhydramine,

Doxylamine,

Hydroxyzine,

Meclizine,

Promethazine,

and

Triprolidine), Antiparkinsonian agents (oral Benztropine and Trihexyphenidyl), and
Antispasmodics

(Atropine,

Belladonna

alkaloids,

Clidinium-Chlordiazepoxide,

Dicyclomine, Hyoscyamine, Propantheline, and Scopolamin) (American Geriatrics
Society, 2015). First-generation antihistamines included in Beers Criteria are associated
with a risk of “confusion, dry mouth, constipation, and other anticholinergic effects or
toxicity” (American Geriatrics Society, 2015, p. 2231). Those Antiparkinsonian agents
included Beers Criteria should be avoided and medications that are more effective in the
treatment of Parkinson’s disease should be used (American Geriatrics Society, 2015).
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Antispasmodics included in Beers Criteria are considered to be highly anticholinergic and
the effectiveness of these specific PIMs is unknown (American Geriatrics Society, 2015).
Antithrombotics represented in Beers Criteria include oral short-acting
Dipyridamole and Ticlopidine. Dipyridamole “may cause orthostatic hypotension”
(American Geriatrics Society, 2015, p. 2231). Dipyridamole and Ticlopidine should be
avoided in favor of safer alternatives that are available (American Geriatrics Society,
2015). Nitrofurantoin, the only anti-infective included in Beers Criteria, is associated with
“pulmonary toxicity, hepatoxicity, and peripheral neuropathy” (American Geriatrics
Society, 2015, p. 2231). These conditions are exacerbated with long-term use, and, given
that safer anti-infective medications are available, Nitrofurantoin should be avoided “in
individuals with creatinine clearance <30 mL/min or for long-term suppression of bacteria”
(American Geriatrics Society, 2015, p. 2231).
Cardiovascular medications represented in Beers Criteria include peripheral alpha1 blockers (Doxazosin, Prazosin, and Terazosin), central alpha blockers (Clonidine,
Guanabenz, Guanfacine, Methyldopa, and Reserpine [>0.1 mg/d]), Disopyramide,
Dronedarone, Digoxin, immediate release Nifedipine, and Amiodarone. Peripheral alpha1 blockers and central alpha blockers included in Beers Criteria are not recommended for
regular treatment of hypertension and are associated with an increased risk of orthostatic
hypotension. Additionally, central alpha blocker PIMs are also associated with a higher
risk of negative effects on the central nervous system, and they may also cause bradycardia.
These Peripheral alpha-1 blockers and central alpha blockers should not be used as an
antihypertensive (American Geriatrics Society, 2015). Disopyramide may increase heart
failure in older adults (American Geriatrics Society, 2015). Individuals with permanent
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atrial fibrillation experience worse outcomes when prescribed Dronedarone (American
Geriatrics Society, 2015). Digoxin is associated with increased mortality and should be
avoided as a first-line treatment of atrial fibrillation and heart failure (American Geriatrics
Society, 2015). Immediate release Nifedipine is associated with an increased risk for
hypotension and precipitating myocardial ischemia (American Geriatrics Society, 2015).
Amiodarone has a greater toxicity compared to other antiarrhythmics when used as firstline treatment of atrial fibrillation (American Geriatrics Society, 2015).
Pain medications represented in Beers Criteria include Meperidine, oral noncyclooxygenase-selective NSAIDs (Aspirin >325 mg/d, Diclofenac, Diflunisal, Etodolac,
Fenoprofen, Ibuprofen, Ketoprofen, Meclofenamate, Mefenamic acid, Meloxicam,
Nabumetone, Naproxen, Oxaprozin, Piroxicam, Sulindac, Tolmetin, Indomethacin, and
Ketorolac), Pentazocine, Skeletal muscle relaxants (Carisoprodol, Chlorzoxazone,
Cyclobenzaprine, Metaxalone, Methocarbamol, and Orphenadrine), and Desmopressin
(American Geriatrics Society, 2015). Meperidine is associated with an increased risk of
neurotoxicity and delirium, and safer opioid alternatives should be used (American
Geriatrics Society, 2015). Pentazocine may cause central nervous system ADEs including
confusion and hallucinations, and safer opioid analgesics should be used (American
Geriatrics Society, 2015). Oral non-cyclooxygenase-selective NSAIDs included in Beers
Criteria may cause gastrointestinal bleeding, peptic ulcer disease, upper gastrointestinal
ulcers, gross bleeding, perforation, or acute kidney injury (American Geriatrics Society,
2015). Skeletal muscle relaxants included in Beers Criteria tend to be poorly tolerated by
this population are associated with an increased risk of anticholinergic ADEs, sedation,
and fractures (American Geriatrics Society, 2015). Desmopressin use is associated with an
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increased risk of hyponatremia, and should not be used for the treatment of nocturia or
nocturnal polyuria (American Geriatrics Society, 2015).
PIMs targeting the central nervous system represented in Beers Criteria include
Antidepressants alone or in combination (Amitriptyline, Amoxapine, Clomipramine,
Desipramine, Doxepin >6 mg/d, Imipramine, Nortriptyline, Paroxetine, Protriptyline, and
Trimipramine), first and second generation antipsychotics, Barbiturates (Amobarbital,
Butabarbital, Butalbital, Mephobarbital, Pentobarbital, Phenobarbital, and Secobarbital),
Short- and intermediate-acting Benzodiazepines (Alprazolam, Estazolam, Lorazepam,
Oxazepam, Temazepam, and Triazolam), Long-acting Benzodiazepines (Clorazepate,
Chlordiazepoxide [alone or in combination with amitriptyline or clidinium], Clonazepam,
Diazepam,

Flurazepam,

and

Quazepam),

Meprobamate,

Nonbenzodiazepine

-

benzodiazepine receptor agonist hypnotics (Eszopiclone, Zolpidem, and Zaleplon),
Ergoloid mesylates, and Isoxsuprine (American Geriatrics Society, 2015). Due to a lack of
efficacy, use of ergoloid mesylates and Isoxsuprine should be avoided in older adults
(American Geriatrics Society, 2015). Antidepressants included in Beers Criteria are
considered to be “highly anticholinergic, sedating, and cause orthostatic hypotension”
(American Geriatrics Society, 2015, p. 2233). Older adults using first and second
generation antipsychotics have an increased risk of stroke and cognitive decline, and
individuals with dementia have can experience increased mortality. These medications
should be avoided in the older adult population except to treat schizophrenia and bipolar
disorder or for short-term use during chemotherapy (American Geriatrics Society, 2015).
Barbiturates included in Beers Criteria are associated with greater likelihood of physical
dependence and overdose (American Geriatrics Society, 2015). Benzodiazepine use is
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associated with an increased risk of “cognitive impairment, delirium, falls, fractures, and
motor vehicle crashes” (American Geriatrics Society, 2015, p. 2233). Benzodiazepinereceptor agonists are associated with similar ADEs. Benzodiazepine use is also associated
with a higher rate or hospitalization and emergency department visits and should be
avoided in this population (American Geriatrics Society, 2015). Meprobamate is highly
sedative and should be avoided due to the increased likelihood of physical dependence
(American Geriatrics Society, 2015).
PIMs targeting the endocrine system represented in Beers Criteria include
Androgens (Methyltestosterone and Testosterone), Desiccated Thyroid, Estrogens with or
without progestins, growth hormone, sliding scale insulin, Megestrol, and long-duration
sulfonylureas (Chlorpropamide and Glyburide) (American Geriatrics Society, 2015).
Androgens and Desiccated Thyroid are associated with cardiac-related ADEs. Androgens
are especially problematic for men with prostate cancer. Androgens may be used to treat
clinical symptoms of hypogonadism, but otherwise should be avoided (American
Geriatrics Society, 2015). Estrogens with or without progestins have the potential to cause
breast and endometrial cancer and are also associated with negative cardiac and cognitive
outcomes (American Geriatrics Society, 2015). Growth hormone use is associated with
“edema, arthralgia, carpal tunnel syndrome, gynecomastia, and impaired fasting glucose
[and should be avoided] except as hormone replacement after pituitary gland removal”
(American Geriatrics Society, 2015, p. 2234). Use of sliding scale insulin and longduration sulfonylureas is associated with an increased risk of hypoglycemia (American
Geriatrics Society, 2015). Megestrol is associated with increased risk of thrombotic events
and death (American Geriatrics Society, 2015).
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PIMs targeting the gastrointestinal system represented in Beers Criteria include
Metoclopramide, orally received mineral oil, and proton-pump inhibitors (American
Geriatrics Society, 2015). Metoclopramide “can cause extrapyramidal effects, including
tardive dyskinesia” (American Geriatrics Society, 2015, p. 2235) and should be avoided
except for treatment of gastroparesis (American Geriatrics Society, 2015). Oral mineral oil
used daily can cause aspiration and should be avoided in favor of safer gastrointestinal
medications (American Geriatrics Society, 2015). Proton-pump inhibitors are associated
with an increased risk of Clostridium difficile and fractures (American Geriatrics Society,
2015).
In addition to those medications that should be avoided all-together in older adults,
Beers Criteria also provides recommendations of medications that should be avoided in
older adults with specific diseases or syndromes. This classification of PIMs is categorized
according to cardiovascular events (heart failure and syncope), central nervous system
conditions (chronic seizures or epilepsy, delirium, dementia or cognitive impairment,
history of falls or fractures, insomnia, and Parkinson’s disease), gastrointestinal conditions
(history of gastric or duodenal ulcers), and kidney and urinary tract conditions (chronic
kidney disease, urinary incontinence in women, and lower urinary tract symptoms in men)
(American Geriatrics Society, 2015).
Individuals with heart failure should avoid NSAIDs and COX-2 inhibitors,
Diltiazem, Verapamil, Thiazolidinediones (pioglitazone and rosiglitazone), Cilostazol, and
Dronedarone. These medications have the potential to “promote fluid retention and
exacerbate heart failure” (American Geriatrics Society, 2015, p. 2237). Individuals with
syncope should avoid Acetylcholinesterase inhibitors, peripheral alpha-1 blockers,
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Doxazosin,

Prazosin,

Terazosin,

Tertiary

tricyclic

antidepressants

(TCAs),

Chlorpromazine, Thioridazine, and Olanzapine. These medications are associated with an
increased risk of orthostatic hypotension and bradycardia (American Geriatrics Society,
2015).
Due to the potential to lower the seizure threshold, individuals with chronic seizures
or epilepsy should avoid using Bupropion, Chlorpromazine, Clozapine, Maprotiline,
Olanzapine, Thioridazine, Thiothixene, and Tramadol (American Geriatrics Society,
2015). Individuals with a high risk of experiencing delirium should avoid using
anticholinergics, antipsychotics, Benzodiazepines, Chlorpromazine, Corticosteroids, H2receptor antagonists (Cimetidine, Famotidine, Nizatidine, Ranitidine, and Meperidine),
and sedative hypnotics. These medications can induce or worsen delirium. Individuals with
dementia or cognitive impairment should avoid anticholinergics, Benzodiazepines, H2receptor antagonists, Nonbenzodiazepine/benzodiazepine receptor agonist hypnotics
(Eszopiclone, Zolpidem, and Zaleplon), and antipsychotics (chronic and as-needed use)
due to adverse events to the central nervous system. Antipsychotics in particular are also
associated with a greater risk of stroke and mortality in individuals with dementia
(American Geriatrics Society, 2015). The use of anticonvulsants (except for seizures and
mood disorders), antipsychotics, Benzodiazepines, Nonbenzodiazepine/benzodiazepine
receptor agonist hypnotics (Eszopiclone, Zaleplon, and Zolpidem), selective serotonin
reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and opioids (except for pain
management due to recent fracture or joint replacement) is not recommended in individuals
with a history of falls or fractures. These medications are associated with a higher risk of
ataxia, impaired psychomotor function, syncope, and may cause additional falls (American
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Geriatrics Society, 2015). Individuals with insomnia should avoid the use of oral
decongestants (Pseudoephedrine and Phenylephrine), Stimulants (Amphetamine,
Armodafinil, Methylphenidate, and Modafinil), and Theobromines (Theophylline and
Caffeine) (American Geriatrics Society, 2015). Due to the potential to worsen symptoms
of Parkinson’s disease, individuals with Parkinson’s should avoid all antipsychotics
(except aripiprazole, quetiapine, and clozapine) and Antiemetics (Metoclopramide,
Prochlorperazine, and Promethazine) (American Geriatrics Society, 2015).
Non-COX-2 selective NSAIDs and doses of aspirin greater than >325 mg per day
“may exacerbate existing ulcers or cause new or additional ulcers” (American Geriatrics
Society, 2015, p. 2239) and should be avoided in individuals with a history of gastric or
duodenal ulcers. Non-COX and COX-selective, oral and parenteral NSAIDs “may increase
risk of acute kidney injury and further decline of renal function” (American Geriatrics
Society, 2015, p. 2239) and should be avoided in individuals with stage 4 chronic kidney
disease. Women with urinary incontinence should avoid estrogen oral and transdermal
(excludes intravaginal estrogen), and peripheral alpha-1 blockers (Doxazosin, Prazosin,
and Terazosin) to prevent the risk of aggravating existing incontinence (American
Geriatrics Society, 2015). Men with lower urinary tract symptoms should avoid strongly
anticholinergic drugs, except antimuscarinics for urinary incontinence. These medications
“may decrease urinary flow and cause urinary retention” (American Geriatrics Society,
2015, p. 2239).
Lastly, Beers Criteria also provides recommendations of medications to use with
caution in older adults. Aspirin should be used with caution in adults over the age of 80
years for the prevention of cardiac events due to a lack of evidence of the risk-to-benefit
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ratio of aspirin use in adults over the age of 80 (American Geriatrics Society, 2015).
Dabigatran, an anticoagulant medication, is associated with an increased risk of
gastrointestinal bleeding compared to other anticoagulants. This medication should be used
with caution in adults over the age of 75 and in adults with a creatinine clearance of <30
mL/minute (American Geriatrics Society, 2015). Prasugrel, a blood thinner, is associated
with an increased risk of bleeding and should be used with caution in adults over the age
of 75 (American Geriatrics Society, 2015). Vasodilators should be used with caution in all
older adults as they “may exacerbate episodes of syncope in individuals with history of
syncope” (American Geriatrics Society, 2015, p. 2240). Beers Criteria also recommends
using caution in all older adults before prescribing the following medications:
Antipsychotics, Diuretics, Carbamazepine, Carboplatin, Cyclophosphamide, Cisplatin,
Mirtazapine, Oxcarbazepine, serotonin–norepinephrine reuptake inhibitors (SNRIs),
selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and
Vincristine (American Geriatrics Society, 2015).
2.5

Limitations of Beers Criteria
Beers Criteria is not without its limitations. As highlighted in section 2.3, Beers

Criteria was developed using an evidence-based approach. An extensive review of the
existing body of literature related to polypharmacy and ADEs specific to the elderly
population was used to guide the development of each version of Beers Criteria (American
Geriatrics Society, 2012). Unfortunately, vulnerable populations are significantly
underrepresented in clinical trials (Herrera et al., 2010). This is especially true for the
elderly population (Herrera et al., 2010), even though they remain the largest consumers of
medication (American Geriatrics Society, 2012). Evidence shows that despite the fact that
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the elderly population suffers from the majority of the disease burden in the U.S., less than
35% of the elderly are represented in clinical trials (Herrera et al., 2010). Although
inclusion of the elderly in clinical trials is problematic due to a variety of issues
(comorbidities, lack of insurance, economic concerns, etc.), there are consequences for not
appropriately including this population in research. Not appropriately representing the
elderly population “may limit generalizability, provide insufficient data about positive or
negative effects of treatment among septic populations, and hinder much-needed access to
new treatments” (Herrera et al., 2010, p. 105). As a result, using an evidence-based
approach to develop Beers Criteria “may underestimate some drug-related problems or
lead to weaker evidence grading” (American Geriatrics Society, 2012, p. 628).
It is important to note that the panel used very specific search criteria to identify
the studies that were used in the decision-making process that ultimately impacted the
published criteria. As is the case in any systematic review with specific search criteria,
potentially valuable studies were likely excluded. Data sources used to identify relevant
citations were limited to Medline, The Cochrane Library, International Pharmaceutical
abstracts, and select references lists from peer-reviewed publications (American Geriatrics
Society, 2012). This search did not include studies published in languages other than
English. Additionally, potentially valuable results published outside of these data sources
such as white papers, technical reports, and Grey Literature sources, were not included in
the development of Beers Criteria (American Geriatrics Society, 2015).
Another limitation of Beers Criteria is that it does not take into account the
individual patient’s medication preferences and lifestyle attributes. While Beers Criteria is
intended to guide clinical decision-making in regards to medication prescribing in the
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elderly at the population level, the criteria does not account for all elderly individuals and
special populations, (American Geriatrics Society, 2015). For example, in individuals
receiving palliative and hospice care, it may be more important to control the patient’s
symptoms (which may require the use of PIMs listed in Beers Criteria) rather than simply
avoiding the use of PIMs all together (American Geriatrics Society, 2012). The risks and
benefits of PIMs listed in Beers Criteria may differ when used within special populations
compared to the risks and benefits of PIMs used in the general population of older adults.
Clinicians also misinterpret the criteria, and many mistakenly believe that the list
of PIMs in Beers Criteria is universally inappropriate (Steinman et al., 2015). Although
Beers Criteria provides a well-developed and extensive list of medications to avoid, it does
not include a list of alternative medications in the criteria (American Geriatrics Society,
2015). This is likely due in part to the complexity of individual patient health conditions
and other medications used to treat a variety of health problems. These complexities require
individualized clinician judgment to appropriately determine which alternative
medications would be appropriate for each individual patient based on their health status.
It should be noted that the criteria were not intended to completely remove clinical
judgment in regards to the needs of the individual patient (Molony, 2003).
Despite its limitations, Beers Criteria remains the most widely used medication
evaluation tool in geriatric care in acute care facilities, outpatient or ambulatory care
facilities, and locations where the elderly are institutionalized. The criteria are widely used
by practicing clinicians, pharmacists, researchers, regulators, and policymakers. Use of the
criteria has expanded beyond geriatric clinical care and is also used in education, research,
and in quality improvement initiatives (American Geriatrics Society, 2015). For example,
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the National Committee for Quality Assurance has included performance measures based
in Beers Criteria for managed care organizations to evaluate PIM use in the elderly within
the Healthcare Effectiveness Data and Information Set (HEDIS) (Stockl, Le, Zhang, &
Harada, 2010). HEDIS is not only used by almost all of the U.S. national healthcare plans,
but it is also considered the gold standard in health care performance measurement
(“HEDIS & Quality Measurement”, 2017). Beers Criteria is a valuable quality measure
and reputable tool used to educate healthcare providers, reduce unnecessary PIM use, and
ultimately improve the level of care elderly patients receive (American Geriatrics Society,
2012). “Beers Criteria have done more than any other tool in the past decade to improve
the awareness of and clinical outcomes for older adults with polypharmacy and for the most
vulnerable older adults at risk of adverse drug events” (Griebling et al., 2016).
2.6

Using Beers Criteria to Describe the Prevalence of PIM Use
The vast majority of research using Beers Criteria has sought to understand the

prevalence of PIM use in the elderly population. This literature review will highlight the
significant findings from these prevalence studies by focusing first on studies that
incorporated Beers Criteria as the only medication evaluation tool, and then by outlining
ways in which Beers Criteria has been used with other screening tools. This review will be
chronological in regards to the version of Beers Criteria used in the studies (beginning with
studies of early versions of Beers Criteria). Studies conducted in the U.S. as well as
research conducted outside the U.S are also presented.
2.6.1

Prevalence of PIMs Using Beers Criteria (U.S. studies)
Eleven studies have used various versions of Beers Criteria to understand the

prevalence of PIM use in the U.S. In these studies, Beers Criteria was the only medication
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evaluation tool used to describe PIM use. Of those studies, one study used the initial version
of Beers Criteria developed in 1991 (Aparasu & Sitzman, 1999), six studies used 1997
Beers Criteria (Aparasu & Mort, 2004; Fick et al., 2001; Gallagher, 2001; Perri et al., 2005;
Piecoro, Browning, Prince, Ranz, & Scutchfield, 2000; Zhan et al., 2001), two studies used
2003 Beers Criteria (Fick, Mion, Beers, & Waller, 2008; Stevenson et al., 2014), and two
studies used 2012 Beers Criteria (Davidoff et al., 2015; Jirón et al., 2016).
Aparasu and Sitzman (1999) conducted a nation-wide study of data files from the
National Hospital Ambulatory Medical Care Survey (NHAMCS) from the 1994 calendar
year to calculate the prevalence of PIM use in the elderly in outpatient settings. Although
the research team used the 1991 Beers Criteria, it is important to note that they did not
include all PIMs on the 1991 Beers Criteria in their study. Instead, Aparasu and Sitzman
(1999) included 20 medications or classes listed in Beers Criteria as those medications that
should be generally avoided in the elderly population. Ten medications or classes that
Beers and colleagues (Beers et al., 1991) classified as inappropriate based on dose amount
or therapy time were excluded from this study. Nearly 10.9 million outpatient visits
occurred in the U.S. in 1994 according to data included in NHAMCS. Aparasu and Sitzman
(1999) calculated the number of outpatient visits that involved one of the 20 PIMs selected
for the study. Results from this study indicate that 1 in 20 prescriptions provided to the
elderly included a PIM. Five of the 20 medications included in the study were responsible
for over 85% of the outpatient visits involving PIMs, and psychotropic and analgesic agents
were the most commonly prescribed PIM (Aparasu & Sitzman, 1999).
Aparasu and Mort (2004), Fick and colleagues (2001), and Zhan and colleagues
(2001) each conducted a nation-wide study of prevalence of PIM use and used 1997 Beers
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Criteria to identify or define PIMs. Using the 1996 Medical Expenditure Panel Survey,
Aparasu and Mort (2004) focused specifically on the use of Beers Criteria psychotropic
medications in community-dwelling older adults. Results from this study indicate that over
two million older adults received a PIM psychotropic medication included in Beers Criteria
in 1996 (Aparasu & Mort, 2004). Fick et al. (2001) conducted a retrospective review of
administrative claims data to examine prescribing of PIMs in a Medicare managed care
setting. PIMs were identified using 1997 Beers Criteria, but not all medications on the 1997
list were included. Fick et al. (2001) included 37 PIMs that should be avoided in the elderly
regardless of dose or diagnosis (Beers, 1997). Of the 2,336 adults over the age 65 that were
included in the database, 24% received a prescription for at least one PIM (Fick et al.,
2001). Similarly, Zhan et al. (2001) conducted a retrospective cohort study using a
nationally representative sample of community-dwelling adults to calculate the prevalence
of PIM use. As was the case in Fick et al. (2001), the 1997 Beers Criteria was used to define
PIMs, but only a subset of 33 medications included on 1997 Beers Criteria were included
in the study (Zhan et al., 2001). Using the 1996 Medical Expenditure Panel Survey, 2,455
individuals were included in the study, and results indicate that “more than 1 in 5 of the
community-dwelling elderly in the U.S. used at least 1 of the 33 drugs” (Zhan et al., 2001,
p. 2826) included on the 1997 Beers Criteria.
Piecoro, Browning, Prince, Ranz, and Scutchfield (2000) conducted a crosssectional retrospective review of Medicaid Pharmacy claims of 64,832 older adults who
received at least one prescription to evaluate the prevalence of PIM use in communitydwelling and nursing home residents of Kentucky. Piecoro and colleagues (2000) used
1997 Beers Criteria to identify at least one PIM used in 27% of patients. Additionally,
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prevalence of PIM use was higher in nursing home residents compared to communitydwelling older adults (Piecoro et al., 2000). Gallagher (2001) studied a sample of 146
patients residing in New York that were diagnosed with congestive heart failure.
Medication use was analyzed, and the 1997 version of Beers Criteria was applied to
identify PIM use. There was a total of 1,161 medications prescribed to this group. Almost
10% of the sample was prescribed a PIM. Additionally, almost 45% were prescribed the
wrong combination of medications (Gallagher, 2001). Perri et al. (2005) also included 1997
Beers Criteria in their evaluation of PIM use in a study that specifically focused on Georgia
nursing home residents. In their cohort design, Perri and colleagues (2005) included 1,117
medical records of elderly patients residing in 15 nursing homes. Using 1997 Beers Criteria
as a guide to define PIMs, a team of pharmacists performed retrospective medication
reviews of each record. Unlike previous studies, Perri et al. (2005) used all medications
listed on 1997 Beers Criteria to identify PIM use. Results from this study indicate that over
46% of Georgia nursing home residents were prescribed at least one PIM in Beers Criteria
(Perri et al., 2005). Additionally, Perri and colleagues (2005) also determined that
polypharmacy increased the likelihood of receiving a PIM.
Stevenson and colleagues (2014) also used nursing home residents in a
retrospective cohort study to examine the use of high-risk PIMs before and after
hospitalization. The 2003 version of Beers Criteria was used to identify high-risk
medications. Not all medications on 2003 Beers Criteria were used in the study, but
Stevenson and colleagues (2014) focused specifically on those medications on 2003 Beers
Criteria categorized with a high severity rating independent of medical condition or
diagnosis (Fick et al., 2003). Several national datasets were used to conduct the analysis,
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including demographic characteristics from the Medicare Beneficiary Summary, inpatient
claims obtained from Medicare Provider and Analysis Review, and pharmacy claims
obtained from Omnicare (Stevenson et al., 2014). The study included 52,559 nursing home
residents over the age of 65 hospitalized and discharged to the same nursing home in 2008.
Stevenson et al. (2014) examined the use of high-risk medications 30 days before
hospitalization and 30 days after return to the nursing home. Over 20% of nursing home
residents that were hospitalized used at least one high-risk PIM before hospitalization.
Interestingly, of that group, less than half were using a high-risk PIM immediately
following discharge. However, 60% had returned to using a high-risk PIM at the end of the
30 days post-discharge (Stevenson et al., 2014). Results from this study indicate that
nursing homes can impact the frequency of PIM use.
Also using 2003 Beers Criteria, Fick, Mion, Beers, and Waller (2008) conducted a
nation-wide retrospective cohort study using administrative claims data to evaluate the
prevalence of PIM use in 17,971 community-dwelling older adults. Not all medications
included on 2003 Beers Criteria were used. Fick and colleagues (2008) included those
medications and classes that should be generally avoided in the elderly (Fick et al., 2003)
to define PIM use, and medications categorized on 2003 Beers Criteria as those to avoid
while considering diagnosis or condition were excluded from this study. Results from this
study indicate that over 40% filled a prescription for one PIM and almost 14% filled a
prescription for two or more PIMs (Fick et al., 2008).
Davidoff et al. (2015) and Jirón et al. (2016) each conducted a retrospective cohort
study that included a national sample of Medicare beneficiaries aged 65 and older and used
the 2012 Beers Criteria to identify the prevalence of PIM use in this group. Davidoff and
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colleagues (2015) identified a sample of 18,475 community dwelling older adults using at
least one prescription medication according to the 2006-2010 Medical Expenditure Panel
Survey. Not all medications included on 2012 Beers Criteria were used in the study.
Davidoff and colleagues (2015) specifically included 36 medication classes classified on
2012 Beers Criteria as medications to avoid in older adults (American Geriatrics Society,
2012). Analysis of the prevalence of PIM use from this study identified over 42% of the
sample filled a prescription for at least one PIM included on 2012 Beers Criteria.
Nonsteroidal anti-inflammatory drugs had the highest prevalence of use in this population
(Davidoff et al., 2015).
Jirón et al. (2016) included 38,250 individuals and 1,308,116 observations derived
from Medicare fee-for-service claims data in their analysis of prevalence of PIM use. Those
medications included on 2012 Beers Criteria classified as medications to avoid and
medications to be used with caution in older adults (American Geriatrics Society, 2012)
were used to define PIMs. Insulin dosed on a sliding scale and all medication classes
categorized on 2012 Beers Criteria as those to avoid in older adults with certain diseases
and conditions (American Geriatrics Society, 2012) were excluded in this analysis. PIM
use for a one month period in 2012 was identified in over 34% of the sample, indicating
that one in three elderly adults use a PIM each month. PIM use over a calendar year period
in 2012 was identified in over 56% of the sample, indicating that one out of every two older
adults is exposed to a PIM each year (Jirón et al., 2016). Polypharmacy (use of five or more
medications in this study) was identified in almost 40% of the population, and nearly 10%
used 10 or more medications. Results from this study, as well as the previous studies
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mentioned above, indicate that the prevalence of PIM use in the U.S. remains a clinical
concern.
2.6.2

Prevalence of PIMs Using Beers Criteria (Non-U.S. studies)
Sixteen studies using Beers Criteria as the only medication evaluation tool have

been conducted outside of the U.S. to describe prevalence of PIM use in other parts of the
world. There were no studies identified that used the 1991 initial version of Beers Criteria
to describe PIM prevalence outside of the U.S. Of the 16 international studies of PIM
prevalence, two studies used both the 1997 and 2003 versions of Beers Criteria (Martins,
Soares, Mil, & Cabrita, 2006; Van Der Hooft et al., 2005), six studies used the 2003 version
of Beers Criteria (Gallagher, Barry, Ryan, Hartigan, & Omahony, 2007; Kondo et al., 2014;
Lai et al., 2009; Lin, Peng, Chen, Lin, Hwang, 2011; Niwata, Yamada, & Ikegami, 2006;
Ruggiero et al., 2010), one study used both the 2003 and 2012 versions of Beers Criteria
(Tsao et al., 2016), and six studies used the 2012 version of Beers Criteria (Ble et al., 2015;
Danisha et al., 2015; Dörks, Herget-Rosenthal, Schmiemann, Hoffmann, 2016; Nam, Han,
Kim, Bae, & Lee, 2016; Narayan & Nishtala, 2015; Reich, Rosemann, Rapold, Blozik, &
Senn, 2014).
Martins, Soares, Mil, and Cabrita (2006) conducted an observational crosssectional study to identify PIM use in 213 elderly outpatients residing in Lisbon, Portugal.
Twelve community pharmacies were selected to identify patients that presented with a
prescription for two or more medications. Select medications from the 1997 and 2003
versions of Beers Criteria were used to define PIMs. There were 1,543 total medications
reported, and the sample was prescribed an average of 7 medications. The maximum
number of medications observed in a patient was 17 (Martins et al., 2006). Using 1997
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Beers Criteria, a PIM was identified in almost 28% of the patients. The 2003 Beers Criteria
was more robust in identifying PIM use. Almost 39% of the patients were prescribed at
least one PIM according to 2003 Beers Criteria (Martins et al., 2006).
Van Der Hooft and colleagues (2005) also used the 1997 and 2003 versions of
Beers Criteria to examine the prevalence of PIM use in the Netherlands from 1997 through
2001. Medications included on either version of Beers Criteria that were not marketed in
the Netherlands were excluded. This population-based cohort study included ambulatory
adults aged 65 years and older. Results identified 20% of patients were using at least one
PIM each year (Van Der Hooft et al., 2005).
The 2003 version of Beers Criteria has been used most frequently to define PIM
use in other countries. Gallagher, Barry, Ryan, Hartigan, and Omahony (2007) conducted
a prospective, observational study to determine the prevalence of PIM use within
community-dwelling older adults that were hospitalized. The study population included
597 consecutive acute care admissions, and over 95% of the sample was taking at least one
medication. Beers Criteria were used to identify 32% of patients who used at least one PIM
prior to hospitalization. Polypharmacy (use of 5 or more medications in this study) was
also attributed to a greater likelihood of using PIMs included on 2003 Beers Criteria
(Gallagher et al., 2007).
Two studies conducted in Japan used 2003 Beers Criteria. Kondo et al. (2014)
focused specifically on PIM use in patients receiving hemodialysis. Using a cross-section
design, data of 1,367 hemodialysis patients over the age of 65 was analyzed. Beers Criteria
were modified to account for PIMs available in Japan and was used to identify PIMs in the
cohort. The frequency of PIM use in this population was 57%. Similar to previous studies,
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the greater the number of mediations used, the greater the likelihood of PIM use. For
example, in patients consuming greater than 10 medications, 75% were classified as
inappropriate (Kondo et al., 2014). Niwata, Yamada, and Ikegami (2006) employed a
retrospective, cross-sectional study of PIM use in 17 LTC facilities. Beers Criteria was
used to identify PIMs, and medications included on 2003 Beers Criteria that were not
available in Japan or medications in which long-term use was unable to be tracked were
excluded. Prescription data was analyzed for 1,669 LTC residents aged 65 and older. Over
21% of patients received at least one PIM (Niwata et al., 2006).
Two studies conducted in Taiwan used 2003 Beers Criteria. Lai et al. (2009)
evaluated the prevalence of PIM prescribing in ambulatory care settings. Beers Criteria
was modified to exclude medications not available or medications classified as controlled
substances in Taiwan, and the remaining medications included on 2003 Beers Criteria were
used to identify PIMs. Patients aged 65 years and older and covered by the national health
insurance program were included. Of the 176,661,994 ambulatory care visits involving a
medication prescription that occurred from 2001 to 2004, almost 20% of the visits
represented a prescription of a PIM included on 2003 Beers Criteria (Lai et al., 2009). Lin,
Peng, Chen, Lin, and Hwang (2011) conducted a retrospective analysis of 327 patients over
the age of 65 receiving care in an outpatient community health center in rural Taiwan.
Using a modified version of 2003 Beers Criteria to identify PIMs, 105 PIMs were identified
in the study sample, and almost 28% of the patients were prescribed at least one PIM (Lin
et al., 2011).
Ruggiero et al. (2010) employed a prospective study to analyze PIM use in 31
Italian LTC facilities. A total of 1,716 residents aged 65 years and older receiving long-
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term medication treatment (continuous use of a medication at least 3 months before
baseline) were evaluated at baseline, 6 month, and 12 month time periods (Ruggiero et al.,
2010). The 2003 version of Beers Criteria was used to identify PIMs. The average number
of medications consumed per patient was over 5, and almost 50% of the cohort received at
least one PIM. Nearly 20% received two or more PIMs (Ruggiero et al., 2010).
Using both the 2003 and 2012 Beers Criteria, Tsao and colleagues (2016) describe
the prevalence of PIM use in frail elderly patients receiving home care in Taiwan. Using a
retrospective study design, 145 patients over the age of 60 receiving prescription
medications for chronic diseases for longer than four weeks were included in analysis (Tsao
et al., 2016). The 2003 and 2012 versions of Beers Criteria were used separately to identify
PIMs. Medications listed on 2012 Beers Criteria that should be used with caution
(American Geriatrics Society, 2012) were excluded from analysis. Of the 145 patients
analyzed, 81 patients (just under 60%) received PIMs according to 2003 Beers Criteria,
compared to 97 patients (almost 70%) that received PIMs based on 2012 Beers Criteria.
The 2012 Beers Criteria has been used in six prevalence studies (Ble et al., 2015;
Danisha et al., 2015; Dörks, Herget-Rosenthal, Schmiemann, Hoffmann, 2016; Nam, Han,
Kim, Bae, & Lee, 2016; Narayan & Nishtala, 2015; Reich, Rosemann, Rapold, Blozik, &
Senn, 2014) in Germany, India, Korea, New Zealand, Switzerland, and the United
Kingdom. Dörks, Herget-Rosenthal, Schmiemann, and Hoffmann (2016) focused on one
medication class represented in Beers Criteria. The goal of this multi-center cross-sectional
study was to examine the prevalence of NSAID use specifically in German nursing home
patients with severe renal failure (Dörks et al., 2016). A total of 685 patients were included
in the study, of which 106 patients had severe renal failure. Roughly 20% of the total study
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population and 20% of the severe renal failure group were treated with at least on NSAID
included on 2012 Beers Criteria (Dörks et al., 2016). Danisha and colleagues (2015)
conducted a prospective observational prevalence study in a 350-bed inpatient hospital in
India. All patients over the age of 60 that were hospitalized were included in the study
(n=200), and 1,690 prescriptions were analyzed. The 2012 version of Beers Criteria was
applied to define PIMs. Over 50% of the 200 patients were prescribed at least one PIM
(Danisha et al., 2015).
Four population level studies of PIM prevalence were conducted using 2012 Beers
Criteria (Ble et al., 2015; Nam, Han, Kim, Bae, & Lee, 2016; Narayan & Nishtala, 2015;
Reich, Rosemann, Rapold, Blozik, & Senn, 2014). Ble and colleagues (2015) adapted 2012
Beers Criteria for the United Kingdom in their prevalence study. The study was limited to
an analysis of 34 drugs or classes to avoid in older adults. Three cross-section samples of
primary care medical records from 2003-2004, 2007-2008, and 2011-2012 were analyzed
to understand the prevalence of PIM use and prescribing patterns over time (Ble et al.,
2015). A sample of 13,900 primary care patients aged 65 years and older was included for
analysis. The total number of medications and PIMs deemed high risk were calculated for
each year for each patient included in the study. Results from this study demonstrate that
the number of medications used increased over time. Nearly 40% of patients were exposed
to a PIM deemed to be high-risk, and over 17% of those patients were classified as longterm consumers of PIMs. Increase in polypharmacy was also detected, and the number of
patients using 10 or more medications increased to 24% by 2011-2012 (Ble et al., 2015).
Narayan and Nishtala (2015) performed a cross-sectional analysis pharmaceutical
claims data to examine the prevalence of PIM use in older adults living in New Zealand.
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A total of 537,387 community-dwelling and residential care individuals were included in
the analysis. Those medications from 2012 Beers Criteria available in New Zealand were
used to identify PIMs. PIM use was identified in over 40% of the individuals. Nearly 80%
of those were prescribed at least one PIM, and over 20% were prescribed two or more
PIMs. Reich, Rosemann, Rapold, Blozik, and Senn (2014) used five years of insurance
claims data to describe prevalence of PIM use in community-dwelling managed care
patients living in Switzerland. The 2012 version of Beers Criteria was used to identify
PIMs. Over 22% of managed care patients were prescribed at least one PIM (Reich et al.,
2014).
A retrospective cross-sectional population based study was conducted in Korea to
study the prevalence of PIM use in elderly outpatients (Nam, Han, Kim, Bae, & Lee, 2016).
Select classes of medications represented in 2012 Beers Criteria were used to identify
PIMs. Some medication classes were excluded, and those medications not available in
Korea were also excluded. Using outpatient prescription claims data for three years (20092011), Nam et al. (2016) included 523,811 adults aged 65 years or older that filled at least
one prescription during the study period. A total of 45,727,527 prescriptions were
analyzed. Over 80% of the patients included were prescribed at least one PIM included in
Beers Criteria (Nam et al., 2016).
2.6.3

Prevalence of PIMs Using Beers Criteria and other evaluation tools (U.S.

studies)
While Beers Criteria remains the most frequently used medication evaluation tool
for the elderly in clinical practice (Griebling et al., 2016), few studies have been conducted
that have used Beers Criteria and at least one additional medication evaluation process to
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describe the prevalence of PIM use in the U.S. Two studies used the 1997 version of Beers
Criteria along with another tool. One study was conducted on a national level (Goulding,
2004), and one study was conducted at the state level (Cannon, Choi, & Zuniga, 2006).
Two additional state-level studies were conducted in VA settings in Iowa using the 2003
version of Beers Criteria along with the MAI (Lund, Carnahan, Egge, Chrischilles, &
Kaboli, 2010; Steinman et al., 2006).
Goulding (2004) examined trends in the prevalence of PIM use in patients receiving
care in ambulatory care settings. Data from two national datasets were used, including the
National Ambulatory Medical Care Survey, which provides data from physician office
settings, and the National Hospital Ambulatory Medical Care Survey, which provides data
from hospital outpatient and emergency departments (Goulding, 2004). Only those
medications included on 1997 Beers Criteria that were classified as medications that should
generally be avoided regardless of medical condition or medication dosage (Beers, 1997)
were included in the study. In addition to using Beers Criteria to identify PIMs, Goulding
(2004) also used a drug classification developed by Dr. Chunliu Zhan in 2001 (Zhan et al.,
2001). The 1997 Beers Criteria provides a list of PIMs and classifies the medications based
on high or low severity (Beers, 1997). Dr. Zhan further categorized the medications
included on 1997 Beers Criteria into specific groups, and Goulding focused specifically on
those medications classified as always avoid” or “rarely appropriate” (Goulding, 2004). In
1995 and 2000 Goulding (2004) identified that nearly 8% of ambulatory care visits
included a prescription for at least one PIM included on 1997 Beers Criteria. Additionally,
of those PIMs prescribed, nearly 4% of the PIMs were classified by Zhan (Zhan et al.,
2001) as never or rarely appropriate (Goulding, 2004).
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In a retrospective chart review of older adults receiving home healthcare in Texas,
Cannon, Choi, and Zuniga (2006) analyzed medication use of 786 patients to determine
prevalence of PIM use in home health settings. In addition to using the 1997 Beers Criteria
to identify PIMs, Cannon and colleagues (2006) also used criteria from the
Multidisciplinary Medication Management Project developed by the American Medical
Directors Association and the American Society of Consultant Pharmacists. This criterion
was developed to improve prescribing in LTC settings, and Cannon and colleagues (2006)
used the criteria to identify those medications with a dangerous drug interaction. Over 30%
of the patients included in the study were prescribed at least one PIM, and of those
medications 10% were considered to have a dangerous drug interaction. Polypharmacy was
also identified in this study, with 8 medications on average that were used in home health
patients and nearly 40% of patients receiving polypharmacy (Cannon et al., 2006).
Lund and colleagues (2010) and Steinman et al. (2006) studied patients over the
age of 65 receiving care in VA facilities in Iowa. Both studies included 2003 Beers Criteria
and the MAI. In a sample of 236 patients, Lund and colleagues (2010) identified issues of
PIM use and polypharmacy. According to the MAI, patients received over 10 medications
on average. Almost half of the sample was prescribed at least one medication included on
2003 Beers Criteria (Lund et al., 2010). Steinman et al. (2006) conducted a cross-sectional
study in which outpatient veterans over the age of 65 using five or more medications were
included in the study (n=196). Steinman and colleagues (2006) used 2003 Beers Criteria
to identify PIMs. The MAI was used to determine whether the medications were duplicate
therapies, ineffective, or not indicated for use in this population (Steinman et al., 2006).
The researchers also used the Assessment of Underutilization of Medications to determine
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whether medications were underused (Steinman et al., 2006). Results from this study
indicate that patients were prescribed an average of 8 medications. PIMs included on 2003
Beers Criteria were prescribed to 65% of the sample, of which 57% were prescribed a
duplicate, ineffective, or not indicated medication according to MAI (Steinman et al.,
2006). Using both 2003 Beers Criteria and the Assessment of Underutilization of
Medications, both inappropriate and underuse of medications was identified in 64% of
patients (Steinman et al., 2006).
2.6.4

Prevalence of PIMs Using Beers Criteria and other evaluation tools (Non-

U.S. studies)
Fourteen studies have used Beers Criteria and at least one additional medication
evaluation process to describe the prevalence of PIM use outside of the U.S. Most of the
international research of the prevalence of PIM use has used Beers Criteria and
STOPP/START (Blanco-Reina, Ariza-Zafra, Ocaña-Riola, & León-Ortiz, 2014; Dalleur et
al., 2015; Fadare et al., 2015; Gallagher & O’Mahony, 2008; Grace et al., 2014; Hudhra et
al., 2014; Nicieza-Garcia, Salgueiro-Vazquez, Jimeno-Demuth, & Manso, 2016; Oliveira
et al., 2015; Rongen et al., 2016; Ubeda et al., 2012; Yang et al., 2015). One study used
Beers Criteria and the IPET (Barry, O'Keefe, O'Connor, & O'Mahony, 2006), one study
used Beers Criteria, IPET, and STOPP/START (Di Giorgio, Provenzani, & Polidori,
2016), and one study (Chang et al., 2015) used Beers Criteria and a Taiwan-specific
evaluation process to evaluate prevalence of PIM use. Those studies which used Beers
Criteria and the IPET (Barry, O'Keefe, O'Connor, & O'Mahony, 2006) or Beers Criteria
and STOPP/START (Blanco-Reina, Ariza-Zafra, Ocaña-Riola, & León-Ortiz, 2014;
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Fadare et al., 2015; Grace et al., 2014; Oliveira et al., 2015) that have been discussed
previously in section 2.2 are not included in this section.
Chang et al. (2015) conducted a national cross-section study of PIM use in
ambulatory care settings in Taiwan. The 2012 Beers Criteria was used along with a list of
PIMs specifically generated for Taiwan to identify PIMs in 1,164,701 patients over the age
of 65 that visited an ambulatory care center in 2009 (Chang et al., 2015). Beers Criteria
was successful in identifying over 86% of patients that received at least on PIM compared
to 73% of patients using PIM according to the Taiwan list of PIMs (Chang et al., 2015). Di
Giorgio, Provenzani, and Polidori (2016) compared 2012 Beers Criteria, STOPP/START,
and the IPET to describe PIM use in before and during hospitalization in a sample of Italian
older adults. After analyzing 1,027 hospitalizations, STOPP/START identified 21% of
patients with PIMs at admission and 27% who received a PIM during hospitalization
compared to 28% of PIM users at admission and 25% during hospitalization according to
the IPET (Di Giorgio et al., 2016). Beers Criteria was the most successful medical
evaluation tool to identify PIM use in this population. Results indicate that 24% of patients
used a PIM at admission and 49% were prescribed a PIM during hospitalization (Di
Giorgio et al., 2016).
An additional seven studies (Dalleur et al., 2015; Fadare et al., 2015; Gallagher &
O’Mahony, 2008; Grace et al., 2014; Hudhra et al., 2014; Nicieza-Garcia, SalgueiroVazquez, Jimeno-Demuth, & Manso, 2016; Rongen et al., 2016; Ubeda et al., 2012; Yang
et al., 2015) identified in the literature that were not previously discussed in section 2.2.2
used Beers Criteria and STOPP/START to evaluate PIM use prevalence in the elderly.
Gallagher and O’Mahony (2008) and Ubeda and colleagues (2012) each used 2003 Beers
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Criteria and STOPP/START. Gallagher and O’Mahony (2008) conducted a prospective
study of acute care admissions in a teaching hospital in Ireland. A total of 715 consecutive
admissions were analyzed for PIM use. PIM use in the population was as high as 35%
according to STOPP/START and 25% using 2003 Beers Criteria (Gallagher and
O’Mahony, 2008). Ubeda and colleagues (2012) conducted a cross-sectional retrospective
study of 81 institutionalized patients residing in a region of Spain. Medication and clinical
records were reviewed, and STOPP/START and 2003 Beers Criteria were used to identify
as many as 48% of nursing home patients received a PIM (Ubeda et al., 2012).
Dalleur et al. (2015), Hudhra et al. (2014), Nicieza-Garcia, Salgueiro-Vazquez,
Jimeno-Demuth, and Manso (2016), Rongen et al. (2016), and Yang et al. (2015) each used
the 2012 version of Beers Criteria and STOPP/START to evaluate prevalence of PIM use.
Dalleur and colleagues (2015) included 567 Belgian primary care patients over the age of
80 in their cross-sectional analysis. Beers Criteria was successful in identifying PIM use in
32% of the sample according (Dalleur et al., 2015). Using a cross-sectional design, Hudhra
and colleagues (2014) analyzed prescriptions in 624 patients over the age of 65 discharged
from a hospital in Spain. Almost 23% of the patients were prescribed at least one PIM
included on 2012 Beers Criteria at discharge, and roughly 14% of patients were prescribed
PIMs at discharge that are included on both 2012 Beers Criteria and 2008 STOPP criteria
(Hudhra et al., 2014). Nicieza-Garcia, Salgueiro-Vazquez, Jimeno-Demuth, and Manso
(2016) focused specifically on PIM prevalence in community-dwelling older patients
receiving polypharmacy (10 or more medications used daily in this study) in Spain. Over
63% of patients receiving polypharmacy were also using at least one PIM included on 2012
Beers Criteria (Nicieza-Garcia et al., 2016). Rongen and colleagues (2016) conducted a
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cross-sectional study evaluating PIM use in 164 psychiatric hospital patients in the
Netherlands. A total of 1,269 medications were evaluated, and almost 50% of patients were
using a PIM include on 2012 Beers Criteria (Rongen et al., 2016). Yang and colleagues
(2015) studied PIM use in 141 disabled patients with chronic disease aged 65 years and
older from Taiwan. STOPP criteria and 2012 Beers Criteria each identified at least one
PIM in almost 67% of the sample (Yang et al., 2015).

Beers Criteria is commonly used to evaluate PIM use in the elderly in clinical and
residential settings, and there are other medication evaluation tools available to clinicians
to appropriately evaluate medication use in the elderly. However, PIM use in older adults
has been prevalent for several decades and is likely to continue in the years ahead. The
prevalence of PIMs is not limited to just a few select healthcare settings. Rather PIM use
has been detected in all healthcare settings, including acute care, ambulatory care, primary
care, psychiatric facilities, VA centers, long term care, and home care settings. Use of PIMs
included in Beers Criteria remains a widespread health concern for the elderly population.
Not only is the prevalence of PIM use in older adults a national health concern in the U.S.,
but research indicates that PIM use is a global problem as well.
2.7

Using Beers Criteria to Measure Health Outcomes
Although it is important to understand the frequency of PIM use in various

healthcare settings, it is just as important to consider the consequences those medications
can have on the health and well-being of patients. While previous research of Beers Criteria
has focused primarily on prevalence of PIM use, some studies have examined the negative
health outcomes associated with PIM use in the U.S. and globally. The studies included in
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this review will highlight the significant and negative outcomes that are associated with
using PIMs included in Beers Criteria based on research conducted in the U.S., Australia,
Japan, Sweden, and Taiwan. The primary health outcomes represented in research of Beers
Criteria include hospitalizations, ED visits, institutionalization in LTC facilities, ADEs,
and impact on quality of life.
2.7.1

Hospitalizations, ED Visits, & Institutionalization
Nine studies included in this review measured the impact PIMs included in Beers

Criteria has on hospitalizations, ED visits, or LTC admission (Brown, Hutchison, Li,
Painter, & Martin, 2016; Budnitz, Shehab, Kegler, & Richards, 2007; Chin et al., 1999;
Fillenbaum et al., 2004; Klarin, Wimo, & Fastbom, 2006; Lau, Kasper, Potter, Lyles, &
Bennett, 2005; Price, Holman, Sanfilippo, & Emery, 2014; Price, Holman, Sanfilippo, &
Emery, 2015; Zuckerman et al., 2006). Using the 1991 and 1997 Beers Criteria and data
from the 1996 Medical Expenditure Panel Survey Nursing Home Component, Lau, Kasper,
Potter, Lyles, and Bennett (2005) studied the relationship between PIM use and
hospitalization within a sample of 3,372 patients over the age of 65 that stayed in a nursing
home for three consecutive months or longer. Results from this study indicate that patients
receiving a PIM included in Beers Criteria had over 1.2 greater odds of being hospitalized
the following month compared to patients that were not using a PIM (Lau et al., 2005).
Patients using PIMs for two consecutive months had close to a 30% greater risk for
hospitalization compared to patients taking non-PIMs (Lau et. al, 2005). Additionally,
patients using Beers Criteria PIMs had a 28% greater risk of death compared to patients
not using PIMs (Lau et al., 2005).
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Chin and colleagues (1999) conducted a prospective cohort study that included 898
patients that were admitted to a Chicago ED in 1995 and 1996. Medications that patients
received in the ED and at discharge were collected, and patients were surveyed during their
ED visit and at two weeks and three months post-discharge (Chin et al., 1999). The team
used 1997 Beers Criteria to identify PIMs. Health outcomes, specifically ED revisits and
hospitalizations, were calculated. Within three months of discharge from the ED, almost
20% of patients returned to the ED and almost 20% were hospitalized. Additionally, 10%
of the patients included in the study experienced a death (Chin et al., 1999). Of the patients
that experienced an ED revisit, hospitalization, or death, over 20% previously used a PIM
(Chin et al., 1999).
Klarin, Wimo, and Fastbom (2006) employed a population-based, longitudinal
study to analyze the relationship between PIMs and hospitalization within a cohort of 785
community-dwelling residents of rural Sweden over the age of 75. Hospitalization and
mortality data was collected for three years, and 1997 Beers Criteria was used to identify
PIM use (Klarin et al., 2006). Results from this study demonstrate that PIM use was present
in almost 20% of the cohort, and PIM use was associated with an increased-risk for
hospitalization (Klarin et al., 2006). Fillenbaum et al. (2004) also used 1997 Beers Criteria
in their analysis of PIM related hospitalizations. Community-dwelling patients included in
the study that used a PIM in Beers Criteria had a 20% greater risk of hospitalization.
Budnitz and colleagues (2007) conducted a nationally representative study using public
health surveillance data to estimate the frequency and risk of an ED visit for patients over
the age of 65 using select PIMs included on 2003 Beers Criteria. Budnitz et al. (2007)
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analyzed 177,504 ED visits of which almost 4% of the ED visits were attributed to a Beers
Criteria PIM generated ADE.
Two studies included in this review (Price, Holman, Sanfilippo, & Emery, 2014;
Price, Holman, Sanfilippo, & Emery, 2015) included an analysis of hospitalizations due to
PIM use in Australia. Price et al. (2014) conducted an analysis of pharmaceutical claims
for 251,305 older adults using medications classified as high risk. Eight specific high-risk
PIMs represented in 2003 Beers Criteria were included in the study. Results from this study
indicate that all included medications (amiodarone, diazepam, digoxin, ferrous sulphate,
indomethacin, naproxen, oxazepam, and temazepam) were associated with increased risk
of hospitalization (Price et al., 2014). Indomethacin and naproxen (both are NSAIDs and
included on 2003 Beers Criteria) were attributed to the greatest risk for hospitalization.
Price and colleagues (2015) also studied rates of hospitalization in patients receiving PIMs
on 2003 Beers Criteria. Patients in this study also received varying levels of primary care.
A total of 245,436 Australians over the age of 65 with at least one pharmaceutical claim of
a PIM included on 2003 Beers Criteria were analyzed (Price et al., 2015). Results from this
study indicate that regardless of the level of primary care received, using PIMs included in
Beers Criteria increased the risk of hospitalization as much as 36% (Price et al., 2015).
Brown and colleagues (2016) conducted a retrospective cohort study analyzing
managed care administrative data for 174,275 commercially insured adults over the age of
65. Both 2003 and 2012 Beers Criteria were used in the study, as well as STOPP criteria
to determine the relationship between PIMs and hospitalizations and ED visits. Over 41%
of the cohort used a PIM. Results from this study indicate that using PIMs was associated
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with anywhere from two to three times greater risk for hospitalization and ED visits (Brown
et al., 2016).
Zuckerman and colleagues (2006) conducted a retrospective cohort study using
three years of data from the MarketScan Medicare Supplemental and Coordination of
Benefits database to examine the relationship between PIM use and admission into LTC
facilities. Patients were included if they were over the age of 65 and had not previously had
a nursing home admission for one year prior to the study (Zuckerman et al., 2006). Subjects
were followed until they were admitted to a nursing home, lost to follow-up, or the twoyear study period ended. A total of 487,383 subjects were included in the study, and 22,042
were admitted to a nursing home (Zuckerman et al., 2006). Medication use was also
analyzed, and PIMs were identified using 2003 Beers Criteria. Results from this study
indicate that patients receiving a PIM in Beers Criteria had a 31% increased risk of being
admitted to a nursing home compared to patients that used non-PIMs (Zuckerman et al.,
2006).
2.7.2

ADEs
Four studies (Brown, Hutchison, Li, Painter, & Martin, 2016; Chang et al., 2005;

Kanaan et al., 2013; Onda et al., 2015) included in this review specifically analyzed ADEs
attributed to use of PIMs included in Beers Criteria. Previously discussed above, Brown
and colleagues (2016) also included risk of experiencing an ADE due to PIM use as one of
the primary outcomes of interest. As was the case with hospitalizations and ED visits in
this study, PIM use was also associated with an increased risk of experiencing an ADE
(Brown et al., 2016).
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Chang et al. (2005) employed a prospective cohort study in Taiwan to evaluate if
PIMs included on 1997 Beers Criteria were associated with ADEs in an outpatient setting.
The study included 882 patients over the age of 65 that were prescribed at least one
medication at an outpatient visit (Chang et al., 2005). Participants were surveyed one week
following the outpatient visit, and information collected during the survey included ADEs
that occurred within one week of receiving the prescription. All reported ADEs were
independently evaluated. Of the 882 participants, phone surveys were completed for 550
patients. Almost 12% of the respondents were using a PIM, and a total of 126 patients
experienced an ADE within one week of the outpatient visit (Chang et al., 2005). In this
study, Beer Criteria PIM use was associated with a higher risk of experiencing an ADE.
Additionally, medication non-compliance and polypharmacy were also associated with a
higher risk of ADEs (Chang et al., 2005).
Using a nation-wide survey completed by pharmacists in Japan, Ondo et al. (2015)
identified PIM-related ADEs present in older adults receiving home health care. The 2003
version of Beers Criteria, modified for medications available in Japan, was used to classify
medications as PIMs. Survey data for 4,243 patients was analyzed. Almost 3,000 total
PIMs were prescribed, and almost 50% of those surveyed received a PIM prescription.
PIMs were responsible for 182 ADEs (Ondo et al., 2015). Ondo and colleagues (2015)
identified five PIMs included in Beers Criteria that were responsible for the majority of
ADEs, and short-acting benzodiazepines were responsible for almost 41% of ADEs. The
most common ADEs attributed to benzodiazepine use included lightheadedness,
sleepiness, and drowsiness (Ondo et al., 2015).
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Kanaan and colleagues (2013) conducted a review of 1,000 consecutive ambulatory
care discharge records from Massachusetts. The goal was to identify ADEs that occur
within 45 days post-discharge (Kanaan et al., 2013). Patients included in the study were
over the age of 65 and discharged to the community. Medications responsible for the ADEs
were recorded, and 2012 Beers Criteria was used to identify PIMs. From the 1,000 records,
330 drug-related events occurred within the 45 day period post-discharge and 242 were
categorized as an ADE (Kanaan et al., 2013). Of the 242 ADEs identified, “35% were
considered to be preventable, 32% of which were serious and 5% life threatening” (Kanaan
et al., 2013, p. 1896). Within the class of preventable ADEs, over 50% were occurred as a
result of medication prescribing errors (i.e. wrong medication or wrong dose prescribed)
(Kanaan et al., 2013). Results from this study indicate that Beers Criteria PIMs were
responsible or almost 17% of the ADEs (Kanaan et al., 2013).
2.7.3

Quality of Life
Two studies (Fu, Liu, & Christensen, 2004; Franic & Jiang, 2006) included in this

review investigated the relationship between Beers Criteria PIMs and the impact on quality
of life or health status. Fu, Liu, and Christensen (2004) conducted a national study of the
impact PIM use has on health outcomes, specifically on self-perceived health status. The
Medicare Expenditure Panel Survey served as the data source in the study, and 2,305
patients were selected to be representative of the U.S. population of adults over the age of
65. Information collected in this data source included an individual patient’s rating of their
own health status (very good, good, fair, or poor) compared to others their age (Fu et al.,
2004). Not all medications included in Beers Criteria were used in the study. Twenty-three
medications included on 1997 Beers Criteria were used to define PIM use in the population.
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Within the sample, 306 patients were classified as PIM users. Results from the survey data
indicate that PIM use is significantly more likely to negatively impact a patient’s perception
of their health status compared to patients that use medications classified as appropriate
(Fu et al., 2004).
Franic and Jiang (2006) also used the Medicare Expenditure Panel Survey in their
longitudinal retrospective cohort study of the relationship between select PIMs included
on 2003 Beers Criteria and health-related quality of life. Two common and widely used
measures, the Short Form-12 and EuroQol’s EQ-5D, were used to measure health related
quality of life (Franic & Jiang, 2006). Participants were divided into case and control
groups. There were 74 patients that received PIMs were included in the case group, and
370 patients that had appropriate medication use served as controls. The case group
received more medications in general compared to the control group, with over 77% of
cases received anywhere from five to 20 medications (Franic & Jiang, 2006). The number
of prescriptions patients used is important to highlight as results from this study indicate
that the number of prescriptions is a predictor for impact on health related quality of life.
Results from this study also indicate that PIM use was associated with worse scores on the
measures of health-related quality of life (Franic & Jiang, 2006).

As PIM use remains prevalent throughout the U.S. and other parts of the world,
evidence suggests that Beers Criteria medications are linked to negative health outcomes,
and it is expected that poor outcomes will continue as Beers Criteria medications continue
to be prescribed in the future. Based on results from previous research, PIM use has serious
implications on the health and well-being of older adults. PIM users face a greater risk of
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hospitalization and institutionalization than those elderly patients using appropriate
medications. Mortality rates are also impacted by PIM use, and elderly patients face a
greater risk of death when prescribed PIMs. Patients are also more likely to experience a
PIM-related ADE. ADEs attributed to PIMs in Beers Criteria negatively impact a patient’s
quality of life and are associated with a decline in functional status and diminished ability
to perform activities of daily living.
2.8

Using Beers Criteria in Technology-Based Studies
As the use of technology assisted programs and electronic medical records becomes

more prevalent, it is important to highlight how Beers Criteria has previously been
integrated into technology-based intervention studies aimed to modify clinician behavior
as it relates to medication management in elderly patients. A recently published study
conducted in Canada developed a new technology system to evaluate clinical decision
making within electronic medical records and the impact it has on improving medication
prescribing in the elderly (Alagiakrishnan et al., 2016). Colleagues in Boston,
Massachusetts conducted a prospective before-and-after study to evaluate whether PIM
prescriptions could be reduced through a computerized order entry warning (CPOE) system
(Mattison, Afonso, Ngo, & Mukamal, 2010). Terrell and colleagues (2009) and Raebel and
colleagues (2007) each utilized a randomized, controlled trial using computer-assisted
support to reduce PIM prescribing in the elderly.
Recognizing the impact polypharmacy and inappropriate medication use has in the
elderly, Alagiakrishnan and colleagues (2016) aimed to demonstrate that incorporating
medication alerts into an electronic medical record can improve medication safety.
Additionally, the research team evaluated how this alert technology would best be used by
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clinicians without disrupting their clinical workflow. An interesting component of this
study was the use of both qualitative and quantitative methods (an approach not commonly
used in previous studies of Beers Criteria). The intervention used was the Seniors
Medication Alert and Review Technology, referred to as SMART. The 2012 version of
Beers Criteria was integrated in the SMART application. Several types of events were
collected including if clinicians accepted the SMART guidance, if they rejected the
guidance and their reason for rejecting, and if they selected a recommendation or evidence
link in the SMART system for review (Alagiakrishnan et al., 2016). One notable result of
this study was the improvement in adhering to Beers Criteria recommendations through
the SMART system. Clinicians were somewhat familiar with Beers Criteria, but were not
adept in applying Beers Criteria recommendations in their clinical care routine. The
medication alerts and the use of SMART encouraged clinicians to pay close attention to
the drugs patients were already on and to give careful consideration before prescribing
additional medications. Embedding Beers Criteria recommendations directly into the
technology saved time in that clinicians did not have to stop to look up the
recommendations during their clinical routine (Alagiakrishnan et al., 2016).
Mattison and colleagues (2010) incorporated medication-specific alerts into a noncommercialized CPOE system developed in-house within an academic medical center in
Boston. Three medication classes included on 2003 Beers Criteria were used in the study.
All medications were prescribed through the CPOE system, and the system was used with
all hospitalized patients over the age of 65. The primary purpose of the CPOE system was
to alert clinicians when PIMs were ordered and to recommend changing the PIM dose or
recommend an alternative medication. The study team calculated the number of orders of
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medications represented in the three select medication classes that were prescribed to
patients admitted within a six-month period before the CPOE system was in place. The
newly implemented system was tested for roughly five months, after which all medication
orders were recorded for a three-year period. Before-and-after analyses were conducted,
and the mean rate of PIM prescribing decreased from 11.56 to 9.94 orders per day
(Mattison et al., 2010). Results also indicated an immediate reduction in the rate of PIM
orders upon CPOE implementation, and the decrease in PIM orders was sustained over
time. Additionally, adherence to the medication warnings was monitored, and clinicians
showed no signs of being fatigued by repeated alerts and warnings. Results from this study
indicate that CPOE systems can be a useful tool to positively impact clinician prescribing
patterns. Incorporating alerts and alternative medication recommendations in such systems
has the potential to decrease the number of PIMs ordered for elderly hospitalized patients
(Mattison et al., 2010).
Raebel and colleagues (2007) conducted a prospective intervention trial that
included all ambulatory care patients over the age of 65 represented in the Kaiser
Permanente Colorado health maintenance organization. All 59,680 elderly health plan
members were randomized to either an intervention or usual care group, and patients and
providers (clinicians and pharmacists) were blinded to the group assignments. Patients
randomized to the usual care group were prescribed medications according to usual clinical
practice. Eleven PIMs, of which nine are represented in 2003 Beers Criteria, were selected
prior to the study by a group of physicians and pharmacists specializing in geriatric care to
be included as medications of interest in the intervention group. A medication warning
system was used to alert a pharmacist when a patient in the intervention group was
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prescribed one of the 11 PIMs. Upon receiving the medication alert, pharmacists
communicated the medication warning to the provider by phone. Pharmacists did not
receive these warnings for patients in the usual care group (Raebel et al., 2007). A total of
1,187 patients were dispensed at least one of the 11 PIMs included in the study. Medication
alerts and pharmacist intervention impacted PIM use. Of the patients randomized to the
usual care group, 2.2% were dispensed a PIM compared to 1.8% of patients randomized to
the intervention group (Raebel et al., 2007). Raebel and colleagues (2007) also demonstrate
the importance of collaboration between healthcare providers that work specifically with
the elderly population, which is something that cannot be imposed through computerized
systems. In this study, pharmacists were alerted when a PIM was prescribed, but
minimizing PIM dispensing required the pharmacists and physicians to collaborate to
discuss safer medication alternatives (Raebel et al., 2007).
A more recent randomized trial (Terrell et al., 2009) was implemented to evaluate
the use of a computerized decision support system to reduce PIM use in elderly adults
discharged from the ED. Sixty-three physicians from an academic hospital in Indiana were
randomized to an intervention or a usual care control group. Nine medications represented
in 2003 Beers Criteria were selected by an expert panel to be included in the intervention.
The panel also selected safer alternative medications for each of the nine PIMs.
Computerized decision support was only available to the physicians in the intervention
group. When the ED physician attempted to prescribe one of the select nine PIMs at patient
discharge, the computer system alerted the physician. The physician could choose to order
one of the pre-determined safer alternative medications or ignore the alert and
recommendations all together (Terrell et al., 2009). The intervention lasted for

67
approximately 18 months. At least one of the select PIMs was prescribed during 3.9% of
the visits managed by the usual care physicians, compared to 2.6% of the visits managed
by a physician in the intervention group. When comparing the number of PIMs to all
medications prescribed by physicians, the proportion of prescribed PIMs decreased from
5.4% to 3.4% (Terrell et al., 2009).
2.9

Using Beers Criteria to Quantify Impact of PIM Use on Healthcare Costs
Few studies included in this literature review used Beers Criteria medications in

their evaluation of economic outcomes related to PIM use. Very limited information is
available linking the use of PIMs included in Beers Criteria to the overall impact on
healthcare costs on a national level. The limited research that is available includes
information derived from what is now an outdated version of Beers Criteria. Only two
studies were identified that represented a primary goal of quantifying the economic impact
that PIM ADEs have on healthcare costs (Fu et al., 2007; Stockl et al., 2010).
Fu and colleagues (2007) were the first to include healthcare cost analyses in a
study of PIMs included on the 2003 version of Beers Criteria. This retrospective cohort
study aimed to describe how PIM use is related to healthcare expenditures and to quantify
the incremental healthcare expenditures related to PIM use (Fu et al., 2007). Fu and
colleagues (2007) used the 2000–2001 Medical Expenditure Panel Survey, a nationally
representative survey of the U.S. non-institutionalized population that captures healthcare
utilization, expenditures, payment source, and insurance coverage. The sample included
patients over the age of 65 at the start of 2000 that were continuously enrolled in all five
rounds of the Medical Expenditure Panel Survey. Rounds one and two were used as a
washout period, and patients receiving any PIMs included on 2003 Beers Criteria in rounds
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one and two were excluded. This ensured that all patients included in the analysis began
without PIM exposure. Patients that received at least one PIM in rounds three and/or four
were classified as the exposed group, and patients not receiving a PIM in rounds three and
four were classified as the unexposed group. To ensure all healthcare expenditures
associated with PIM use were captured in the analysis, patients receiving a PIM in round
5 were also excluded (Fu et al., 2007).
Stockl and colleagues (2010) also conducted a retrospective cohort study of the risk
of experiencing select ADEs while on a limited number of PIMs and the costs associated
with those specific PIMs. Pharmacy and medical claims data from a managed care
organization were analyzed. Using the 2003 version of Beers Criteria, 23 anticholinergics
and sedative hypnotics classified with a high ADE severity rating and 4 adverse event
categories were included in the study (Stockl et al., 2010). Patients over the age of 65
receiving one of the 23 PIMs comprised the exposed group, and patients not receiving one
of the 23 PIMs were classified as controls (Stockl et al., 2010).
Although national healthcare expenditure figures associated with Beers Criteria
PIM use are limited, these two studies suggest that PIM use is associated with higher
healthcare costs. Fu et al. (2007) reported that average costs for patients in the group
exposed to Beers Criteria PIMs were over $6,800 compared to costs of nearly $5,000 for
the unexposed group. Similarly, Stockl et al. (2010) reported higher costs in their PIM
groups as well. In the anticholinergic group, the adjusted total healthcare costs for the
exposed group was $18,400 compared to just over $15,000 in the group exposed to
anticholinergic PIMs in Beers Criteria. Those exposed to sedative hypnotics had nearly
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$27,500 in total healthcare costs compared to $22,500 total costs for non-exposed (Stockl
et al., 2010).
2.10

Propensity Score Matching
While randomized controlled trials continue to serve as the gold standard to analyze

interventions (Spieth et al., 2016), there is growing interest in using observational, or
nonrandomized, data to estimate treatment effect. Researchers have no control over
treatment assignment in observational data (D’Agostino & Rubin, 2000), and since
randomization is not possible in observational studies, careful design and statistical
techniques are needed to appropriately manage these data (Stuart, 2010). First developed
by Rosenbaum and Rubin (1983), PSM is a statistical approach used to create baseline
matched comparison groups where they do not otherwise exist in observational data.
Treated patients are often significantly different than untreated patients in observational
studies due to variation in baseline characteristics (Austin, 2011). The large differences
that may exist in treatment and control groups in observational studies can lead to bias in
the interpretation of treatment effect (D’Agostino & Rubin, 2000). As is the case for any
study of observational data, the risk of selection bias and the threats to internal validity are
much higher compared to randomized controlled trials. Although randomization is not
possible in observational studies, PSM techniques are used to analyze observational data
in a way that mimics some of the characteristics of a randomized controlled trial by creating
two balanced samples, one that received treatment and a sample that did not receive
treatment, that are comparable on all observed differences (Austin, 2011). If these methods
are used successfully to closely model selection into one group or the other they may be
referred to as quasi-experimental design.
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The term matching in PSM refers to the process of balancing the distribution of
observed baseline covariates in the treatment and control groups (Stuart, 2010), and the
propensity score represents the likelihood of receiving treatment based on the covariates
(D’Agostino & Rubin, 2000). The PSM procedure includes multiple steps.
The first step is to select the covariates that are hypothesized to be related to the
treatment and sometimes the outcome, although there remains some controversy here.
Once covariates have been selected based on clinical knowledge, a multivariable logistic
regression is performed to model selection into one comparison group or the other
conditional on all of the covariates (Garrido et al., 2014; Stuart, 2010). The logistic
regression results in one probability per person of selecting into the treatment group, this
is the propensity score. Including a variable that is not associated with the treatment will
have little impact on the propensity score. However, not including a variable that is
associated with treatment is much more detrimental in terms of bias (Stuart, 2010). The
second step is to use a mathematical algorithm to one person who received treatment to a
similar person who did not based on similarity of propensity score. These algorithms are
available in most statistical software packages today. Next it is important to confirm the
propensity score is balanced across the treatment and control groups, i.e. that it was a good
match.
There is not a single ideal matching algorithm or technique. Instead, the ideal
matching technique is the one that best balances the groups at baseline to reduce selection
bias (Garrido et al., 2014). Researchers should choose whether to match controls with or
without replacement (i.e. whether a control should be matched to more than one treated
individual) (Austin, 2011). Matching controls with replacement is useful when there are
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few similar controls to match and compare to individuals in the treatment group (Stuart,
2010), however this has some ramification with regard to non-independence between
subjects which may have to be accounted for in the final analysis. In greedy matching, or
nearest neighbor matching, a treated individual is selected at random and matched the
control with the propensity score that is closest to the randomly selected treated individual
(Austin, 2011). Greedy matching performs best when there is no competition for controls
(Stuart, 2010). Researchers can also choose to employ nearest neighbor matching within a
pre-specified caliper, or required maximum distance allowed between the treated
propensity score and the control. Another technique, optimal matching, ensures that the
total overall difference between the propensity score of the matched pairs is minimized
(Austin, 2011). Greedy matching is ideal to generate well matched treatment and control
groups, and optimal matching is ideal to generate well matched pairs within the treated and
control groups (Stuart, 2010).
After matching is complete, the quality of the matched samples should be evaluated
to ensure the covariates are balanced appropriately across the treatment and comparison
groups. Matching techniques may need to be modified and the propensity score may need
to be redefined in order to create new treatment and comparison groups that achieve
balance after matching (Garrido et al., 2014; Stuart, 2010). Once treatment and comparison
groups with adequate balance are finalized, the researcher can continue to the outcomes
analysis (Stuart, 2010). Adequate balance is often indicated as being achieved when the
standardized differences in means or proportions in each variable used in the propensity
score model is less than 0.2 (Stuart, 2010).
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The primary advantage of PSM is that baseline characteristics are similar between
comparison groups. This ensures that observed differences, or covariates, are similar
between groups (Austin, 2011) and this, alone, has been shown to reduce selection bias by
at least 90% (Rubin). However, weakness remains as PSM cannot account for unobserved
factors that may impact treatment assignment and outcome and hidden bias may still exist
after matching (Garrido et al., 2014). Another challenge of PSM is that the propensity score
must be estimated. Errors in propensity score modeling can also result in bias of the
estimated treatment effect (Imai & Ratkovic, 2014). Despite its limitations, PSM offers
advantages to health services researchers in that observational data can be used to
understand how the treatment effects multiple outcomes (i.e. cost and health outcomes)
(Garrido et al., 2014).
2.10.1 Beers Criteria Research using Propensity Score Matching
Fu and colleagues (2007) and Stockl and colleagues (2010) are the only studies
identified in this literature review that included Beers Criteria and PSM techniques. In their
analysis examining differences in total healthcare expenditures, Fu and colleagues (2007)
identified 115 patients classified as being exposed (received at least one PIM on 2003 Beers
Criteria during the washout period) and 605 patients classified as being unexposed (did not
receive a PIM on 2003 Beers Criteria during the washout period). PSM (simple matching
with caliper) was used to match exposed and unexposed patients. To ensure balance of
baseline characteristics observed in the sample of patients, and to minimize sample
selection bias, several covariates were included in the matching: age, race, gender,
insurance type, total number of prescriptions in 2001, baseline health conditions measured
by Charlson comorbidity index and SF-12 physical condition summary, and healthcare
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expenditures for 2000 (expenditures associated with emergency room visits, inpatient
visits, outpatient visits, office-based visits, homecare, and prescription drug use) (Fu et al.,
2007). The sample was balanced across each group, with 103 included in the exposed group
matched to 103 in the unexposed group. Based on analysis of these matched groups with
similar demographic and baseline characteristics, Fu and colleagues (2007) estimated that
the incremental healthcare expenditures associated with PIM use in the elderly in 2001 was
over $7 billion.
Using medical and pharmacy claims from a U.S. managed care organization, Stockl
and colleagues (2010) classified patients to an exposed group if they received one of 23
selected medications represented in 2003 Beers Criteria included in the analysis. Patients
not receiving one of the 23 medications of interest served as controls. The 23 medications
were categorized to one of four medication groups that patients could be matched to:
Anticholinergics, Narcotics, Trimethobenzamide Hydrochloride, and Sedative Hypnotics
(Stockl et al., 2010). Patients in the exposed and control groups were matched on a one-toone basis using PSM. The sample was balanced across each group, and an equal number
of exposed patients and controls were included in the Anticholinergics, Narcotics,
Trimethobenzamide Hydrochloride, and Sedative Hypnotic groups. Covariates used in the
matching included demographics, health plan type, Charlson Comorbidity Index, number
of Beers Criteria medications other than index medication during 180 day pre-period, sum
of days supply for non-Beers Criteria anticholinergics during 180 day pre-period, preperiod claims for specific medications with potential to cause cognitive impairment, days
supply for opioid agonists or partial agonists other than index medication during preperiod, pre-period claims for specific medications with potential to cause extrapyramidal
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effects, pre-period claims for specific medications with potential to cause sedation, preperiod claims for specific hypotensive medications with potential to increase risk of fall or
fracture, and pre-period claims for specific conditions that may increase the risk of fall or
fracture (Stockl et al., 2010). Results from this study indicate that patients using
medications from the four Beers Criteria categories included in this study had higher
medical expenses at baseline compared to controls (Stockl et al., 2010).
Studies of Beers Criteria employing PSM are limited, and the few studies that have
been conducted utilized, what are now, outdated versions of Beers Criteria and or a limited
set of Beers Criteria. A current economic analysis is needed to determine the increased
health care costs associated with using PIMs included in a more current version of Beers
Criteria.
2.11

Summary
People over the age of 65 are living longer, and, as a result, require more

medications to manage an increasing number of health problems as they age.
Polypharmacy, the use of multiple medications concurrently by the same patient to treat
one or more health conditions, is prevalent and problematic in this population. The use of
too many medications, and especially those medications classified as potentially
inappropriate in Beers Criteria, is associated with an increased risk for drug interactions,
medication non-adherence, decline in functional status, and ADEs. These events often
require an ED visit, hospitalization, or institutionalization, which in turn drives up
healthcare costs. ADEs are especially detrimental to the healthcare system and are
responsible for billions of dollars in healthcare spending. One strategy that will address
increasing healthcare costs prevalent in older adults is to reduce unnecessary ADEs,
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especially those events associated with potentially inappropriate medications included in
Beers Criteria.
Several medication evaluation tools are used throughout the world; however, Beers
Criteria remains the most frequently used tool in geriatric care. Previous studies of
medications included in Beers Criteria indicate that PIM use occurs frequently in outpatient
care, primary care, acute care, psychiatric centers, LTC settings, and home health care.
Many commonly used medications may not be appropriate for this population, placing
older adults at greater risk for negative health outcomes and a decline in quality of life.
PIM use negatively impacts healthcare utilization and is associated with a higher frequency
of outpatient visits, hospitalizations, and ED visits compared to patients not using PIMs.
These unnecessary visits ultimately impact healthcare expenditures and are taxing for
individual patients and their families, healthcare settings, third party payers, and federal
health programs.
Evaluating the relationship between PIM use, healthcare utilization, and healthcare
spending is clearly an underrepresented area in the literature, and was one of the primary
aims of this dissertation. No published studies were found that included a current,
nationwide cost analysis of PIM use in the elderly. Studies that have incorporated a recent
version (2012 or 2015) of Beers Criteria have failed to offer information related to cost or
spending as a result of healthcare utilization associated with using medications included in
Beers Criteria. Given the modifications to Beers Criteria over the years, it is difficult to
determine whether the analyses of Fu and colleagues (2007) and Stockl and colleagues
(2010) remain relevant to current medication use. Our goal was to analyze utilization and
costs in the framework of the current healthcare environment while using PSM to control
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for selection bias. We also elected to use a more recent version of Beers Criteria that
allowed us to examine those medications that have been added to Beers Criteria since the
2003 version used by Fu et al. (2007) and Stockl et al. (2010). Additionally, to our
knowledge, no one has compared healthcare utilization and cost of using medications
included in Beers Criteria compared to alternative medications not included in Beers
Criteria.
The primary aim of this dissertation was to demonstrate the impact that using PIMs
included in Beers Criteria has on healthcare resource utilization and spending by including
medications that are relevant to today’s prescribing practices. We also sought to reveal how
healthcare costs associated with using Beers Criteria medications differ from using
alternative, and arguably safer, medications not included in Beers Criteria. Given the
number of health conditions and medications used within the elderly population, a wellmanaged medication regimen is imperative to minimize unnecessary hospitalizations and
decrease healthcare costs.
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III.

METHODOLOGICAL BACKGROUND
Americans are living longer, and, as a result, the elderly population continues to

increase dramatically. More than 20% of the total U.S. population will be represented by
adults over the age of 65 in the coming decades (Ortman et al., 2014). The growing elderly
population is a burden to the U.S. healthcare system, and as the aging population continues
to grow, healthcare costs are expected to increase as much as 25% by the year 2030
(Centers for Disease Control and Prevention, 2013). One factor responsible for the high
cost of healthcare in the elderly population is an increased use of medications to treat a
growing number of health problems. The rate of medication use in the elderly population
will continue to rise in the coming years (Page et al., 2010). Older adults are often
prescribed medications that are not medically necessary, and, as a result, are seven times
more likely to experience a negative health outcome attributed to medication use that
require an emergency room visit and/or hospitalization (Budnitz et al., 2011). It was
estimated that over $7 billion in annual incremental healthcare expenditures in 2001 were
related to inappropriate medication use in community dwelling individuals over the age of
65 (Fu et al., 2007). Medications included in Beers Criteria may be especially inappropriate
for use in adults aged 65 and older. Novel strategies are needed to reduce PIM use in order
to minimize the burden the elderly population has on the healthcare system.
We conducted a retrospective cohort study to quantify healthcare resource
utilization and healthcare costs attributable to using PIMs included in 2012 Beers Criteria.
Community-dwelling Medicare patients with private supplementary insurance were
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included in the study, and healthcare utilization and costs were analyzed using 2013 Truven
Health Marketscan® Commercial Claims and Encounters Database (Truven Health
Analytics, 2017). We compared hospital admissions, days spent in the hospital, and total
healthcare costs generated from inpatient and outpatient visits and prescription medication
use for patients that received medications in Beers Criteria compared to a well-matched
group of patients that received medications not included in Beers Criteria.
Aim 1
To examine the healthcare resource utilization for Medicare patients who receive
medications included in Beers Criteria compared to a well-matched group of Medicare
patients who do not receive medications included in Beers Criteria.
Hypotheses
H1: The odds of hospital admission in a group of patients who receive Beers Criteria
medications is greater than the odds of hospital admission in a group of patients who do
not receive Beers Criteria medications.
H0: OR Hospital Admissions (Beers Criteria group) = OR Hospital Admissions
(Control group)
Ha: OR Hospital Admissions (Beers Criteria group) ≥ OR Hospital Admissions
(Control group)
H2: Among patients who had a hospitalization, the mean number of days admitted to the
hospital is greater in patients who receive Beers Criteria medications compared to patients
who do not receive Beers Criteria medications.
H0: µ Hospital Days (Beers Criteria group) = µ Hospital Days (Control group)
Ha: µ Hospital Days (Beers Criteria group) ≥ µ Hospital Days (Control group)
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Aim 2
To determine the total healthcare costs for Medicare patients who receive medications
included in Beers Criteria compared to a well-matched group of Medicare patients who do
not receive medications included in Beers Criteria.
Hypothesis
H1: Total healthcare costs are greater in patients who receive Beers Criteria medications
compared to patients who do not receive Beers Criteria medications.
H0: µ Healthcare Cost (Beers Criteria group) = µ Healthcare Cost (Control group)
Ha: µ Healthcare Cost (Beers Criteria group) ≥ µ Healthcare Cost (Control group)
3.1

Study Design
The health services research aims in this retrospective cohort study required a

specialized set of methodological approaches. A summary of the study design is depicted
in Figures 3.1 and 3.2. Data was purchased from Truven Analytics, a company that
maintains healthcare utilization and cost records linked at the patient level. One year (2013)
of health insurance billing data was analyzed using the Marketscan® insurance database
containing files for paid claims generated by over 40 million continuously insured
individuals covered by commercial insurance and Medicaid and Medicare supplemental
benefits. Data for community-dwelling patients aged 65 and over were included in this
study. A preliminary review of the 2013 Marketscan® sample indicated a minimum of 4.1
million covered lives 65 or older were represented in the database.
Patients were divided into either a treatment group (patients that received Beers
Criteria medications) or control/comparison group (patients that received non-Beers
Criteria medications). In order to appropriately assign patients to these groups, all patients
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were observed for a three-month baseline period from January 1, 2013 through March 31,
2013. PIM use was identified using the list of 2012 Beers Criteria medications represented
in Table 3.1 since this was the most recently updated Beers Criteria prior to the data
collection year.
A total of 138 medications from eight therapeutic areas in 2012 Beers Criteria were
included in the study. We obtained each individual National Drug Code (NDC) number
represented in the 2013 version of Red Book for each of the 138 included Beers Criteria
medications. Red Book includes prescription drug product and pricing information
(Kokoski, 2009). An NDC is a unique, three-segment number comprised of 10 digits
assigned by the U.S. Food and Drug Administration that identifies the manufacturer,
strength, dosage form (i.e. capsule, tablet, liquid), formulation of the drug, and the
commercial package size (U.S. Food and Drug Administration, 2017). We excluded
mineral oil as there are no NDC codes available since this is not a prescription medication.
Phenothiazines were also excluded from our prescription data as this medication is used so
infrequently that NDC codes are limited. A total of 73,644 individual NDC codes were
used to identify Beers Criteria medications in Marketscan®. Individuals that received at
least one Beers Criteria medication during the baseline period were categorized into the
treatment group, and patients that did not receive a medication included in Beers Criteria
in the baseline period were assigned to the control group.
During the baseline period, inpatient records were used to construct the Charlson
Score (outlined further in section 3.5) (Quan et al., 2011), and patients were classified as 1
for having a hospital admission or 0 for not having a hospital admission during baseline.
Outpatient visits were used to construct a score for Elixhauser Comorbidity indicator
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conditions (outlined further in section 3.5) (Elixhauser et al., 1998) observed at baseline.
A frailty index (outlined further in section 3.5) was used to classify patients at baseline into
three groups: robust, pre-frail, or frail (Faurot et al., 2015; Rockwood, Andrew, &
Mitnitski, 2007). This process was applied to both the treatment and control groups.
To ensure that patient characteristics were similar during the baseline period, PSM
techniques (outlined further in section 3.5) were used to match patients treated with Beers
Criteria medications and controls that did not receive Beers Criteria medications. Patients
were matched on age, gender, geographic region, hospital admission, member days, frailty,
Charlson Comorbidity Score, and 26 Elixhauser Comorbidity Indicators. All patients that
received a Beers Criteria medication in the baseline period, designated as the treated group,
were matched in a 1:1 fashion to controls that did not receive a Beers Criteria medication
in the baseline period.
The primary outcomes for this study were 1) having at least one hospital admission;
2) of those that were hospitalized, the total number of hospital admissions and the total
numbers of days spent in the hospital; and 3) total costs derived from inpatient visit,
outpatient visit, and prescription drug costs. After PSM matching was completed, and the
treatment and control groups were determined to meet PSM balance standards of less than
or equal to 0.2 standardized differences for each matched covariate, inpatient and
outpatient encounters and prescription drug use was analyzed post-baseline for 275 days
(April 1 through December 31, 2013). A detailed description of the Marketscan® database,
including advantages and limitations to using this database, and the statistical analyses used
to address the aims of this study are included in this chapter.
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Figure 3.1: Treatment & Control Group Design
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Figure 3.2: Analysis of Primary Outcome Measures

84
Table 3.1: 2012 Beers Criteria Medications Used in Study
Beers Medications & Classes
Anticholinergics
1st Generation Antihistamines
Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyproheptadine,
Dexbrompheniramine, Dexchlorpheniramine, Diphenhydramine, Doxylamine,
Hydroxyzine, Promethazine, Triprolidine
Antiparkinson Agents
Benztropine, Trihexyphenidyl
Antispasmodics
Belladonna alkaloids, Clidinium-Chlordiazepoxide, Dicyclomine, Hyoscyamine,
Propantheline, Scopolamine
Antithrombotics
Antithrombotic
Dipyridamole, Ticlopidine
Anti-infective
Anti-infective
Nitrofurantoin
Cardiovascular
Alpha1 Blocker
Doxazosin, Prazosin, Terazosin
Alpha Agonist, Central
Clonidine, Guanabenz, Guanfacine, Methyldopa, Reserpine
Antiarrhythmic
Amiodarone, Digoxin, Disopyramide, Dofetilide, Dronedarone, Flecainide, Ibutilide,
Procainamide, Propafenone, Quinidine, Sotalol
Antihypertensive
Nifedipine
Diuretic
Spironolactone
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Central Nervous System
Tertiary TCA
Amitriptyline, Chlordiazepoxide-amitriptyline, Clomipramine, Doxepin, Imipramine,
Perphenazine-amitriptyline, Trimipramine
1st Generation Antipsychotic
Chlorpromazine, Fluphenazine, Haloperidol, Loxapine, Molindone, Perphenazine,
Pimozide, Promazine, Thioridazine, Thiothixene, Trifluoperazine, Triflupromazine
2nd Generation Antipsychotic
Aripiprazole, Asenapine, Clozapine, Iloperidone, Lurasidone, Olanzapine,
Paliperidone, Quetiapine, Risperidone, Ziprasidone
Anxiolytic
Meprobamate
Barbiturates
Amobarbital, Butabarbital, Butalbital, Mephobarbital, Pentobarbital, Phenobarbital,
Secobarbital
Benzodiazepines Short Acting
Alprazolam, Estazolam, Lorazepam, Oxazepam, Temazepam, Triazolam
Benzodiazepines Long Acting
Chlordiazepoxide, Chlordiazepoxide-amitriptyline, Clidinium-chlordiazepoxide,
Clonazepam, Clorazepate, Diazepam, Flurazepam, Quazepam
Ergoloid
Ergoloid mesylates
Nonbarbiturate Sedative
Chloral hydrate
Nonbenzodiazepine hypnotics
Eszopiclone, Zaleplon, Zolpidem
Vasodilator
Isoxsuprine
Endocrine
Hormones
Desiccated thyroid, Estrogens, Growth Hormone, Insulin, Megestrol,
Methyltestosterone, Testosterone
Sulfonylurea
Chlorpropamide, Glyburide
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Gastrointestinal
Antiemetic
Trimethobenzamide
Gut Motility Stimulator
Metoclopramide
Pain
Narcotic
Meperidine, Pentazocine
NonCOX NSAIDs
Aspirin, Diclofenac, Diflunisal, Etodolac, Fenoprofen, Ibuprofen, Ketoprofen,
Meclofenamate, Mefenamic acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin,
Piroxicam, Sulindac, Tolmetin
NSAIDs
Indomethacin, Ketorolac
Skeletal Muscle Relaxants
Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol,
Orphenadrine

3.2

Study Population
Community-dwelling Medicare patients aged 65 and older with private

supplementary insurance represented in the Truven Health Marketscan® Commercial
Claims and Encounters Database for the year 2013 were the target population to examine
the aims of this study. Marketscan® does not capture data for poor or dually insured
individuals, and this study did not include poor or dually insured individual patients in the
study population. We selected 2013 data because this is the most current data available
through Marketscan® that can capture prescription drug use based on a recent version of
Beers Criteria. Unfortunately, a full year of data was not available at the time of this project
to use 2015 Beers Criteria. As a result, we used 2012 Beers Criteria to identify PIM use in
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the study population. We selected patients aged 65 and older to align with the Beers Criteria
age of interest given that the criteria are intended for the care of individuals specifically
aged 65 and older. The 2013 Marketscan® database contains a minimum of 4.1 million
covered lives that are 65 or older.
3.2.1

Medicare Coverage in the Elderly
Established in 1966, Medicare is a single-payer, national health insurance program

funded by payroll taxes, beneficiary premiums, and general revenue and provides coverage
for beneficiaries over the age of 65, the disabled, and end-state rental disease patients. The
program is comprised for four parts, each covering specific healthcare services. Medicare
Part A is hospital insurance to cover expenses generated from hospital admissions, LTC,
home care, and hospice care. Part B provides coverage for outpatient services and medical
supplies. Part C represents the Medicare Advantage Plan offered by private companies.
Medicare Part D provides prescription drug coverage. In 2015, Medicare provided
coverage to over 45 million elderly Americans (Altman & Frist, 2015). Medicare has been
attributed to improved access to care in the elderly, a reduction in healthcare disparities,
and has positively impacted life expectancy since its creation (Altman & Frist, 2015).
As adults age, they are more likely to experience an increase in chronic conditions
and a decline in functional status. Nearly half of Medicare beneficiaries have at least four
chronic conditions, over 30% experience some level of functional cognitive, and/or mental
impairment, and over 25% of beneficiaries perceive their health to be fair or poor (Altman
& Frist, 2015). Chronic conditions and poor functional status result in an increased
likelihood of requiring an ED visit or hospitalization, and these conditions are also
attributed to increased Medicare spending on inpatient services, LTC, and home health
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(Neuman, Cubanski, Huang, & Damico, 2015). Medicare spending exceeded $585 billion
in 2013 (Altman & Frist, 2015). In 2011, nearly 25% of Medicare beneficiaries were over
the age of 80, and this group was responsible for roughly 33% of total Medicare spending
(Neuman et al., 2015). Approximately 32% of the Medicare population aged 70 to 79, and
these beneficiaries are responsible for 30% of Medicare spending (Neuman et al., 2015).
The 65 to 69 age group was responsible for 15% of total Medicare spending (Neuman et
al., 2015). The largest share of Medicare spending in beneficiaries over the age of 65 was
on inpatient care, and inpatient service expenses increased more than 2.5 times in 66 to 89year-old beneficiaries (Neuman et al., 2015). As the U.S. elderly population continues to
grow in the years ahead, the number of Medicare beneficiaries and the total Medicare
spending will increase as well. This phenomenon will not only strain the Medicare system,
but other payers as well (Neuman et al., 2015).
3.3

Administrative Claims Data
Every patient encounter within the healthcare system (i.e. hospitalizations,

outpatient office visits, use of prescription medications) generates healthcare
administrative data (Cadarette & Wong, 2015). This data is available for large populations
and includes information related to individual health services that are used (Riley, 2009).
Administrative claims databases were originally created for administrative or billing
purposes and, more specifically, to manage payments for services rendered by healthcare
providers in managed care organizations or nationally funded health programs (Suissa &
Garbe, 2007). Health insurance claims and encounter data from Medicare, Medicaid, and
the Veterans’ Health Administration are a common source of administrative claims data in
the U.S. (Riley, 2009). “Medicare has the broadest population-based administrative data
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system in the health arena, covering about 97% of the elderly” (Riley, 2009, p.51). Claims
data from private insurance payers are also available and frequently used, and managed
care plans, state hospital discharge datasets, and hospital data are used to describe
healthcare utilization and costs on an individual level (Riley, 2009). Additionally, drug
dispensing data is also available in claims databases to describe medication use. Although
dispensing data reflect specific medications that were dispensed as opposed to actual
prescriptions written, drug dispensing data can also be used to infer prescribing patterns
(Cadarette & Wong, 2015).
Administrative claims data are frequently used in research to study utilization,
benefits, negative outcomes, and costs of health care delivery (Cadarette & Wong, 2015).
Cost-analyses are especially common given that administrative claims records often
include the billed charges or the amount that was actually paid for a given service (Riley,
2009). Economic research of health conditions and diseases often requires patient-level
data represented in administrative claims data to capture healthcare services used, the costs
associated with specific services, and healthcare costs generated over time (Riley, 2009).
Patient-level data files can be linked by a unique patient identifier and use of healthcare
services and the costs associated with those services can often be tracked longitudinally
(Suissa & Garbe, 2007).
3.3.1

Marketscan®
Truven Health Analytics created the Marketscan® warehouse to address a growing

need for quality data for privately insured individuals in the U.S. This warehouse is
comprised of nine fully integrated claims databases containing the largest collection of
employer-based patient data in the U.S. These databases include over 28 billion patient
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records for 22 million covered lives and reflect healthcare utilization and costs for all
aspects of care (Hansen & Chang, 2011).
The Marketscan® Commercial Claims and Encounters Database, one of nine
Marketscan® databases, is a nationally representative administrative claims database that
consists of de-identified, standardized medical and pharmaceutical claims data. In addition
to providing data for all claims generated by commercially insured individuals annually,
the Marketscan® insurance database also includes a number of key data elements,
including demographic information, type of admission and date, diagnosis codes,
diagnosis-related group, financial information such as total and net payments, and drug
information including national drug code. A unique enrollee identifier is assigned to each
individual in Marketscan®, and these member identification codes allow researchers to
follow patients longitudinally over time (Truven Health, 2016).
3.3.2

Advantages and Limitations of Marketscan®
There are numerous advantages to using administrative databases, including

Marketscan® data, commonly used in research to examine health related questions.
Administrative data, also known as billing data or archival data, are commonly used in
research to examine health related questions. Retrospective billing data are readily
available and less costly to obtain (Suissa & Garbe, 2007). Patients represented in
administrative databases can be followed over long, continuous periods of time offering
advantages for retrospective studies. Administrative databases are advantageous for their
large sample sizes that enable health services researchers to generalize results to a larger
population providing stronger external validity than is generally seen in smaller
randomized study designs (Suissa & Garbe, 2007). These databases also include vulnerable
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subgroups, such as the elderly population represented in this study. Marketscan® has the
largest convenience sample available in proprietary databases. Marketscan® captures the
full continuum of care in all settings, including hospital visits that were important to this
study.

The data contains individual-level healthcare claims and hospital discharge

information from large employers, managed care organizations, hospitals, Medicare, and
Medicaid (Hansen & Chang, 2011).
Marketscan® offers the advantage of high-quality coding, and a diagnosis is coded
on 99% of all claims. Other coding advantages of Marketscan® include procedure coding
on claims and payment and charge information (Hansen & Chang, 2011). However, one
weakness of administrative databases is the variation of coding practices and the possibility
that potential errors may occur in diagnosis coding. Coding is used specifically for billing
purposes, and information represented in these databases is not collected for research
purposes (Suissa & Garbe, 2007). Coding practices may threaten the internal validity of
this study; however, many coding weaknesses were equally present in both the treatment
and control groups resulting in a marginal effect estimate not biased by most coding
variation. Considering that we had to rely on coding information and billing data which
may not be completely accurate, we may have unintentionally excluded patients that should
be included in the sample based on these errors and coding limitations. Additionally, some
individuals were excluded from the sample population given that medium and small
employers are not represented in Marketscan® data (Hansen & Chang, 2011).
Marketscan® databases are based on a large sample, but this is sample is not random. There
may be hidden biases in the data.
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Retrospective research based on these data must be done with care and with the
awareness that issues might arise given the unalterable challenges of administrative data.
We addressed these weaknesses through statistical techniques such as propensity score
matching (outlined in further detail below). These techniques allowed us to create a wellmatched control group in order to examine differences between the Beers Criteria and nonBeers Criteria groups. Any data-related bias is expected to be equally distributed across
both groups, ensuring that the non-random sample represented in Marketscan® remains
the ideal source of data for this study.
Important to note is the inclusion of detailed prescription drug information in
Marketscan® data, and this was of particular interest in this study. The database includes
complete information on drug use patterns and outpatient prescriptions (Hansen & Chang,
2011). This database offers a distinct advantage over other databases for research on
medication use. Other administrative databases do not include prescription drug
information or these databases only track individual drug prescription trends or prescription
fills. Marketscan® data combine clinical visits and prescription drug data to allow for
analyses necessary to understand the impact of medication use on healthcare utilization
and healthcare costs (Hansen & Chang, 2011).
This particular database was especially valuable to address the aims of this study.
Marketscan® data allowed us to study healthcare resource utilization (Aim 1) and measure
total healthcare costs in a well-matched group of Medicare patients that received either
Beers Criteria or non-Beers Criteria medications (Aim 2). The use of Marketscan® data
to answer these health services and cost-related questions about PIM use is essential,
especially in situations where prospectively collected data are not feasible.
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3.4

Study Variables
Claims data from the Marketscan® Commercial Claims and Encounters Database

were analyzed and data elements representing demographic information, inpatient and
outpatient medical information, financial information, and prescription drug use were
included in this study. Table 3.2 outlines the specific variables used in the PSM design
phase of this dissertation, and Table 3.3 outlines the data elements that were used for final
outcomes analysis. Patient data on age, gender, geographical region of residence, number
of days insured (member days), and a binary variable of any hospital admission during
baseline was used to define demographic characteristics that were used for dataset
construction and for PSM. Patient race was not used because this variable is not available
in Marketscan®. Inpatient and outpatient records were used to construct baseline health
measure variables used in PSM. Prescription drug variables included a binary variable for
having received any medication included in Beers Criteria, NDC number, and generic
product ID. Healthcare utilization variables used for data analysis included hospital
admission, number of hospital admissions for those that had a hospital admission, and
number of days hospitalized for those that had a hospital admission. The sum of inpatient
visit costs, outpatient visit costs, and prescription drug costs as well as total costs were used
in final analysis. A comprehensive list of all variables included in the final dataset is
included in Appendix M.
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Table 3.2: Variables used in PSM
Demographic Information

Healthcare Coverage
Hospital Admissions
Baseline Health Measures

Age
Gender
Geographic Region
Member Days
Hospital Admission (yes/no)
Frailty Score (robust, pre-frail, frail)
Charlson Comorbidity Score
Elixhauser Comorbidity Indicators
Asthma
Cardiac dysrhythmias
Chronic obstructive pulmonary disease
Chronic renal failure
Conduction disorders of the heart
Congestive Heart Failure
Cystic fibrosis
Diabetes with chronic complications
Diabetes without chronic complications
Diverticulosis and diverticulitis
Epilepsy
Heart valve disorders
Hepatitis
HIV infection
Hypertension
Multiple sclerosis
Otitis media
Parkinson’s Disease
Peri-; endo-; and myocarditis
Pulmonary heart disease
Rheumatoid arthritis
Schizophrenia
Senile
Sickle cell anemia
Systemic lupus erythematosus
Vertigo
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Table 3.3: Variables used for dataset construction and final analysis
Demographic Information

Healthcare Utilization
Information
Drug Information

Financial Information

3.5

Patient ID
Age
Gender
Geographic Region
Member Days
Hospital admission (yes/no)
Number of hospital admissions
Number of days hospitalized
Received any beers medication (yes/no)
National Drug Code
Generic product ID
Sum of inpatient visit costs
Sum of outpatient visit costs
Sum of prescription drug costs
Total costs

Propensity Score Matching
PSM techniques are used to analyze observational data in a way that mimics some

of the characteristics of a randomized controlled trial (Austin, 2011). For the purposes of
this study, PSM was used to create a control group where a control did not otherwise exist
to design a quasi-randomized study structure (Rosenbaum & Rubin, 1983). These
techniques ensured that we created a well-matched control group to examine differences
between the Beers Criteria (treatment) and non-Beers Criteria (control) groups. We used
this technique to equally distribute any measured bias, or hidden bias correlated with any
PSM variables, across both groups, ensuring that the non-random sample represented in
the Marketscan® observational databases behaved more like a randomized design with
selection bias control.
PSM allowed us to attribute excess poor outcomes in the study groups, on an
averaged population level, to the causative factor of use of Beers Criteria or non-Beers
Criteria medications because average baseline characteristics between the groups were the
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same. If this were a randomized study, we would take a large cohort of screened patients
that needed a medication for a particular condition and randomize them to receive either a
Beers Criteria or a non-Beers Criteria medication. The resulting poor outcomes in the Beers
Criteria group, for example, should be able to be attributed to being on the Beers Criteria
medication (or vice versa), allowing us to determine the negative outcomes that may be
attributed to Beers Criteria or non-Beers Criteria medications. PSM controlled for most
sources of selection bias, allowing us to make causal inferences where there was nonrandom assignment (Heckman, Ichimura, Smith, & Todd, 1996).

PSM reduces or

eliminates the effects of confounding by indication when using observational data (Austin,
2011).
In the first step of the propensity score matching process, we performed a logistic
regression analysis to estimate the propensity of being allocated to the Beers Criteria group.
Known available variables, including age, gender, geographic region, hospital admission,
member days, and baseline health measures (frailty, Charlson Comorbidity Score, and 26
Elixhauser Comorbidity Indicators), that were related to the likelihood of receiving Beers
Criteria medications were included as covariates in the logistic regression model in order
to create similar treatment and control groups (Brookhart et al., 2006). Controlling for these
patient characteristics ensured that the differences we observed in the groups were not due
to baseline imbalance across these populations. In a set of subjects, all of whom have the
same propensity score, the distribution of observed baseline covariates was the same
between the Beers Criteria and non-Beers Criteria individuals.
We used 1:1 greedy matching in our propensity model in which a treated individual
was selected at random and matched to a control individual with the propensity score
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closest to the randomly selected treated individual (Austin, 2011). This process was
repeated until all Beers Criteria patients were matched to a control patient or until a control
patient could not be found to match to a treated patient. Greedy matching is ideal to
generate well matched treatment and control groups (Stuart, 2010). The propensity model
was considered final when appropriate balance between groups of all the covariates
included in the propensity score logistic regression model was indicated by standardized
differences less than 0.2 (Stuart, 2010). This method eliminates over 90% of those
differences that are inherent in the analysis of observational data and minimizes the chance
for selection bias (Austin & Mamdani, 2006; Austin, 2009).
3.5.1

Baseline Health Conditions Used in Propensity Score Matching
One key step in PSM was to ensure observed baseline characteristics were balanced

between the treatment and control groups. If this were a randomized trial, we would assume
that the characteristics observed in the group that received Beers Criteria medications
would be balanced with those characteristics observed in the control group (patients that
did not receive Beers Criteria medications). In our study, by comparing matched treatment
and control groups with the same observable characteristics we were able to mimic the
characteristics of a randomized controlled trial.
It is well recognized that patients with multiple chronic conditions have an
increased risk of having poor health outcomes and experiencing medical events that
ultimately impact healthcare utilization and cost (Sambamoorthi, Tan, & Deb, 2015). Often
time patients with multiple chronic conditions are also categorized as frail (Weiss, 2011).
For the purposes of this dissertation, baseline health conditions were a key covariate to
include in PSM. We used the Charlson Comorbidity Index, Elixhauser Comorbidity
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Indicators, and a frailty measure to account for baseline health conditions in both the treated
and control groups in PSM matching.
The Charlson Comorbidity Index was developed by Charlson, Pompei, Ales, and
MacKenzie (1987) to evaluate and classify those comorbid conditions that impact the risk
of death within patients participating in longitudinal studies. A review of 559 hospital
medical records identified 17 comorbidity variables that were associated with death within
one year. A weighted score was applied to each of the 17 conditions. This weighted index
considers the presence and number of comorbid conditions and the severity of those
conditions (Charlson et al., 1987). A Charlson score is derived by identifying specific
comorbid conditions included in the index, scoring each condition using pre-determined
points, and accounting for additional points associated with the patient’s age group
(Charlson et al., 1987). What was originally created for use with medical records, the
Charlson Comorbidity Index has been applied to administrative data generated from
hospital discharges. Deyo and colleagues (1992), Romano et al. (1993), and D’Hoore and
colleagues (1996) independently adapted the index for use in research using International
Classification of Diseases (ICD) diagnosis and procedure codes, specifically ICD-9 and
ICD-9-CM. Quan and colleagues (2011) also developed ICD-10 coding algorithms that to
apply the Charlson Comorbidity Index to administrative data. Considering advancements
in treatment and management of chronic diseases and improved mortality rates since the
initial development of the Charlson Comorbidity Index, Quan and colleagues (2011)
updated the work of Charlson et al. (1987) to include a weighted index of 12 comorbidities
and a maximum score of 24. A higher score indicates a greater likelihood of death within
one year (Quan et al., 2011). The 12 comorbidities included in the Charlson Comorbidity
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Score in this study were: AIDS/HIV, any malignancy (including leukemia and lymphoma),
chronic pulmonary disease, congestive heart failure, dementia, diabetes with chronic
complications, hemiplegia or paraplegia, metastatic solid tumor, mild liver disease,
moderate or severe liver disease, renal disease, and rheumatologic disease.
The Elixhauser Comorbidity Index (1998) was developed using administrative data
to not only enhance measures of comorbidity represented in administrative databases but
to also predict health outcomes. In developing this index, Elixhauser and colleagues (1998)
defined comorbidity as a clinical condition present before hospitalization. Although
unrelated to the primary reason for hospitalization, the comorbidities included in the index
are highly likely to impact mortality and resource use once hospitalized (Elixhauser et al.,
1998). Accounting for both acute and chronic conditions, comorbidities were selected for
the index based on a review of the literature and the ICD-9-CM coding manual (Elixhauser
et al., 1998). Carl van Walraven and colleagues (2009) later translated the binary variables
presented in the Elixhauser Comorbidity Index into a single numeric score to be applied to
hospital administrative databases to predict inpatient mortality. Similar to the Charlson
Comorbidity Index, the Elixhauser Comorbidity Index accounts for comorbidities
associated with mortality. However, this index also accounts for comorbidities associated
with increased inpatient length of stay and hospital charges (Elixhauser et al., 1998). In this
study, we used outpatient records to identify 29 Elixhauser comorbidity indicators, and
these indicators were used as a dichotomous variable as being present or not present prior
to hospitalization. We excluded three of the 29 Elixhauser Comorbidity Indicators (chronic
ulcers of the skin, late stroke, and paralysis) as there were no subjects included in the study
that had these conditions. The following 26 conditions were used in PSM: asthma, cardiac
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dysrhythmias, chronic obstructive pulmonary disease, chronic renal failure, conduction
disorders of the heart, congestive heart failure, cystic fibrosis, diabetes with and without
chronic complications, diverticulosis and diverticulitis, epilepsy, heart valve disorders,
hepatitis, HIV infection, hypertension, multiple sclerosis, otitis media (middle ear
infection), Parkinson’s disease, pericarditis, endocarditis, and myocarditis, pulmonary
heart disease, rheumatoid arthritis, schizophrenia, senile, sickle cell anemia, systemic lupus
erythematosus, and vertigo.
Frailty is associated with negative health outcomes (Faurot et al., 2015) and can
serve as a source of confounding bias in pharmacoepidemiologic studies (Kim &
Schneeweiss, 2014). Frail patients are already susceptible to a greater risk of negative
health outcomes, and clinicians are likely to modify treatment patterns based on the
individual condition of the patient. The riskier the condition or intervention is, the more
likely a clinician will let frailty impact their judgment regarding the type of treatment that
patient receives. In other words, physicians are likely to modify their treatment because
they use frailty to bias their judgment (Kim & Schneeweiss, 2014). Frailty is not frequently
documented in medical records, and it is unlikely that frailty will be captured in claims data
any time in the near future (Faurot et al., 2015). Given that pharmacoepidemiologic and
observational studies of administrative claims data must rely on clinical information
provided by the treating clinician, it is likely that these studies will be negatively impacted
by prognostic factors, such as frailty, that are not captured in the claims data (Kim &
Schneeweiss, 2014).
Using a sample of Medicare beneficiaries, Faurot et al. (2015) developed an
algorithm in which dependency on activities of daily living may serve as a proxy to
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measure frailty in administrative claims data. “Claims that identify ADL [activities of daily
living] dependency, used in conjunction with those referring to comorbidity, may serve as
proxy for frailty” (Faurot et al., 2015, p. 60). The diagnostic and procedure codes that were
associated with dependency on activities of daily living, and therefore predictors of frailty,
included use of durable medical equipment (home hospital bed, wheelchair, and home
oxygen), podiatry care, and rehabilitation care (Faurot et al., 2015). We chose these
predictors and used the frailty score developed by Faurot and colleagues (2015) to separate
frailty from our measures of comorbid conditions. For the purposes of this study, patients
were categorized as being robust (frailty category 0), pre-frail (frailty category 1), and frail
(frailty category 2) (Rockwood, Andrew, & Mitnitski, 2007). Controlling for these frailty
predictors in PSM was expected to minimize bias and improve balance between Beers
Criteria treated individuals and controls.
3.6

Statistical Analysis
Once PSM techniques were complete, and the matched Beers Criteria treatment

group and non-Beers Criteria controls were finalized based on propensity scores, an
analytical data set derived from the Marketscan® database was used to conduct analyses
for the two aims. Healthcare utilization outcomes of interest included any hospital
admission, number of hospital admissions (of those that were admitted), and total days in
the hospital (of those that were admitted). We defined cost outcomes of interest from the
perspective of an insurer. For the purposes of this study, insurance payments were denoted
as costs and measured as the aggregated total in insurance payments captured for each
patient during the follow up period in 2013 (post-baseline). Payments by type of resource
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used were also examined for inpatient payments, outpatient services, and prescription
medications.
Descriptive statistics and crude outcome estimates were compared for the treatment
and control groups by using Chi-square tests for categorical variables and two sample
Student’s t-tests for continuous variables. Mean and standard deviation was calculated to
describe age, number of days insured (member days), and Charlson Comorbidity Score
before and after PSM, and t-tests were used to test for differences in these variables in the
treatment and control groups. Mean and standard deviation was also calculated to describe
the number of days those in the treatment group were exposed to each Beers Medication
class after PSM. Frequency and percent was calculated to describe gender, geographical
region, hospital admission, frailty category, and 26 Elixhauser Comorbidity Indicators
before and after PSM, and Chi-square statistics were used to test for differences in these
variables in the treatment and control groups.
Unadjusted and adjusted risk of hospital admission, number of admissions (for
those that were hospitalized), and number of days spent in the hospital (for those that were
hospitalized) during the follow-up period were calculated (Aim 1). Frequency and percent
was calculated to describe unadjusted hospital admissions. Of those that had a hospital
admission, mean and standard deviation was calculated to describe unadjusted number of
admissions and unadjusted number of days hospitalized. We used a logistic regression to
predict the risk (adjusted odds ratio) of hospital admission for treated and control patients
while controlling for baseline covariates (age, gender, geographic region, hospital
admission, member days, frailty, Charlson Comorbidity Score, and 26 Elixhauser
Comorbidity Indicators). A zero-inflated Poisson model was used to calculate the adjusted
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number of hospital admissions for treated and control patients that experienced at least one
hospitalization during follow up while controlling for baseline covariates. We used a
negative binomial count model to calculate the adjusted number of days spent in the
hospital for treated and control patients that experienced at least one hospitalization during
follow up.
Inpatient visit costs, outpatient visit costs, prescription medication costs, total
unadjusted costs, and total adjusted costs during the follow-up period were analyzed for
the treatment and control groups. Means and standard deviations were used to calculate
unadjusted inpatient visit, outpatient visit, prescription medication, and total costs. A two
sample Student’s t-test was used to test for differences in healthcare costs between the
treatment and control groups. We used generalized linear modeling, first described by
Nelder and Wedderburn (1972), to test the hypothesis that Beers Criteria medications are
associated with higher healthcare costs compared to non-Beers Criteria medications (Aim
2). Healthcare cost data are usually right skewed, and as mean costs increases variability
increases. Studies using generalized linear modeling for cost analysis have shown good
distributional fit when using the gamma response distribution with a log link function
(Moran, Solomon, Peisach, & Martin, 2007). To adjust for the expected non-normal
distribution of healthcare costs in this study, we used a Gamma distributed generalized
linear model with a logarithmic link function to calculate the adjusted total healthcare costs
for treated and control patients.
3.7

Summary
This retrospective cohort study used research strategies not previously included in

utilization and cost analyses of medication classes represented in 2012 Beers Criteria to
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compare healthcare utilization and healthcare costs for patients that received medications
included in Beers Criteria compared to patients that received medications not included in
Beers Criteria. Prescription drug use and inpatient and outpatient visits were described
using medical and pharmaceutical claims data represented in Marketscan® Commercial
Claims and Encounters Database. Community-dwelling Medicare patients aged 65 years
and older with supplementary commercial health insurance represented in 2013
Marketscan® were included to examine the differences in utilization and cost when
medications were prescribed according to Beers Criteria versus when they are not
prescribed according to these criteria. Inpatient and outpatient visits and prescription drug
records were extracted. Records for services received through March 31, 2013 were
separated and used for the construction of baseline measures. Records from April 1 st and
later were separated and used for constructing the cost and event measures. Patients that
received medications that are contraindicated due to Beers Criteria (treatment group) were
matched, and compared, to patients that received non-Beers Criteria medications (control
group). We examined the healthcare resource utilization for patients who received
medications included in Beers Criteria compared to a well-matched group of patients who
did not receive medications included in Beers Criteria (Aim 1). The costs of inpatient and
outpatient visits and prescription drug use was analyzed and total adjusted costs were
compared between the treatment and control groups. (Aim 2). This was the first study to
analyze healthcare utilization rates and overall healthcare costs for patients that were
prescribed medications that adhere to Beers Criteria guidelines versus patients with the
same conditions that were prescribed medications that do not adhere to Beers Criteria
guidelines.
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IV.

RESULTS

4.1

Study Groups
The 2013 Marketscan® database contains 4,146,894 covered lives that are 65 or

older and that were potentially eligible for inclusion in this study. Of these patients, we
extracted 3,512,540 patients (84.7%) that had at least one prescription medication claim
during a three-month baseline period from January 1, 2013 through March 31, 2013. We
used National Drug Codes (NDC) represented in the 2013 version of Red Book for each
medication included in Beers Criteria to identify 1,297,636 patients (37%) that were
prescribed a PIM included in Beers Criteria during baseline. These patients were classified
as the treatment group. Alternatively, 2,214,904 patients (63%) received a prescription
medication during baseline not represented in Beers Criteria according to the NDC. These
patients were classified as the control group.
4.1.1

Demographics and Characteristics Before Matching
The Treatment and Control groups differed significantly with respect to age,

gender, geographical region, hospital admission, number of days enrolled in insurance plan
(member days), frailty, Charlson Comorbidity Score, and most Elixhauser Comorbidity
Indicators (Table 4.1). The treatment cohort had a statistically significant higher average
age (74.0 versus 73.4 years, p-value<0.0001), than the control cohort. A greater proportion
of patients included in the study were female (53.9%), and more of these females received
medications included in Beers Criteria (58.4% female in the treatment group versus 51.2%
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female in the control group, p-value<0.0001). The treatment group comprised of a higher
proportion of individuals that were admitted to the hospital (3.8% versus 2.0%, pvalue<0.0001). On average, the treatment group was also insured longer (355 member days
versus 348 member days, p-value<0.0001).
Those that received medications in Beers Criteria had more comorbid conditions
and were frail. The mean Charlson comorbidity score for patients treated with Beers
Criteria was 0.09 (compared to a mean score of 0.05 in the control group) and ranged from
0-15 at baseline. Of those patients classified as frail, 4.3% received medications included
in Beers Criteria compared to 2.4% that did not receive a Beers Criteria medication (pvalue<0.0001). In general, the treatment group had a greater proportion of each Elixhauser
Comorbidity Indicator included in this study compared to the control group. The greatest
differences in comorbid indicators among the treatment and control groups included
hypertension (37.0% in the treatment group versus 29.5% in the control group, pvalue<0.0001), conduction disorders of the heart (14.1% in the treatment group versus
8.5% in the control group, p-value<0.0001), and cardiac dysrhythmias (12.7% in the
treatment group versus 7.6% in the control group, p-value<0.0001).
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Table 4.1: Demographics and Characteristics Before Matching of Elderly Patients that
Received Prescription Medications During Baseline Period
Overall
N= 3,512,540

Treatment
N= 1,297,636

Control
N= 2,214,904

p-value*

Age a

73.6 (±6.8)

74.0 (±6.8)

73.4 (±6.8)

<.0001

Female Gender b

1,891,911 (53.9)

757,179 (58.4)

1,134,732 (51.2)

<.0001

Geographical Region b
Northeast
North Central
South
West
Unknown

858,061 (24.4)
914,256 (26.0)
913,578 (26.0)
760,253 (21.6)
66,392 (1.9)

291,603 (22.5)
359,890 (27.7)
378,051 (29.1)
257,403 (19.8)
10,689 (0.8)

566,458 (25.6)
554,366 (25.0)
535,527 (24.2)
502,850 (22.7)
55,703 (2.5)

Hospital Admission b

93,115 (2.7)

48,870 (3.8)

44,245 (2.0)

<.0001

Member Days a

350.2 (±51.2)

354.7 (±43.5)

347.6 (±55.1)

<.0001

<.0001

Frailty Score b

<.0001

Robust

2,754,407 (78.4)

930,800 (71.7)

1,823,607 (82.3)

Pre-frail

649,186 (18.5)

311,361 (24.0)

337,825 (15.3)

Frail

108,947 (3.1)

55,475 (4.3)

53,472 (2.4)

Charlson Comorbidity Score a

0.1 (±0.5)

0.09 (±0.6)

0.05 (±0.4)

<.0001

Elixhauser Comorbidity
Indicators b
Asthma

88,923 (2.5)

41,360 (3.2)

47,563 (2.2)

<.0001

Cardiac dysrhythmias

331,772 (9.5)

164,646 (12.7)

167,126 (7.6)

<.0001

Chronic obstructive pulmonary
disease

221,536 (6.3)

105,497 (8.1)

116,039 (5.2)

<.0001

Chronic renal failure

121,542 (3.5)

56,523 (4.4)

65,019 (2.9)

<.0001

Conduction disorders of the
heart

372,287 (10.6)

183,034 (14.1)

189,253 (8.5)

<.0001

Congestive heart failure

106,323 (3.0)

55,825 (4.3)

50,498 (2.3)

<.0001

Cystic fibrosis

133 (0.0)

64 (0.0)

69 (0.0)

Diabetes with chronic
complications

232,229 (6.6)

107,375 (8.3)

124,854 (5.6)

0.008
<.0001
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Diabetes without chronic
complications

521,671 (14.9)

228,960 (17.6)

292,711 (13.2)

<.0001

Diverticulosis and diverticulitis

65,847 (1.9)

28,475 (2.2)

37,372 (1.7)

<.0001

Epilepsy

20,519 (0.6)

9,491 (0.7)

11,028 (0.5)

<.0001

Heart valve disorders

134,302 (3.8)

59,126 (4.6)

75,176 (3.4)

<.0001

Hepatitis

7,689 (0.2)

3,434 (0.3)

4,255 (0.2)

<.0001

HIV infection

1,448 (0.0)

595 (0.1)

853 (0.0)

Hypertension

1,134,065 (32.3)

479,773 (37.0)

654,292 (29.5)

<.0001

Multiple sclerosis

5,181 (0.1)

2,556 (0.2)

2,625 (0.1)

<.0001

Otitis media

32,743 (0.9)

14,004 (1.1)

18,739 (0.9)

<.0001

Parkinson’s Disease

26,341 (0.8)

12,431 (1.0)

13,910 (0.6)

<.0001

Peri-; endo-; and myocarditis

41,308 (1.2)

21,157 (0.9)

20,151 (0.9)

<.0001

Pulmonary heart disease

29,495 (0.8)

13,587 (1.1)

15,908 (0.7)

<.0001

Rheumatoid arthritis

44,272 (1.3)

21,231 (1.6)

23,041 (1.0)

<.0001

Schizophrenia

2,805 (0.1)

1,905 (0.2)

900 (0.0)

<.0001

Senile

80,738 (2.3)

38,115 (1.9)

42,623 (1.9)

<.0001

Sickle cell anemia

241 (0.0)

85 (0.2)

156 (0.0)

Systemic lupus erythematosus

12,084 (0.3)

5,905 (0.5)

6,179 (0.3)

<.0001

Vertigo

78,277 (2.2)

36,386 (2.8)

41,891 (1.9)

<.0001

0.001

0.59

a

Mean (±SD)
N (%)
* p-values were calculated using two sample t-test
b

4.1.2

Propensity Score Matching Results
The mean propensity score in both the treated group and control group was 0.40

(minimum score of 0.05 and maximum score of 0.93 in both groups). A total of 39
potentially biasing factors (age, gender, geographic region, hospital admissions, member
days, frailty [robust, pre-frail, frail], Charlson Comorbidity Score, and 26 Elixhauser
Comorbidity Indicators) were assessed for patients treated with Beers Criteria medications
and controls that received medications not in Beers Criteria through PSM. We excluded
three of the 29 Elixhauser Comorbidity Indicators (chronic ulcers of the skin, late stroke,
and paralysis) from our propensity model as there were no subjects included in the study
that had these conditions. In controlling for these factors, we can be sure that baseline
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characteristics were similar between comparison groups given that observed differences,
or covariates, were similar between groups (Austin, 2011).
A graph of the standardized difference in means is represented in Figure 4.1. As
depicted in the graph, we achieved improved balance across all 39 covariates included in
the propensity model given that all standardized mean differences for the matched
observations are within the recommended limits of -0.25 and 0.25 after matching
(represented by the shaded area) (Rubin, 2001). We also reduced selection bias of these
known factors by matching on propensity score, which is one of the primary goals of PSM
(Stuart, 2010; Rosenbaum & Rubin, 1983). The standardized difference in means and
percent reduction in bias for each of the 39 covariates used in the propensity model are also
represented in Table 4.2.
Figure 4.1: Standardized Mean Differences
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Table 4.2. Demographics, Characteristics, and Reduction in Bias After Matching During
Baseline Period
Total matched
N= 2,595,254

Treatment
N= 1,297,627

Control
N= 1,297,627

SD*

%Reduction
in Bias

Age a

74.0 (±6.8)

73.9 (±6.8)

74.1 (±6.9)

-0.02

74.62

Female Gender b

1,507,587 (58.1)

757,171 (58.4)

750,416 (57.8)

-0.01

92.69

Geographical Region b
Northeast
North Central
South
West
Unknown

585,293 (22.6)
716,286 (27.6)
750,264 (28.9)
520,746 (20.1)
22,665 (0.9)

291,603 (22.5)
359,885 (27.7)
378,048 (29.1)
257,402 (19.8)
10,689 (0.8)

293,690 (22.6)
356,401 (27.5)
372,216 (28.7)
263,344 (20.3)
11,976 (0.9)

-0.00
0.01
0.01
-0.01
-0.01

94.82
90.08
90.93
84.03
94.14

Hospital Admission b

86,951 (3.4)

48,863 (3.8)

38,088 (2.9)

0.05

53.05

Member Days a

354.8 (±42.7)

354.7 (±43.5)

354.9 (±41.8)

-0.01

96.34

Robust

1,880,420 (72.5)

930,800 (71.7)

949,620 (73.2)

-0.03

86.32

Pre-frail

612,118 (23.6)

311,359 (24.0)

300,759 (23.2)

0.02

90.66

Frail

102,716 (4.0)

55,468 (4.3)

47,248 (3.6)

0.04

65.96

Charlson Comorbidity
Score a

0.1 (±0.6)

0.09 (±0.6)

0.07 (±0.5)

0.04

50.69

Asthma

80,745 (3.1)

41,358 (3.2)

39,387 (3.0)

0.01

85.39

Cardiac dysrhythmias

314,924 (12.1)

164,637 (12.7)

150,287 (11.6)

0.04

78.50

Chronic obstructive
pulmonary disease

203,171 (7.8)

105,489 (8.1)

97,682 (7.5)

0.02

79.19

Chronic renal failure

110,783 (4.3)

56,517 (4.4)

54,266 (4.2)

0.01

87.79

Conduction disorders
of the heart

351,845 (13.6)

183,025 (14.1)

168,820 (13.0)

0.03

80.31

Congestive heart
failure

100,790 (3.9)

55,820 (4.3)

44,970 (3.5)

0.05

58.65

Cystic fibrosis

122 (0.0)

64 (0.0)

58 (0.0)

0.00

74.55

Frailty Score b

Elixhauser
Comorbidity Indicators
b
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Diabetes with chronic
complications

213,359 (8.2)

107,369 (8.3)

105,990 (8.2)

0.00

95.97

Diabetes without
chronic complications

459,253 (17.7)

228,953 (17.6)

230,300 (17.8)

-0.00

97.66

Diverticulosis and
diverticulitis
Epilepsy

57,205 (2.2)

28,474 (2.2)

28,731 (2.2)

-0.00

96.09

18,518 (0.7)

9,491 (0.7)

9,027 (0.7)

0.00

84.69

Heart valve disorders

117,893 (4.5)

59,125 (4.6)

58,768 (4.5)

0.00

97.63

Hepatitis

6,771 (0.3)

3,434 (0.3)

3,337 (0.3)

0.00

89.69

HIV infection

1,216 (0.1)

595 (0.1)

621 (0.1)

-0.00

72.71

Hypertension

972,418 (37.5)

479,764 (37.0)

492,654 (38.0)

-0.02

86.63

Multiple sclerosis

4,918 (0.2)

2,555 (0.2)

2,363 (0.2)

0.00

81.14

Otitis media

28,506 (1.1)

14,001 (1.1)

14,505 (1.1)

-0.00

83.34

Parkinson’s Disease

24,621 (1.0)

12,431 (1.0)

12,190 (0.9)

0.00

94.37

Peri-; endo-; and
myocarditis
Pulmonary heart
disease
Rheumatoid arthritis

39,016 (1.5)

21,154 (1.6)

17,862 (1.4)

0.02

64.80

26,232 (1.0)

13,585 (1.1)

12,647 (1.0)

0.01

78.02

41,679 (1.6)

21,231 (1.6)

20,448 (1.6)

0.01

89.87

Schizophrenia

2,776 (0.1)

1,898 (0.2)

878 (0.1)

0.03

25.96

Senile

75,108 (2.9)

38,113 (2.9)

36,995 (2.9)

0.01

91.49

Sickle cell anemia

170 (0.0)

85 (0.0)

85 (0.0)

0.00

100.00

Systemic lupus
erythematosus

11,455 (0.4)

5,905 (0.5)

5,550 (0.4)

0.00

84.46

Vertigo

72,004 (2.8)

36,382 (2.8)

35,622 (2.8)

0.00

93.58

a

Mean (±SD)
N (%)
* Standardized
Difference
b

Matching treated and control patients resulted in an 89.6% total reduction in bias
all covariates. Several Elixhauser Comorbidity Indicators demonstrated the greatest
amount of reduction in bias compared to all 39 covariates used in matching, including
sickle cell anemia (100%), diabetes without chronic complications (97.7%), and heart
valve disorders (97.6%). Of the other variables, member days had the greatest amount of
reduction bias (96.3%). The least amount of percentage reduction in bias was observed in
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Schizophrenia (26.0%), Charlson Comorbidity Score (50.7%), and hospital admission
(53.1%).
Each of the 39 matched covariates resulted in statistically equal treatment and
control groups on these known potentially biasing factors. As shown in Table 4.2, the
standardized mean differences for all covariates were well under the recommended
maximum standardized difference value of 0.25 (Rubin, 2001). We reported the
standardized mean differences in this study as we expected p-values to be statistically
significant due to the large sample size. The largest standardized mean difference after
matching was observed in hospital admissions (0.05) and Congestive Heart Failure (0.05).
4.1.3

Demographics and Characteristics After Matching
As shown in Table 4.2, after PSM the total matched sample size was reduced from

3,512,540 to 2,595,254 patients. After using 1:1 matching techniques, the Beers Criteria
treated and control groups were each comprised of a sample of 1,297,627 patients included
in analysis. The average age of the matched population was 74.0 years. A greater
proportion of patients after matching were female (58.1%). On average, the matched
population was insured for 354.8 days.
After matching, there were small differences observed in age, sex, hospital
admissions, member days, frailty, and Charlson Comorbidity Score between treated
individuals and controls (Table 4.2). The smallest differences were observed in age,
member days, geographical region, and Charlson Comorbidity Score. The largest
differences were observed in sex, hospital admissions, and frailty. The proportion of
females that received medications included in Beers Criteria was 58.4% versus 57.8%
proportion of controls that did not receive Beers Criteria medications. The treatment group
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comprised a slightly higher proportion of individuals that were admitted to the hospital
(3.8% versus 2.9%). Of those patients classified as frail, 3.8% received medications
included in Beers Criteria compared to 2.9% that did not receive a Beers Criteria
medication.
While not all differences in Elixhauser Comorbidity Indicators were completely
eliminated after matching, we observed a much better fit with the largest differences
detected in hypertension, conduction disorders of the heart, and cardiac dysrhythmias.
Prior to matching, there was a 7.5% difference in the proportion of treated individuals with
hypertension compared to controls. After matching the difference in the proportion of
hypertension between the treatment and control groups was reduced to 1.0%. There was a
5.6% difference in the proportion of treated individuals with conduction disorders of the
heart compared to controls before matching, and the proportion difference between groups
was reduced to 1.1% after matching. Prior to matching, there was a 5.1% difference in the
proportion cardiac dysrhythmias. After matching the difference in the proportion of cardiac
dysrhythmias between the treatment and control groups was reduced to 1.1%. The
proportion of all other Elixhauser Comorbidity Indicators among the treatment and control
groups was under one percent.
4.1.4

Exposure to Beers Criteria Medications After Matching
Table 4.3 represents the average number of days treated individuals were exposed

to each Beers Criteria medication class after matching. Of the 29 medication classes
included in this study, the greatest exposure to Beers Criteria medications was observed in
three cardiovascular drugs: Alpha1 Blockers, Antihypertensive, and Antiarrhythmic.
Patients that received Alpha1 Blockers (Doxazosin, Prazosin, or Terazosin) were exposed
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to these PIMs on average 288 days. Of patients that received an Antihypertensive in Beers
Criteria (Nifedipine), they were exposed on average 285.5 days. Patients that received a
Beers Criteria Antiarrhythmic (Amiodarone, Digoxin, Disopyramide, Dofetilide,
Dronedarone, Flecainide, Ibutilide, Procainamide, Propafenone, Quinidine, or Sotalol)
during the study were exposed to these PIMs on average 278.6 days. The shortest exposure
to a Beers Criteria medication was observed in the Antiemetic (used for Gastrointestinal
disorders) and Narcotic medication classes. Patients were exposed to an Antiemetic
(Trimethobenzamide) for 34.6 days on average, and average exposure to a narcotic
(Meperidine, Pentazocine) did not exceed 35.9 days.

Table 4.3: Days Exposed to Beers Medications During Study After Matching
Beers Medications & Classes
Anticholinergics
1st Generation Antihistamines
Brompheniramine, Carbinoxamine, Chlorpheniramine,
Clemastine, Cyproheptadine, Dexbrompheniramine,
Dexchlorpheniramine, Diphenhydramine, Doxylamine,
Hydroxyzine, Promethazine, Triprolidine

Mean Days Exposed
(SD)
57.4 (88.0)

Antiparkinson Agents
Benztropine, Trihexyphenidyl

209.4 (137.1)

Antispasmodics
Belladonna alkaloids, Clidinium-Chlordiazepoxide,
Dicyclomine, Hyoscyamine, Propantheline, Scopolamine

89.9 (112.3)

Antithrombotics
Antithrombotic
Dipyridamole, Ticlopidine

256.2 (122.0)

Anti-infective
Anti-infective
Nitrofurantoin

37.5 (78.7)
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Cardiovascular
Alpha1 Blocker
Doxazosin, Prazosin, Terazosin

288.0 (123.8)

Alpha Agonist, Central
Clonidine, Guanabenz, Guanfacine, Methyldopa, Reserpine

227.0 (146.6)

Antiarrhythmic
Amiodarone, Digoxin, Disopyramide, Dofetilide,
Dronedarone, Flecainide, Ibutilide, Procainamide,
Propafenone, Quinidine, Sotalol

278.6 (148.3)

Antihypertensive
Nifedipine

285.5 (125.0)

Diuretic
Spironolactone

235.8 (130.3)

Central Nervous System
Tertiary TCA
Amitriptyline, Chlordiazepoxide-amitriptyline,
Clomipramine, Doxepin, Imipramine, Perphenazineamitriptyline, Trimipramine

224.6 (146.1)

1st Generation Antipsychotic
Chlorpromazine, Fluphenazine, Haloperidol, Loxapine,
Molindone, Perphenazine, Pimozide, Promazine,
Thioridazine, Thiothixene, Trifluoperazine,
Triflupromazine

128.8 (145.7)

2nd Generation Antipsychotic
Aripiprazole, Asenapine, Clozapine, Iloperidone,
Lurasidone, Olanzapine, Paliperidone, Quetiapine,
Risperidone, Ziprasidone

233.2 (166.1)

Anxiolytic
Meprobamate

182.0 (134.0)

Barbiturates
Amobarbital, Butabarbital, Butalbital, Mephobarbital,
Pentobarbital, Phenobarbital, Secobarbital

104.4 (129.3)

Benzodiazepines Short Acting
Alprazolam, Estazolam, Lorazepam, Oxazepam,
Temazepam, Triazolam

139.5 (136.8)
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Benzodiazepines Long Acting
Chlordiazepoxide, Chlordiazepoxide-amitriptyline,
Clidinium-chlordiazepoxide, Clonazepam, Clorazepate,
Diazepam, Flurazepam, Quazepam

127.1 (131.8)

Ergoloid
Ergoloid mesylates

229.7 (120.8)

Nonbarbiturate Sedative
Chloral hydrate

38.6 (23.3)

Nonbenzodiazepine hypnotics
Eszopiclone, Zaleplon, Zolpidem

173.7 (134.0)

Vasodilator
Isoxsuprine

205.5 (152.4)

Endocrine
Hormones
Desiccated thyroid, Estrogens, Growth Hormone, Insulin,
Megestrol, Methyltestosterone, Testosterone
Sulfonylurea
Chlorpropamide, Glyburide
Gastrointestinal
Antiemetic
Trimethobenzamide
Gut Motility Stimulator
Metoclopramide
Pain
Narcotic
Meperidine, Pentazocine

240.4 (146.3)

272.5 (120.9)

34.6 (63.0)

74.9 (102.2)

35.9 (78.7)

NonCOX NSAIDs
Aspirin, Diclofenac, Diflunisal, Etodolac, Fenoprofen,
Ibuprofen, Ketoprofen, Meclofenamate, Mefenamic acid,
Meloxicam, Nabumetone, Naproxen, Oxaprozin,
Piroxicam, Sulindac, Tolmetin

115.0 (125.0)

NSAIDs
Indomethacin, Ketorolac

40.0 (53.3)
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Skeletal Muscle Relaxants
Carisoprodol, Chlorzoxazone, Cyclobenzaprine,
Metaxalone, Methocarbamol, Orphenadrine

4.2

67.8 (96.7)

Aim 1 Results
Aim 1: To examine the healthcare resource utilization for Medicare patients who

receive medications included in Beers Criteria compared to a well-matched group of
Medicare patients who do not receive medications included in Beers Criteria.
Hypothesis 1: The odds of hospital admission in a group of patients who receive
Beers Criteria medications is greater than the odds of hospital admission in a group of
patients who do not receive Beers Criteria medications.
Hypothesis 2: Among patients who had a hospitalization, the mean number of days
admitted to the hospital is greater in patients who receive Beers Criteria medications
compared to patients who do not receive Beers Criteria medications.
The unadjusted risk for hospitalization was calculated for the treatment and control
groups. A total of 213,106 (62.0%) patients treated with Beers Criteria medications had at
least one hospital admission during the follow up period compared to a total of 130,489
(38.0%) patients that received medications not in Beers Criteria (p-value <0.0001) (Table
4.4). Of those treated and control patients that were admitted to the hospital, patients that
received Beers Criteria medications had more hospital visits on average during follow up
compared to those that received medications not in Beers Criteria (1.26 versus 1.20 average
number of admissions; p-value <0.0001) (Table 4.4). Additionally, patients that received
Beers Criteria medications spent more days in the hospital during follow up compared to
control patients (6.63 versus 6.11 average number of days in hospital; p-value <0.0001)
(Table 4.4).
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Table 4.4: Unadjusted and Adjusted Risk of Hospital Admission, Number of
Admissions, and Hospital Days During Follow Up Period
Adjusted*

Unadjusted

Any Admission

Treatment
Group

Control Group

Treatment
Group

213,106 (62.0)a

130,489 (38.0)a

1.78 (1.76-1.79)c

b

b

Control Group

Reference

d

Number of Admissions 1.26 (±0.68)
1.20 (±0.56)
1.26 (1.26-1.27)
1.19 (1.18-1.20) d
Number of Days in
6.63 (±9.85)b
6.11 (±9.40)b
6.48 (6.45-6.50) d
5.89 (5.86-5.92) d
Hospital
a
N (%)
b
Mean (±SD)
c
Adjusted OR (95% CI)
d
Mean (95% CI)
* Estimates adjusted for age, gender, geographic region, hospital admissions, member days, frailty,
Charlson Comorbidity Score, and Elixhauser Comorbidity Indicators

We used a logistic regression to predict the risk of hospital admission for treated
and control patients while controlling for age, gender, geographic region, hospital
admission, member days, frailty, Charlson Comorbidity Score, and 26 Elixhauser
Comorbidity Indicators. The adjusted risk (odds ratio) for hospital admission while using
Beers Criteria medications was calculated, and patients using Beers Criteria medications
have 77.5% higher odds of a hospital admission compared to patients not using Beers
Criteria medications (AOR=1.78; 95% CI 1.76 – 1.79; p-value <0.0001) (Table 4.4).
We used a zero-inflated Poisson model to calculate the adjusted number of hospital
admissions for treated and control patients that experienced at least one hospitalization
during follow up while controlling for age, gender, geographic region, hospital admission,
member days, frailty, Charlson Comorbidity Score, and 26 Elixhauser Comorbidity
Indicators. Adjusted results did not vary significantly compared to the unadjusted number
of hospital admissions. Patients that received Beers Criteria medications that were
hospitalized during follow up had 1.26 average number of hospital admissions compared
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to 1.19 average number of hospital admissions for patients that did not receive Beers
Criteria medications that were hospitalized during follow up (p-value <0.0001) (Table 4.4;
Figure 4.2).

Mean

Figure 4.2: Adjusted Number of Hospital Admissions with 95% Confidence Intervals
1.28
1.27
1.26
1.25
1.24
1.23
1.22
1.21
1.2
1.19
1.18
1.17
Patients treated with Beers
Criteria

Control Patients

We used a negative binomial count model to calculate the adjusted number of days
spent in the hospital for treated and control patients that experienced at least one
hospitalization during follow up. Unadjusted and adjusted results varied slightly, but this
difference was not statistically significant. After controlling for age, gender, geographic
region, hospital admission, member days, frailty, Charlson Comorbidity Score, and 26
Elixhauser Comorbidity Indicators, patients that received Beers Criteria medications spent
on average 6.48 days in the hospital during follow up compared to control patients who
spent on average 5.89 days in the hospital (p-value <0.0001) (Table 4.4; Figure 4.3).
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Figure 4.3: Adjusted Number of Days in Hospital with 95% Confidence Intervals
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We also calculated the marginal number of days spent in the hospital (Figure 4.4).
The sample of patients that received Beers Criteria medications (213,106 patients) were in
the hospital a total of 1,380,543 days during follow up. The sample of patients that received
medications not in Beers Criteria (130,489 patients) were in the hospital a total of 768,123
days during follow up. The marginal number of days hospitalized, or the number of hospital
days that may have been saved not using Beers Criteria medications, was 612,420 days.
Figure 4.4: Adjusted Average Number of Days Spent in Hospital
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4.3

Aim 2 Results
Aim 2: To determine the total healthcare costs for Medicare patients who receive

medications included in Beers Criteria compared to a well-matched group of Medicare
patients who do not receive medications included in Beers Criteria.
Hypothesis 1: Total healthcare costs are greater in patients who receive Beers
Criteria medications compared to patients who do not receive Beers Criteria medications.
Total inpatient visit costs, outpatient visit costs, and prescription medication costs
were calculated to determine the total unadjusted healthcare costs for patients treated with
Beers Criteria medications and patients treated with medications not in Beers Criteria
(Table 4.5; Figure 4.5). The average total cost of inpatient visits for patients treated with
Beers Criteria during the nine month follow up period in 2013 was $4,760 compared to
$2,566 average total inpatient cost for patients treated with medications not in Beers
Criteria (p-value <0.0001). Average outpatient visit costs during the nine month follow up
period in the treated sample was $7,492 and $4,912 in the control group (p-value <0.0001).
Average prescription medication costs during the nine month follow up period were also
higher for the treatment group. Those treated with Beers Criteria medications were
responsible for an average of $2,734 in prescription drug costs compared to $1,102 average
prescription drug costs in the control group (p-value <0.0001). Total inpatient, outpatient,
and prescription drug costs were higher on average for patients that received Beers Criteria
medications during the follow up period.
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Table 4.5: Inpatient Visit, Outpatient Visit, Prescription Medication, and Total Study
Costs During Follow Up Period*
Treatment Group

Control Group

p-value^

Mean (SD)

Mean (SD)

Inpatient Visit Cost

4,760 (23,238)

2,566 (16,055)

<0.0001

Outpatient Visit Cost
Prescription Medication Cost
Total Unadjusted Study Cost

7,492 (21,909)
2,734 (5,590)
14,987 (36,033)

4,912 (23,962)
1,102 (3,633)
8,580 (30,962)

<0.0001
<0.0001
<0.0001

Adj. Mean (95% CI)
Adj. Mean (95% CI)
Total Adjusted Study Cost+
13,404 (13,373-13,436)
7,310 (7,293-7,327)
<0.0001
* All costs are in 2013 US$; charges have been rounded to the nearest dollar
^ p-values were calculated using two sample t-test
+Estimates adjusted for age, gender, geographic region, hospital admissions, member days, frailty,
Charlson Comorbidity Score, and Elixhauser Comorbidity Indicators

Figure 4.5: Unadjusted Inpatient Visit, Outpatient Visit, and Prescription Medication
Costs During Follow Up Period
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Using the total costs from inpatient and outpatient visits and prescription
medications, the average total unadjusted study cost per patient was calculated for both
cohorts (Table 4.5; Figure 4.6). The total cost of healthcare for patients treated with Beers
Criteria was $14,987 per patient during the follow up period compared to $8,580 total
healthcare costs per patient treated with medications not in Beers Criteria (p-value
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<0.0001). Total healthcare costs generated during the nine month follow up period were
higher on average for patients that received Beers Criteria medications in 2013.
We used a Gamma distributed generalized linear model with a logarithmic link
function to calculate the adjusted total healthcare costs generated during the follow up
period for treated and control patients. Differences in the unadjusted and adjusted costs
were not statistically significant. After controlling for age, gender, geographic region,
hospital admission, member days, frailty, Charlson Comorbidity Score, and 26 Elixhauser
Comorbidity Indicators, the adjusted total healthcare cost per patient for those that received
Beers Criteria medications was $13,404. The adjusted total healthcare cost per patient for
controls was $7,310 (p-value <0.0001) (Table 4.5; Figure 4.6). Based on the per patient
total cost, and considering the total study population, we estimate that $23.2 billion in
inpatient, outpatient, and medication costs were attributed to patients that received Beers
Criteria medications in 2013, compared to $12.6 billion annual healthcare costs attributed
to control patients.
Figure 4.6: Average Total Healthcare Costs During Follow Up Period
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4.4

Summary
After matching patients treated with Beers Criteria medications and controls that

did not receive Beers Criteria medications through 1:1 PSM methods, the treatment and
control groups were similar with respect to age, gender, geographical region, hospital
admission, number of days enrolled in insurance plan (member days), frailty, Charlson
Comorbidity Score, and 26 Elixhauser Comorbidity Indicators. All 39 potentially biasing
factors included in the matching model were well balanced after matching. We can
conclude that our observational study is comprised of well-matched treatment and control
groups and is unlikely to have much selection bias.
Using medications included in Beers Criteria is associated with greater odds of
hospital admission. Of those that are hospitalized, patients using Beers Criteria medications
have a greater risk of more hospital admissions and a greater risk of spending more days
in the hospital compared to patients treated with medications not in Beers Criteria. The
total adjusted healthcare costs were significantly higher in the cohort of patients treated
with Beers Criteria medications compared to controls treated with medications not in Beers
Criteria. Using medications included in Beers Criteria is also associated with significantly
higher annual inpatient, outpatient, and medication costs.
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V.

Discussion
The primary objective of this retrospective cohort study was to quantify healthcare

resource utilization and healthcare costs attributable to using PIMs included in 2012 Beers
Criteria. A total of 73,644 individual NDC codes representing 138 medications from eight
therapeutic areas were used to identify 2012 Beers Criteria medications. We compared
hospital admissions, days spent in the hospital, and total healthcare costs generated from
inpatient and outpatient visits and prescription medication use for patients that received
PIMs in Beers Criteria compared to a well-matched group of patients that received
medications not included in Beers Criteria. The aims of this study are innovative in that
risk of hospitalization, hospitalization rates, days admitted to the hospital, and total costs
attributable to all PIMs listed in Beers Criteria have not been previously published.
Additionally, these outcomes have also not been compared to a well-matched group of
patients that received medications not included in Beers Criteria.
To address the aims of this research, a specialized set of methodological approaches
was required. PSM was used to create a control group where a control did not otherwise
exist to design a quasi-randomized study structure (Rosenbaum & Rubin, 1983). We used
this technique to equally distribute measured bias and hidden bias correlated with any
covariates across both groups, ensuring that the non-random sample represented in
Marketscan® behaved more like a randomized design with selection bias control. Few
studies of Beers Criteria have used PSM techniques. To our knowledge, our study is the
first to employ PSM techniques while using a current version of Beers Criteria.
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Fu et al. (2007) and Stockl et al. (2010) are the only studies of Beers Criteria
identified that incorporated PSM techniques. Although both studies also employed 1:1
PSM techniques, the sample size of patients exposed and unexposed to 2003 Beers Criteria
PIMs in these previous studies varied considerably compared to our sample size of matched
treated and control patients. In the Fu et al. (2007) study, the final sample population
included 103 patients in the exposed and unexposed groups. Stockl et al. (2010) included
37,358 controls and patients exposed to Anticholinergics, 395 controls and patients
exposed to Narcotics, 1,085 controls and patients exposed to Trimethobenzamide
Hydrochloride, and 13,542 controls and patients exposed to Sedative Hypnotics. In
comparison, our study sample was comprised of 1,297,627 matched patients in the
treatment and control groups. Additionally, the number of covariates included in PSM
varied between previous studies and our study. Whereas Fu et al. (2007) included 14
covariates and Stockl et al. (2010) included 11 variables in PSM, our study included 39
potentially biasing patient demographic and baseline health covariates.
Consistent with previous studies of medication use in the elderly, our research
indicates that prescription medication use in older adults remains prevalent. Nearly 85%
of patients aged 65 and older included in this study had at least one prescription medication
claim during a three-month baseline period in 2013. Older people have more health
problems, take more medications, and are more likely to experience negative health
outcomes that require hospitalization (Budnitz, Lovegrove, Shehab, & Richards, 2011).
Even more concerning, older adults are often prescribed medications that are not medically
necessary. Incidence of Beers Criteria medication use in the elderly has been well
established in previous research.
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Despite the adoption of Beers Criteria among a variety of healthcare professionals
and settings associated with geriatric care, PIM prescribing in the elderly remains prevalent
(Page, Linnebur, Bryant, & Ruscin, 2010). Recent studies of Medicare claims generated
by community-dwelling elderly patients using medications included in 2012 Beers Criteria
support the claim that PIM use in older adults continues to be prevalent nearly 30 years
after the introduction of Beers Criteria guidelines, and our study results are aligned with
these findings (Davidoff et al., 2015; Jirón et al., 2016). Davidoff and colleagues (2015)
reported nearly 43% of older adults that filled a prescription for at least one PIM included
on 2012 Beers Criteria. Jirón and colleagues (2016) reported over 34% of elderly patients
used a 2012 Beers Criteria medication during a one month baseline period in 2012.
Although not one of our primary objectives, findings from our study are consistent with
prevalence rates presented in recent studies. We identified 37% of patients receiving
prescription medications were prescribed at least one PIM included in 2012 Beers Criteria
during a three-month baseline period in 2013.
Our study offers several advantages and novel design approaches that have not been
previously incorporated in research of Beers Criteria. We used a current version of Beers
Criteria that coincides with recent prescribing practices among clinicians treating elderly
patients. More importantly, we included all medications in Beers Criteria classified as
potentially inappropriate for all older adults. This is especially innovative as most previous
studies have used a limited number of medications included in Beers Criteria. Including all
medications in Beers Criteria classified as potentially inappropriate for all older adults was
also advantageous in that we had a very large sample size, even after matching, compared
to previous studies. Using PSM, a technique not frequently used in Beers Criteria research,
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allowed us to control for most sources of selection bias and to make causal inferences
where there was non-random assignment (Heckman, Ichimura, Smith, & Todd, 1996). We
also accounted for many potentially biasing demographic and health factors through PSM
and in our outcomes analyses. To our knowledge, no study has been published that has
incorporated all of these design factors to analyze unadjusted and adjusted hospitalization
rates, describe risk of hospitalization, determine the marginal number days PIM users are
hospitalized, calculate unadjusted inpatient, outpatient, and prescription drug costs, and
report adjusted total costs for patients treated with Beers Criteria medications compared to
patients treated with alternative medications. As a result, this study provides stronger
evidence compared to previous studies that prescribing PIMs included in 2012 Beers
Criteria has a significant effect on risk of hospitalization, number of hospital admissions,
days spent hospitalized, inpatient visit costs, outpatient visit costs, and total annual costs
to payers.
5.1

Aim 1 Discussion
The first aim of this study was to examine the healthcare resource utilization for

Medicare patients who received medications included in Beers Criteria compared to a wellmatched group of Medicare patients who did not receive medications included in Beers
Criteria. Healthcare utilization outcomes of interest included any hospital admission,
number of hospital admissions (of those that were admitted), and total days in the hospital
(of those that were admitted). The unadjusted risk for hospitalization was significantly
higher in the sample of patients treated with Beers Criteria medications. A greater
proportion of treated patients experienced at least one hospital admission during the followup period compared to control patients. Of those treated and control patients that were
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admitted to the hospital, patients that received Beers Criteria medications had more hospital
visits on average during follow up compared to those that received medications not in Beers
Criteria.
Results from a much earlier study of utilization also support the notion that
healthcare utilization is greater among patients using Beers Criteria medications. A
retrospective review of administrative claims data for a sample of Medicare managed care
patients revealed that patients using 1997 Beers Criteria medications had, on average, a
greater number of inpatient, ED, and outpatient visits (Fick et al., 2001). Case and
comparison groups were generated based on whether patients filled a prescription for a
PIM included in 1997 Beers Criteria, however, these groups were not equal in sample size
(Fick et al., 2001). Unlike our study, patients were not matched using PSM. Baseline health
measures were more limited compared to our study. Our study accounted for inpatient and
outpatient comorbid conditions and frailty, and Fick and colleagues (2001) only used the
Charlson Comorbidity Index. Despite these design and sample size differences, Fick et al.
(2001) also found that patients using Beers Criteria PIMs had higher healthcare resource
utilization. We reported that patients receiving Beers Criteria medications had an average
of 1.26 hospital admissions, which is higher than the average number of hospital
admissions PIM users experienced as reported in Fick et al. (2001). The mean number of
hospital admissions for patients using Beers Criteria medications in the Fick et al. (2001)
study was 0.58, and, like our study, this was significantly higher than the mean number of
inpatient visits for patients not using Beers Criteria medications.
While our study results are limited to the U.S. population, it is important to
highlight that higher rates of hospitalization associated with using medications in Beers
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Criteria have been identified in other parts of the world as well. A population-based,
longitudinal study of community-dwelling residents of rural Sweden found an association
between using PIMs in 1997 Beers Criteria and risk of hospitalization. Analysis of three
years of hospitalization and mortality data confirmed that PIM use was associated with an
increased-risk for hospitalization (Klarin et al., 2006). Eight PIMs represented in 2003
Beers Criteria were included in an analysis of pharmaceutical claims for 251,305 older
adults residing in Australia. Results from this study indicate that all included medications
(amiodarone, diazepam, digoxin, ferrous sulphate, indomethacin, naproxen, oxazepam,
and temazepam) were associated with an increased risk of hospitalization (Price et al.,
2014). Not all medications included in Beers Criteria are available or used in other
countries, and there are likely differences in prescribing practices, use of healthcare
resources, and other factors that make it difficult to compare international studies of Beers
Criteria to our study or to other studies conducted within the U.S. Regardless, we found it
important to highlight these studies to demonstrate that healthcare resource utilization
associated with PIM use is not just problematic in the U.S.
Patients included in our study that used Beers Criteria medications had 77.5%
higher odds of a hospital admission compared to patients not using Beers Criteria
medications. Community-dwelling patients that used a PIM in 1997 Beers Criteria had a
20% greater risk of hospitalization (Fillenbaum et al., 2004). Results from a retrospective
cohort study of managed care administrative data for 174,275 commercially insured older
adults showed that using PIMs included in 2003 and 2012 Beers Criteria was associated
with anywhere from two to three times greater risk for hospitalization and ED visits (Brown
et al., 2016). Caution should be used when comparing previous hospitalization risk rates to
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our results. Unlike our study, previous studies used what are now outdated versions of
Beers Criteria or did not account for all medications included in Beers Criteria. Considering
that our study accounts for risk of hospitalization associated with all medications classified
as potentially inappropriate in Beers Criteria, the underlying issue remains clear that any
PIM use is associated with increased risk of hospitalization.
Our study included community-dwelling patients, but a study of nursing home
patients provides evidence that risk of hospitalization among institutionalized patients
using Beers Criteria medications is also of concern. Results from a study using 1991 and
1997 Beers Criteria and data from the 1996 Medical Expenditure Panel Survey Nursing
Home Component revealed that patients institutionalized for three consecutive months or
longer that received a PIM included in Beers Criteria had over 1.2 greater odds of being
hospitalized compared to patients that were not using a PIM (Lau et al., 2005). Continued
PIM use (defined as using PIMs for two consecutive months) was associated with nearly a
30% greater risk for hospitalization (Lau et. al, 2005). Additionally, patients using Beers
Criteria PIMs had a 28% greater risk of death compared to patients not using PIMs (Lau et
al., 2005). Results from Lau et al. (2005) study are dated, but this study justifies the concern
regarding inappropriate medication use across all elderly populations. More current
research is needed to determine if hospitalization and death rates remain higher among
institutionalized PIM users compared to those using alternative medications.
Results from our study demonstrate that patients that received Beers Criteria
medications spent on average more days in the hospital during follow up compared to
control patients. The sample of patients that received Beers Criteria medications were in
the hospital a total of 1,380,543 days during follow up in 2013 compared to controls that
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were hospitalized a total of 768,123 days during follow up. Unlike previous studies of
healthcare resource use, we were also interested in determining the marginal number of
days patients were hospitalized. The number of hospital days that may have been saved in
2013 if patients were not prescribed Beers Criteria medications was an astounding 612,420
days. These additional days spent in the hospital are unnecessary and preventable with
appropriate medication management. More important to note, though, is the increased
burden that unnecessary hospitalizations have on patients and caregivers as well as the
healthcare system. These visits are costly to payers and determinantal to patient quality of
life.
Our study provides more current hospitalization rates, risk of hospital admission,
and length of stay that are aligned with recent prescribing guidelines presented in 2012
Beers Criteria. Results from this study and results from preceding studies of earlier versions
of Beers Criteria provide historical evidence that risk of hospitalization remains high and
hospitalization rates associated with PIM use has not improved over the years even though
Beers Criteria guidelines have been in place for nearly 30 years.
5.2

Aim 2 Discussion
The second aim of this study was to determine the total healthcare costs for

Medicare patients who receive medications included in Beers Criteria during the follow up
period compared to a well-matched group of Medicare patients who do not receive
medications included in Beers Criteria. We defined cost outcomes of interest from the
perspective of an insurer. For the purposes of this study, insurance payments were denoted
as costs and measured as the aggregated total in insurance payments captured for each
patient during the follow up period in 2013. Inpatient visit costs, outpatient visit costs,
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prescription medication costs, total unadjusted costs, and total adjusted costs during the
follow-up period were anaylized for the treatment and control groups.
Total inpatient, outpatient, and prescription drug costs were higher on average for
patients that received Beers Criteria medications during the follow up period. The average
total cost of inpatient visits for patients treated with Beers Criteria was $4,760 compared
to $2,566 average total inpatient cost for the control group. Average outpatient visit costs
in the treated sample was $7,492 and $4,912 in the control group. Those treated with Beers
Criteria medications during the follow up period had an average of $2,734 in prescription
drug costs compared to $1,102 average prescription drug costs in the control group.
A previous analysis of facility, provider, and prescription drug payments based on
1997 Beers Criteria supports our results that PIM use is associated with higher costs (Fick
et al., 2001). In this study, claims for patients with continuous health maintenance
organization enrollment from June 1, 1997, through October 31, 1998 were analyzed, and
all three cost measures were higher in patients treated with select PIMs included in Beers
Criteria ($2,629 inpatient costs, $1,555 average outpatient costs, and $401 average drug
costs) (Fick et al., 2001). The outpatient and prescription drug cost differences between the
two groups were not statistically significant as they were in our study.
There are several differences between our study and the Fick et al. (2001) study
that are important to note. A limited number of Beers Criteria medications were included
in their study, and these medications are from what is now an outdated version of Beers
Criteria. The sample size varies considerably, with 1,297,627 treated and control patients
included in our study compared to 541 treated and 1,795 control patients included in Fick
et al. (2001). Fick and colleagues (2001) controlled for sex, Charlson Comorbidity Index,

134
and total number of prescriptions in their cost analyses, whereas we controlled for age,
gender, geographic region, hospital admissions, member days, frailty, Charlson
Comorbidity Score, and Elixhauser Comorbidity Indicators in our analyses. Different
statistical methods were also used to analyze cost. Fick et al. (2001) used analysis of
covariance models to assess whether total, provider, facility, and prescription costs differed
between their treated and control groups. We used generalized linear modeling to
determine if Beers Criteria medications are associated with higher healthcare costs
compared to non-Beers Criteria medications. Studies using generalized linear modeling for
cost analysis have shown good distributional fit when using the gamma response
distribution with a log link function (Moran, Solomon, Peisach, & Martin, 2007). The
results from Fick et al. (2001) may not be directly comparable to our results, but their study
does offer evidence that PIM use is associated with higher inpatient, outpatient, and drug
costs in general.
We used inpatient, outpatient, and prescription costs to calculate the average
unadjusted total cost of care for patients using Beers Criteria medications in 2013.
Controlling for age, gender, geographic region, hospital admissions, member days, frailty,
Charlson Comorbidity Score, and Elixhauser Comorbidity Indicators, we determined the
adjusted total cost of healthcare per patient for those treated with Beers Criteria during
follow up to be $13,404 compared to $7,310 adjusted average total cost of healthcare per
patient for those treated with medications not in Beers Criteria.
Stockl and colleagues (2010) analyzed claims data to determine pharmacy costs
and medical charges for managed care patients that experienced an adverse drug event
while using anticholinergics, narcotics, trimethobenzamide hydrochloride, or sedative
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hypnotics included in 2003 Beers Criteria. Costs were measured for 360 days. Similar to
our study, adjusted costs were also calculated using generalized linear modeling with a
gamma response distribution with a log link function while adjusting for age, sex, health
plan type, geographic state, Charlson Comorbidity Index, and baseline costs (Stockl et al.,
2010). Annual adjusted total healthcare costs were significantly higher for patients in each
of the four Beers Criteria medication groups compared to controls in each group (Stockl et
al., 2010).
As is the case with Fick et al. (2001), these results may not be directly comparable
to our study. The results from Stockl et al. (2010) are based on a small number of Beers
Criteria medications. The study population was also limited to a Western U.S. managed
care organization. While results from that study may not be representative of all U.S.
elderly patients receiving similar Beers Criteria medications, this study does support our
findings in that total adjusted healthcare costs are higher when patients are prescribed
medications included in Beers Criteria.
Patients treated with Beers Criteria medications in our study were responsible for
significantly greater annual healthcare costs in 2013. As was the case when we analyzed
healthcare utilization, the burden that this particular elderly patient population has on U.S.
healthcare spending is alarming. Medicare spending exceeded $585 billion in 2013
(Altman & Frist, 2015). The largest share of Medicare spending in beneficiaries over the
age of 65 was on inpatient care, and inpatient service expenses increased more than 2.5
times in 66 to 89-year-old beneficiaries (Neuman et al., 2015). As the U.S. elderly
population is expected to continue to rise in the years ahead, the number of Medicare
beneficiaries and total Medicare spending will increase. (Neuman et al., 2015). Looking to

136
the years ahead, we can expect to see further strain on the Medicare system and on other
payers in the U.S as PIM prescribing continues.
5.3

Study Limitations
Consistent with other studies analyzing claims data, our use of administrative

claims data within Marketscan® is not without limitations. Coding is used specifically for
billing purposes, and administrative claims represented in Marketscan® are collected for
the purpose of making healthcare payments and are not collected for use in research (Suissa
& Garbe, 2007). Variations in coding practices are a common limitation of administrative
databases, and there is a possibility that the Marketscan® medical claims used in this study
may be incomplete or potential errors may have occurred in diagnosis coding. It is
important to note, however, that Marketscan® offers the advantage of high-quality coding,
and a diagnosis is coded on 99% of all claims (Hansen & Chang, 2011). Regardless, we
had to rely on coding information and billing data which may not be completely accurate,
and we may have unintentionally excluded patients that should be included in the sample
based on these errors and coding limitations. Coding practices may have threatened the
internal validity of this study. However, many coding weaknesses were equally present in
both the treatment and control groups resulting in a marginal effect estimate not biased by
most coding variation.
Our study population is not inclusive of all elderly patients over the age of 65.
Patients that were not community-dwelling were excluded in our study. Marketscan® does
not capture data for poor or dually insured individuals, and this study did not include poor
or dually insured individual patients in the study population. It is also likely that some
individuals were excluded from our sample population given that medium and small
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employers are not represented in Marketscan® data (Hansen & Chang, 2011).
Marketscan® databases are based on a non-random sample. While there may be hidden
biases in our data, administrative databases are advantageous for their large sample sizes.
Despite the population limitations, we are confident that we have achieved stronger
external validity than is generally seen in smaller randomized study designs (Suissa &
Garbe, 2007) thus allowing us to generalize our results to a larger elderly population.
The aim of our study was to evaluate the overall burden of healthcare utilization
and cost associated with treating patients with PIMs included in Beers Criteria. Our cost
analyses were conducted from the perspective of the insurance company. Thus, other
factors associated with cost, such as premiums, deductibles, co-insurance, and self-paid
expenses, were not included in our analyses. Our focus on healthcare utilization included
inpatient and outpatient visits for community-dwelling individuals. We did not capture
expenditures related to skilled nursing, long-term, palliative, or hospice care. It is likely
that treatment plans and medication regimens are vastly different in individuals receiving
palliative and hospice care compared to community-dwelling patients. In the case of
palliative and hospice care, it may be more important to control the patient’s symptoms
(which may require the use of PIMs listed in Beers Criteria) rather than simply avoiding
the use of PIMs all together (American Geriatrics Society, 2012). The healthcare utilization
and cost of using PIMs listed in Beers Criteria may differ when used within special
populations compared to PIM use in community-dwelling older adults.
We excluded two categories of medications included in Beers Criteria. We did not
include medications classified in Beers Criteria as those to use in caution in older adults or
medications that, if used in older patients, may exacerbate an existing disease or syndrome.
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Medication use within these specific conditions were not the focus of our study. Unlike
previous studies of Beers Criteria, however, we did include all medications classified in
Beers Criteria as potentially inappropriate for use in all older adults in our analyses. Given
the large volume of PIMs that were included in our study (138 individual medications
across eight therapeutic areas and 73,644 individual NDC codes), results from this study
offer significant value and a greater understanding of the association between using Beers
Criteria medications and increased healthcare resource utilization and annual costs.
Although we controlled for many demographic and baseline health measures in our
study, there are factors that we did not control for. We did not control for duration of
medication exposure during the baseline period. Instead, we examined days exposed to
each Beers Criteria medication in the follow up period and after PSM. In the baseline
period, we described inappropriate medication use as a binary variable, categorizing
patients as yes/no if they received any Beers medication (AnyBeers). We did not control
for using individual Beers Criteria medications as analyzing utilization and cost for all
individual Beers Criteria medications was not the purpose of our study. To achieve the
aims of this study, we did control for many common indications that are known to be risk
factors associated with increased use in healthcare resources.
It should be noted that there are other factors related to medication use in the elderly
that could impact healthcare utilization and cost that were not addressed in analyses of this
study. Elderly patients may receive multiple medications or medications that may not be
medically necessary in order to treat a growing number of health problems as they age
(Maher et al., 2013; Hajjar, Cafiero, & Hanlon, 2007). The use of multiple medications
puts the elderly at an increased risk for interactions between drugs (Hajjar, Cafiero, &
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Hanlon, 2007). Medication non-adherence is associated with poor clinical outcomes and
has significant clinical and economic implications. Poorly treated health conditions require
additional medical treatment and often hospitalization (Hughes, 2004). These factors can
also impact healthcare resource utilization. Inpatient and outpatient visit costs and
prescription drug costs associated with treating medical complications due to drug-drug
interactions and medication non-adherence can also impact total annual healthcare costs
associated with PIM use. However, these factors were not the focus of our study.
5.4

Future Directions
Before we can expect a significant clinical change in PIM management in the

elderly population, we first needed to understand the impact using PIMs included in Beers
Criteria has on healthcare resource utilization and costs compared to using alternative
medications not listed in Beers Criteria. Results from this study suggest that elderly patients
that are prescribed medications included in Beers Criteria have a greater risk of hospital
admission compared to patients that use alternative medications not included in Beers
Criteria. Of those patients that are hospitalized, using Beers Criteria medications is also
associated with experiencing more hospital admissions and spending more days in the
hospital compared to using medications not in Beers Criteria. Our results indicate that
significantly higher inpatient, outpatient, medication costs, and annual healthcare costs are
expected when clinicians prescribe medications included in Beers Criteria compared to
patients treated with medications not in Beers Criteria. Results from this study are
meaningful for providers that provide care to the elderly population, pharmacists, older
adults and their caregivers, healthcare administrators and policy makers, and payers. These
findings have implications for provider education, policy reform, and future research.
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Beers Criteria provides a well-developed and extensive list of medications to avoid,
but it does not include a list of alternative medications in the criteria (American Geriatrics
Society, 2015). Individual patient health conditions are complex and often require
specialized medication regimens to treat a variety of health problems. Beers Criteria is not
intended to completely remove clinical judgment in regards to the needs and medication
management of the individual patient (Molony, 2003). Instead, these complexities require
individualized clinician judgment to appropriately determine if alternative, and potentially
safer, medications not included in Beers Criteria would be more appropriate for each
individual patient based on their health status. Results from our study suggest that providers
need to consider the long-term implications that clinical judgment has on the health and
well-being of patients that are prescribed PIMs included in Beers Criteria. An appropriate
and thorough medication review and minimizing use of PIMs included in Beers Criteria
may prevent unnecessary hospitalizations among elderly patients. Prior to this study,
clinicians likely did not appreciate the impact that PIM prescribing has on outpatient
resources, inpatient hospitalization rates, the number of days patients spend in the hospital,
a patient’s quality of life, or the long-term economic consequences on our national
healthcare system.
In the short-term, we hope results from this study will be informative to clinicians
who do not currently use Beers Criteria recommendations to guide their medication
management decisions in elderly patients. While we cannot expect immediate clinical
changes in prescription prescribing across all medication classes used by elderly patients,
results from this study emphasize the importance of enhancing the training and education
providers receive to ensure long-term improvements in medication management regimens
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are implemented in the near future. A key next step for policymakers is to develop
information dissemination plans that will encourage clinicians to perform enhanced
medication reviews and modify medical interventions before prescribing PIMs included in
Beers Criteria to reduce the risk of unnecessary hospitalizations of elderly patients and
minimize the burden this population will have on our national healthcare system in the
future.
Future studies should quantify the cost of PIM use at the patient level, specifically
the potential out of pocket burden associated with PIM use. This study enabled us to
understand the total annualized cost burden that using Beers Criteria medications has on
the healthcare system. Future cost analyses should consider the burden PIM use has on
patient out of pocket expenses such as insurance premiums, deductibles, co-insurance, and
self-paid expenses. Additionally, previous studies have not quantified the current economic
burden of using PIMs included in Beers Criteria in short-term rehabilitation facilities,
skilled nursing facilities, or LTC facilities. Although we have a greater understanding of
healthcare utilization and cost burden among community-dwelling individuals receiving
Beers Criteria medications, researchers should also consider healthcare resource utilization
and economic consequences for institutionalized patients receiving PIMs included in Beers
Criteria.
Researchers should consider a prospective implementation study to develop new,
or improve existing, medication warning systems that can be implemented into existing
electronic medical record systems. These technology improvements should alert clinicians
when an inappropriate medication is prescribed to an elderly patient and enable pharmacy
systems to identify potential prescribing errors before the patient is issued a PIM. Future
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studies should also engage policy makers and healthcare leaders to identify ways in which
our healthcare system can reallocate the money saved by reducing hospitalizations
attributed to PIM use and invest in medication technology system updates. The economic
investment of preventing even a fraction of the number of unnecessary hospitalizations
attributed to PIM use will justify the economic impact of updating electronic medical
systems and implementing meaningful medication technology systems.
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VI.

Conclusion
This study addressed two aims through innovative research strategies not

previously used in utilization and cost analyses of medications classified in 2012 Beers
Criteria as inappropriate for use in older adults. Community-dwelling Medicare patients
with private supplementary insurance were included in the study. Healthcare utilization
and costs were analyzed using 2013 Truven Health Marketscan® Commercial Claims and
Encounters Database. Previous research of Beers Criteria has predominately focused on
the prevalence, potential risk factors, and health outcomes associated with PIM use in the
elderly. This was the first study to analyze healthcare utilization and total healthcare costs
for patients that were prescribed medications that adhere to Beers Criteria versus patients
with similar health conditions that were prescribed medications that do not adhere to Beers
Criteria.
The first aim of this study was to examine the healthcare resource utilization for
Medicare patients who receive medications included in Beers Criteria compared to a wellmatched group of Medicare patients who do not receive medications included in Beers
Criteria. More specifically, we were interested in determining if treating patients with
inappropriate medications included in Beers Criteria is associated with more hospital
admissions and a greater risk of experiencing a hospital admission compared to patients
who do not receive Beers Criteria medications. This study provides evidence that elderly
patients that are prescribed medications included in Beers Criteria have a greater risk of
hospital admission compared to patients that use alternative medications not included in
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Beers Criteria. Of those treated and control patients that were hospitalized, we also
examined whether using Beers Criteria medications is also associated with a greater
number of days spent in the hospital. Results from this study indicate that of those patients
that are hospitalized, using Beers Criteria medications is also associated with a greater
number of hospital admissions and more days spent in the hospital compared to using
medications not in Beers Criteria.
The second aim of this study was to calculate the total healthcare costs for Medicare
patients who receive medications included in Beers Criteria compared patients who do not
receive medications included in Beers Criteria. Inpatient visit, outpatient visit, and
prescription medication costs were higher on average for patients that received Beers
Criteria medications. After controlling for potentially biasing factors, we found the
adjusted total cost of healthcare for patients treated with Beers Criteria to be significantly
higher during the follow up period compared to patients treated with medications not in
Beers Criteria. Patients treated with Beers Criteria medications were also responsible for
significantly greater annual healthcare costs in 2013.
Results from our study suggest that providers should consider the long-term
implications that medication selection has on the health and well-being of patients. Our
results also emphasize the importance of educating providers to ensure sustainable
improvements in medication management regimens are implemented in the near future. It
is imperative that providers, healthcare leaders, and policy makers work together to reduce
the risk of unnecessary hospitalizations of elderly patients and minimize the burden this
population will have on our national healthcare system in the future.
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APPENDICES
Appendix A. Medication Appropriateness Index

Source: “A Method for Assessing Drug Therapy Appropriateness” by Hanlon, J. et al.,
1992, Journal of Clinical Epidemiology, 45, p. 1046.
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Appendix B. Improved Prescribing in the Elderly Tool

The following medications represent potentially inappropriate prescriptions in an elderly
individual:
Beta-blocker and chronic obstructive airways disease
Beta-block and congestive heart failure
Calcium channel blocker (excluding amlodipine and felodipine) and congestive heart
failure
Thiazide diuretic and gout
Long half-life benzodiazepine (chlordiazepoxide, clorazepate, diazepam, flurazepam,
clonazepam, nitrazepam)
Tricyclic antidepressant and glaucoma
Tricyclic antidepressant and heart block
Tricyclic antidepressant with active metabolites (imipramine, doxepin, amitriptyline)
Methylphenidate for depression
Nonsteroidal anti-inflammatory drugs* and peptic ulcer disease
Nonsteroidal anti-inflammatory drugs and hypertension
Long term use of nonsteroidal anti-inflammatory drugs for osteoarthritis
Anticholinergic drugs to treat side effects of antipsychotic medications
Long term diphenoxylate to treat diarrhea
*Consider acetylsalicylic acid as a nonsteroidal anti-inflammatory drug only if the dose
is greater than 1300 mg/day
Source: “Development and validation of an improving prescribing in the elderly tool” by
Naugler, C.T., Brymer, C., Stolle, P., & Arcese, Z.A., 2000, Canadian Journal of
Clinical Pharmacology, 7, p. 106.
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Appendix C. STOPP (Screening Tool of Older Person's Prescriptions)

171

172

173

Source: “STOPP (Screening Tool of Older Person's Prescriptions) and START
(Screening Tool to Alert doctors to Right Treatment) Consensus validation” by
Gallagher, P., Ryan, C., Byrne, S., Kennedy, J., & O'Mahony D., 2008, International
Journal of Clinical Pharmacology and Therapeutics, 46, p. 76-78.
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Appendix D. START (Screening Tool to Alert doctors to Right Treatment)
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Source: “STOPP (Screening Tool of Older Person's Prescriptions) and START
(Screening Tool to Alert doctors to Right Treatment) Consensus validation” by
Gallagher, P., Ryan, C., Byrne, S., Kennedy, J., & O'Mahony D., 2008, International
Journal of Clinical Pharmacology and Therapeutics, 46, p. 79.
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Appendix E. 1991 Beers Criteria

Source: “Explicit criteria for determining inappropriate medication use in nursing home
residents” by Beers, M. H., Ouslander, J. G., Rollingher, I., Reuben, D. B., Brooks, J., &
Beck, J. C., 1991, Archives of Internal Medicine, 151, p. 1829.
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Appendix F. 1997 Beers Criteria

178

Source: “Explicit criteria for determining potentially inappropriate medication use by the
elderly. An update” by Beers, M. H., 1997, Archives of Internal Medicine, 157, p. 15331534.
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Appendix G. 2003 Beers Criteria

180

181

Source: Source: “Updating the Beers Criteria for Potentially Inappropriate Medication
Use in Older Adults” by Fick, D. M., Cooper, J. W., Wade, W. E., Waller, J. L., Maclean,
J. R., & Beers, M. H.., 2003, Archives of Internal Medicine, 163, p. 2719-2721.
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Appendix H. 2012 Beers Criteria
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187

188

189

190

Source: “American geriatrics society updated beers criteria for potentially inappropriate
medication use in older adults” by the American Geriatrics Society 2012 Beers Criteria
Update Expert Panel, 2012, Journal of the American Geriatrics Society, 60, p. 619-627.
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Appendix I. 2015 Beers Criteria
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196

197

198

199

200

201

202

203

Source: “American geriatrics society 2015 updated beers criteria for potentially
inappropriate medication use in older adults” by the American Geriatrics Society 2015
Beers Criteria Update Expert Panel, 2015, Journal of the American Geriatrics Society,
63, p. 2231-2243.
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Appendix J. PIMs to avoid in older adults represented in 1991, 1997, 2003, 2012,
and 2015 Beers Criteria

Brompheniramine

Drug Category/
Area affected
Anticholinergics

Carbinoxamine

Anticholinergics

Antihistamines (1st generation)

-

-

-

✓

✓

Chlorpheniramine

Anticholinergics

Antihistamines (1st generation)

-

✓

✓

✓

✓

Clemastine

Anticholinergics

Antihistamines (1st generation)

-

-

-

✓

✓

Cyproheptadine

Anticholinergics

Antihistamines (1st generation)

-

✓

✓

✓

✓

Dexbrompheniramine

Anticholinergics

Antihistamines (1st generation)

-

-

-

✓

✓

Dexchlorpheniramine

Anticholinergics

Antihistamines (1st generation)

-

✓

✓

✓

✓

Diphenhydramine (oral)

Anticholinergics

Antihistamines (1st generation)

-

✓

✓

✓

✓

Doxylamine

Anticholinergics

Antihistamines (1st generation)

-

-

-

✓

✓

Hydroxyzine

Anticholinergics

Antihistamines (1st generation)

-

✓

✓

✓

✓

Meclizine

Anticholinergics

Antihistamines (1st generation)

-

-

-

-

✓

Promethazine

Anticholinergics

Antihistamines (1st generation)

-

✓

✓

✓

✓

Tripelennamine

Anticholinergics

Antihistamines (1st generation)

-

✓

✓

-

-

Triprolidine

Anticholinergics

Antihistamines (1st generation)

-

-

-

✓

✓

Benztropine (oral)

Anticholinergics

Antiparkinson agents

-

-

-

✓

✓

Trihexyphenidyl

Anticholinergics

Antiparkinson agents

-

-

-

✓

✓

Atropine

Anticholinergics

Antispasmodics

-

-

-

✓

✓

Belladonna alkaloids

Anticholinergics

Antispasmodics

-

✓

✓

✓

✓

Clidinium-Chlordiazepoxide

Anticholinergics

Antispasmodics

-

✓

✓

✓

✓

Dicyclomine

Anticholinergics

Antispasmodics

-

✓

✓

✓

✓

Hyoscyamine

Anticholinergics

Antispasmodics

-

✓

✓

✓

✓

Propantheline

Anticholinergics

Antispasmodics

-

✓

✓

✓

✓

Scopolamine

Anticholinergics

Antispasmodics

-

-

-

✓

✓

Dipyridamole (oral, short
acting)

Antithrombotics

Platelet Inhibitor

✓

✓

✓

✓

✓

Ticlopidine

Antithrombotics

Platelet Inhibitor

-

✓

✓

✓

✓

Beers Drug

Drug class

1991

1997

2003

2012

2015

Antihistamines (1st generation)

-

-

-

✓

✓
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Beers Drug
Nitrofurantoin

Drug Category/
Area affected
Anti-infective drugs

Drug class

1991

1997

2003

2012

2015

Antibiotic

-

-

✓

✓

✓

Doxazosin

Cardiovascular
drugs

Peripheral alpha-1 blocker

-

-

✓

✓

✓

Prazosin

Cardiovascular
drugs

Peripheral alpha-1 blocker

-

-

-

✓

✓

Terazosin

Cardiovascular
drugs

Peripheral alpha-1 blocker

-

-

-

✓

✓

Clonidine

Cardiovascular
drugs

Central alpha blocker

-

-

✓

✓

✓

Guanabenz

Cardiovascular
drugs

Central alpha blocker

-

-

-

✓

✓

Guanfacine

Cardiovascular
drugs

Central alpha blocker

-

-

-

✓

✓

Methyldopa

Cardiovascular
drugs

Central alpha blocker

✓

✓

✓

✓

✓

Methyldopahydrochlorothiazide

Cardiovascular
drugs

Central alpha blocker

✓

✓

✓

-

-

Reserpine

Cardiovascular
drugs

Central alpha blocker

✓

✓

✓

✓

✓

Amiodarone

Cardiovascular
drugs

Antiarrhythmic drugs

-

-

✓

✓

✓

Disopyramide

Cardiovascular
drugs

Antiarrhythmic drugs

-

✓

✓

✓

✓

Dofetilide

Cardiovascular
drugs

Antiarrhythmic drugs

-

-

-

✓

-

Dronedarone

Cardiovascular
drugs

Antiarrhythmic drugs

-

-

-

✓

✓

Digoxin

Cardiovascular
drugs

Antiarrhythmic drugs

-

✓

✓

✓

✓

Flecainide

Cardiovascular
drugs

Antiarrhythmic drugs

-

-

-

✓

-

Ibutilide

Cardiovascular
drugs

Antiarrhythmic drugs

-

-

-

✓

-

Procainamide

Cardiovascular
drugs

Antiarrhythmic drugs

-

-

-

✓

-

Propafenone

Cardiovascular
drugs

Antiarrhythmic drugs

-

-

-

✓

-

Quinidine

Cardiovascular
drugs

Antiarrhythmic drugs

-

-

-

✓

-

Sotalol

Cardiovascular
drugs

Antiarrhythmic drugs

-

-

-

✓

-

Propranolol

Cardiovascular
drugs

Beta blocker

✓

-

-

-

-

Nifedipine (immediate
release)

Cardiovascular
drugs

Calcium channel blockers

-

-

✓

✓

✓

Ethacrynic acid

Cardiovascular
drugs

Diuretic

-

-

✓

-

-

Spironolactone (>25 mg/day)

Cardiovascular
drugs

Diuretic

-

-

-

✓

-

Guanethidine

Cardiovascular
drugs

Antihypertensive

-

-

✓

-

-

Guanadrel

Cardiovascular
drugs

Antihypertensive

-

-

✓

-

-
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Beers Drug
Amitriptyline

Drug Category/
Area affected
Central Nervous
System

Drug class

1991

1997

2003

2012

2015

Antidepressants (TCAs)

✓

✓

✓

✓

✓

Amoxapine

Central Nervous
System

Antidepressants (TCAs)

-

-

-

✓

✓

Chlordiazepoxideamitriptyline

Central Nervous
System

Antidepressants (TCAs)

-

✓

✓

✓

✓

Clomipramine

Central Nervous
System

Antidepressants

-

-

-

✓

✓

Desipramine

Central Nervous
System

Antidepressants (TCAs)

-

-

-

-

✓

Doxepin

Central Nervous
System

Antidepressants (TCAs)

-

✓

✓

✓

✓

Imipramine

Central Nervous
System

Antidepressants (TCAs)

-

-

-

✓

✓

Nortriptyline

Central Nervous
System

Antidepressants (TCAs)

-

-

-

-

✓

Paroxetine

Central Nervous
System

Antidepressants (SSRI)

-

-

-

-

✓

Perphenazine-amitriptyline

Central Nervous
System

Antidepressants (TCAs)

✓

✓

✓

✓

✓

Protriptyline

Central Nervous
System

Antidepressants (TCAs)

-

-

-

-

✓

Trimipramine

Central Nervous
System

Antidepressants (TCAs)

-

-

-

✓

✓

Fluoxetine (daily)

Central Nervous
System

SSRI antidepressant

-

-

✓

-

-

Chlorpromazine

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Fluphenazine

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Haloperidol

Central Nervous
System

Antipsychotic drugs (1st
generation)

✓

-

-

✓

✓

Loxapine

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Mesoridazine

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

✓

✓

-

Molindone

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Perphenazine

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Pimozide

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Promazine

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Thioridazine

Central Nervous
System

Antipsychotic drugs (1st
generation)

✓

-

✓

✓

✓

Thiothixene

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Trifluoperazine

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Triflupromazine

Central Nervous
System

Antipsychotic drugs (1st
generation)

-

-

-

✓

✓

Aripiprazole

Central Nervous
System

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

207

Beers Drug
Asenapine

Drug Category/
Area affected
Central Nervous
System

Drug class

1991

1997

2003

2012

2015

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

Clozapine

Central Nervous
System

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

Iloperidone

Central Nervous
System

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

Lurasidone

Central Nervous
System

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

Olanzapine

Central Nervous
System

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

Paliperidone

Central Nervous
System

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

Quetiapine

Central Nervous
System

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

Risperidone

Central Nervous
System

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

Ziprasidone

Central Nervous
System

Antipsychotic drugs (2nd
generation)

-

-

-

✓

✓

Amobarbital

Central Nervous
System

Barbiturates

-

✓

✓

✓

✓

Butabarbital

Central Nervous
System

Barbiturates

-

✓

✓

✓

✓

Butalbital

Central Nervous
System

Barbiturates

-

✓

✓

✓

✓

Central Nervous
System

Barbiturates

-

✓

✓

✓

✓

Pentobarbital

Central Nervous
System

Barbiturates

✓

✓

✓

✓

✓

Phenobarbital

Central Nervous
System

Barbiturates

-

-

-

✓

✓

Secobarbital

Central Nervous
System

Barbiturates

✓

✓

✓

✓

✓

Alprazolam

Central Nervous
System

Benzodiazepines (Short-acting)

✓

✓

✓

✓

✓

Estazolam

Central Nervous
System

Benzodiazepines (Short-acting)

-

-

-

✓

✓

Lorazepam

Central Nervous
System

Benzodiazepines (Short-acting)

-

✓

✓

✓

✓

Oxazepam

Central Nervous
System

Benzodiazepines (Short-acting)

✓

✓

✓

✓

✓

Temazepam

Central Nervous
System

Benzodiazepines (Short-acting)

-

✓

✓

✓

✓

Triazolam

Central Nervous
System

Benzodiazepines (Short-acting)

✓

✓

✓

✓

✓

Chlordiazepoxide

Central Nervous
System

Benzodiazepines (Long-acting)

✓

✓

✓

✓

✓

Clonazepam

Central Nervous
System

Benzodiazepines (Long-acting)

-

-

-

✓

✓

Clorazepate

Central Nervous
System

Benzodiazepines (Long-acting)

-

✓

✓

✓

✓

Chlordiazepoxideamitriptyline

Central Nervous
System

Benzodiazepines (Long-acting)

-

✓

✓

✓

-

Clidinium-chlordiazepoxide

Central Nervous
System

Benzodiazepines (Long-acting)

-

✓

✓

✓

✓

Mephobarbital
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Beers Drug
Diazepam

Drug Category/
Area affected
Central Nervous
System

Drug class

1991

1997

2003

2012

2015

Benzodiazepines (Long-acting)

✓

✓

✓

✓

✓

Flurazepam

Central Nervous
System

Benzodiazepines (Long-acting)

✓

✓

✓

✓

✓

Halazepam

Central Nervous
System

Benzodiazepines (Long-acting)

-

✓

✓

-

-

Quazepam

Central Nervous
System

Benzodiazepines (Long-acting)

-

✓

✓

✓

✓

Chloral hydrate

Central Nervous
System

Nonbarbiturate sedative and
hypnotic

-

-

-

✓

-

Meprobamate

Central Nervous
System

Anxiolytic

✓

✓

✓

✓

✓

Eszopiclone

Central Nervous
System

Nonbenzodiazepine sedative

-

-

-

✓

✓

Zaleplon

Central Nervous
System

Nonbenzodiazepine sedative

-

-

-

✓

✓

Zolpidem

Central Nervous
System

Nonbenzodiazepine sedative

-

-

-

✓

✓

Ergoloid mesylates

Central Nervous
System

Ergoloid

-

✓

✓

✓

✓

Cyclandelate

Central Nervous
System

Vasodilator

✓

-

✓

-

-

Isoxsuprine

Central Nervous
System

Vasodilator

-

-

✓

✓

✓

Amphetamines

Central Nervous
System

Stimulant

-

-

✓

-

-

Methyltestosterone

Endocrine system

Androgens (hormones)

-

-

✓

✓

✓

Testosterone

Endocrine system

Androgens (hormones)

-

-

-

✓

✓

Desiccated thyroid

Endocrine system

Hormones

-

-

✓

✓

✓

Estrogens with or without
progestins

Endocrine system

Hormones

-

-

✓

✓

✓

Growth hormone

Endocrine system

Hormones

-

-

-

✓

✓

Insulin, sliding scale

Endocrine system

Hormones

-

-

-

✓

✓

Megestrol

Endocrine system

Hormones

-

-

-

✓

✓

Chlorpropamide

Endocrine system

Sulfonylureas, long-duration

✓

✓

✓

✓

✓

Glyburide

Endocrine system

Sulfonylureas, long-duration

-

-

-

✓

✓

Metoclopramide

Gastrointestinal

Gut motility stimulator

-

-

-

✓

✓

Bisacodyl

Gastrointestinal

Laxative

-

-

✓

-

-

Cascara Sagrada

Gastrointestinal

Laxative

-

-

✓

-

-

Mineral oil (oral)

Gastrointestinal

Laxative

-

-

✓

✓

✓

Neoloid

Gastrointestinal

Laxative

-

-

✓

-

-
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Cimetidine

Drug Category/
Area affected
Gastrointestinal

Ranitidine

Beers Drug

Drug class

1991

1997

2003

2012

2015

Antihistamine

✓

-

✓

-

-

Gastrointestinal

Antihistamine

✓

-

-

-

-

Trimethobenzamide

Gastrointestinal

Antiemetics

✓

✓

✓

✓

-

Proton-pump inhibitors*

Gastrointestinal

Proton-pump inhibitors

-

-

-

-

✓

Ferrous sulfate

Gastrointestinal

Minerals & Electrolytes - Iron
deficiency

-

-

✓

-

-

Iron supplements

Gastrointestinal

Minerals & Electrolytes - Iron
deficiency

✓

✓

-

-

-

Meperidine

Pain Medications

Narcotic

-

✓

✓

✓

✓

Aspirin (doses > 325 mg/day)

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Diclofenac

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Diflunisal

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Etodolac

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Fenoprofen

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Ibuprofen

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Ketoprofen

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Meclofenamate

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Mefenamic acid

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Meloxicam

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Nabumetone

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Naproxen

Pain Medications

NSAIDs, oral (Non-COX)

-

-

✓

✓

✓

Oxaprozin

Pain Medications

NSAIDs, oral (Non-COX)

-

-

✓

✓

✓

Piroxicam

Pain Medications

NSAIDs, oral (Non-COX)

-

-

✓

✓

✓

Sulindac

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Tolmetin

Pain Medications

NSAIDs, oral (Non-COX)

-

-

-

✓

✓

Pain Medications

NSAIDs

✓

✓

✓

✓

✓

Ketorolac

Pain Medications

NSAIDs

-

-

✓

✓

✓

Phenylbutazone

Pain Medications

NSAIDs

✓

✓

-

-

-

Pentazocine

Pain Medications

Narcotic

✓

✓

✓

✓

✓

Indomethacin
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Propoxyphene

Drug Category/
Area affected
Pain Medications

Carisoprodol

Beers Drug

Drug class

1991

1997

2003

2012

2015

Narcotic

✓

✓

✓

-

-

Pain Medications

Skeletal muscle relaxants

✓

✓

✓

✓

✓

Chlorzoxazone

Pain Medications

Skeletal muscle relaxants

-

✓

✓

✓

✓

Cyclobenzaprine

Pain Medications

Skeletal muscle relaxants

✓

✓

✓

✓

✓

Metaxalone

Pain Medications

Skeletal muscle relaxants

-

✓

✓

✓

✓

Methocarbamol

Pain Medications

Skeletal muscle relaxants

✓

✓

✓

✓

✓

Orphenadrine

Pain Medications

Skeletal muscle relaxants

-

-

✓

✓

✓

Oxybutynin

Pain Medications

Skeletal muscle relaxants

-

✓

✓

-

-

Desmopressin

Pain Medications

Clotting promoter and
antidiuretic

-

-

-

-

✓

Oxymetazoline

Upper respiratory

Decongestant

✓

-

-

-

-

Phenylephrine

Upper respiratory

Decongestant

✓

-

-

-

-

Pseudoephedrine

Upper respiratory

Decongestant

✓

-

-

-

-
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Appendix K. PIMs to avoid in older adults due to drug–disease or drug–syndrome
interactions that may exacerbate the disease represented in 1997, 2003, 2012, and
2015 Beers Criteria
Beers Drug
Amitriptyline hydrochloride

Disease/Syndrome
Arrhythmias

1991
-

1997
✓

2003
✓

2012
-

2015
-

Doxepin hydrochloride

Arrhythmias

-

✓

✓

-

-

Imipramine hydrochloride

Arrhythmias

-

✓

✓

-

-

Beta Blockers

Asthma

-

✓

-

-

-

Anticholinergic antihistamines

Benign prostatic hyperplasia (BPH)

-

✓

-

-

-

Gastrointestinal antispasmodic drugs

Benign prostatic hyperplasia (BPH)

-

✓

-

-

-

Muscle relaxants

Benign prostatic hyperplasia (BPH)

-

✓

-

-

-

Narcotic drugs

Benign prostatic hyperplasia (BPH)

-

✓

-

-

-

Flavoxate

Benign prostatic hyperplasia (BPH)

-

✓

-

-

-

Oxybutynin

Benign prostatic hyperplasia (BPH)

-

✓

-

-

-

Bethanechol

Benign prostatic hyperplasia (BPH)

-

✓

-

-

-

Anticholinergic antidepressant drugs

Benign prostatic hyperplasia (BPH)

-

✓

-

-

-

Aspirin

Blood Clotting Disorders/Anticoagulant therapy

-

✓

✓

-

-

NSAIDs

Blood Clotting Disorders/Anticoagulant therapy

-

✓

✓

-

-

Dipyridamole

Blood Clotting Disorders/Anticoagulant therapy

-

✓

✓

-

-

Ticlopidine

Blood Clotting Disorders/Anticoagulant therapy

-

✓

✓

-

-

Clopidogrel

Blood Clotting Disorders/Anticoagulant therapy

-

-

✓

-

✓

NSAIDs and Cox-2 inhibitors*

Cardiovascular (heart failure)

-

-

-

✓

Diltiazem

Cardiovascular (heart failure)

-

-

-

✓

✓

Verapamil

Cardiovascular (heart failure)

-

-

-

✓

✓

Pioglitazone

Cardiovascular (heart failure)

-

-

-

✓

✓

Rosiglitazone

Cardiovascular (heart failure)

-

-

-

✓

✓

Cilostazol

Cardiovascular (heart failure)

-

-

-

✓

✓

Disopyramide

Cardiovascular (heart failure)

-

✓

✓

-

-

Dronedarone

Cardiovascular (heart failure)

-

-

-

✓

✓

Alginate Bicarbonate

Cardiovascular (heart failure)

-

✓

✓

-

-

Biphosphate

Cardiovascular (heart failure)

-

✓

✓

-

-

Citrate

Cardiovascular (heart failure)

-

✓

✓

-

-

Phosphate

Cardiovascular (heart failure)

-

✓

✓

-

-

Salicylate

Cardiovascular (heart failure)

-

✓

✓

-

-

Sulfate

Cardiovascular (heart failure)

-

✓

✓

-

-

Phenylpropanolamine hydrochloride

Cardiovascular (hypertension)

-

-

✓

-

-

Pseudoephedrine

Cardiovascular (hypertension)

-

-

✓

-

-

Diet pills

Cardiovascular (hypertension)

-

✓

✓

-

-

Amphetamines

Cardiovascular (hypertension)

-

✓

✓

-

-

AChEls*

Cardiovascular (syncope)

-

-

-

✓

✓

212
Beers Drug

Disease/Syndrome

Doxazosin

Cardiovascular (syncope)

1991
-

Prazosin

Cardiovascular (syncope)

Terazosin

1997

2003

2012

2015

-

-

✓

✓

-

-

-

✓

✓

Cardiovascular (syncope)

-

-

-

✓

✓

Tertiary TCAs*

Cardiovascular (syncope)

-

-

-

✓

✓

Chlorpromazine

Cardiovascular (syncope)

-

-

-

✓

✓

Thioridazine

Cardiovascular (syncope)

-

-

-

✓

✓
✓

Olanzapine

Cardiovascular (syncope)

-

-

-

✓

Beta Blockers

Cardiovascular (Peripheral vascular disease)

-

✓

-

-

-

Bupropion

CNS- Chronic seizures/epilepsy

-

-

✓

✓

✓

Chlorpromazine

CNS- Chronic seizures/epilepsy

-

-

✓

✓

✓

Chlorprothixene

CNS- Chronic seizures/epilepsy

-

✓

-

-

-

Clozapine

CNS- Chronic seizures/epilepsy

-

✓

✓

✓

✓

Maprotiline

CNS- Chronic seizures/epilepsy

-

-

-

✓

✓

Metoclopramide

CNS- Chronic seizures/epilepsy

-

✓

-

-

-

Olanzapine

CNS- Chronic seizures/epilepsy

-

-

-

✓

✓

Thioridazine

CNS- Chronic seizures/epilepsy

-

✓

✓

✓

✓

Thiothixene

CNS- Chronic seizures/epilepsy

-

-

✓

✓

✓

Thorazine

CNS- Chronic seizures/epilepsy

-

✓

-

-

-

Tramadol

CNS- Chronic seizures/epilepsy

-

-

-

✓

✓

Anticholinergics

CNS- Delirium

-

-

-

✓

✓

Antipsychotics

CNS- Delirium

-

-

-

✓

✓

Benzodiazepines

CNS- Delirium

-

-

-

✓

✓

Chlorpromazine

CNS- Delirium

-

-

-

✓

✓

Corticosteroids

CNS- Delirium

-

-

-

✓

✓

Cimetidine

CNS- Delirium

-

-

-

✓

✓

Famotidine

CNS- Delirium

-

-

-

✓

✓
✓

Nizatidine

CNS- Delirium

-

-

-

✓

Ranitidine

CNS- Delirium

-

-

-

✓

✓

Meperidine

CNS- Delirium

-

-

-

✓

✓

Sedative hypnotics

CNS- Delirium

-

-

-

✓

✓

Thioridazine

CNS- Delirium

-

-

-

✓

-

Anticholinergics

CNS- Dementia/Cognitive Impairment

-

-

-

✓

✓

Benzodiazepines

CNS- Dementia/Cognitive Impairment

-

-

-

✓

✓

H2-receptor antagonists

CNS- Dementia/Cognitive Impairment

-

-

-

✓

✓

Eszopiclone

CNS- Dementia/Cognitive Impairment

-

-

-

-

✓

Zolpidem

CNS- Dementia/Cognitive Impairment

-

-

-

✓

✓

Zaleplon

CNS- Dementia/Cognitive Impairment

-

-

-

-

✓

Antipsychotics, chronic & as needed

CNS- Dementia/Cognitive Impairment

-

-

-

✓

✓

Anticonvulsants

CNS- history of falls/fractures

-

-

-

✓

✓

Antipsychotics

CNS- history of falls/fractures

-

-

-

✓

✓

Benzodiazepines

CNS- history of falls/fractures

-

✓

✓

-

-
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Beers Drug

Disease/Syndrome

Eszopiclone

CNS- history of falls/fractures

1991
-

Zolpidem

CNS- history of falls/fractures

Zaleplon

1997

2003

2012

2015

-

-

✓

✓

-

-

-

✓

✓

CNS- history of falls/fractures

-

-

-

✓

✓

TCAs

CNS- history of falls/fractures

-

-

-

✓

✓

SSRIs

CNS- history of falls/fractures

-

-

-

-

✓

Opiods

CNS- history of falls/fractures

-

-

-

-

✓
✓

Pseudoephedrine

CNS- Insomnia

-

-

-

✓

Phenylephrine

CNS- Insomnia

-

-

-

✓

✓

Amphetamine

CNS- Insomnia

-

-

✓

✓

✓

Armodafinil

CNS- Insomnia

-

-

-

-

✓

Methylphenidate

CNS- Insomnia

-

✓

✓

✓

✓

Modafinil

CNS- Insomnia

-

-

-

-

✓

Pemoline

CNS- Insomnia

-

-

-

✓

-

Theophylline

CNS- Insomnia

-

✓

✓

✓

✓

Caffeine

CNS- Insomnia

-

-

-

✓

✓

Beta agonists

CNS- Insomnia

-

✓

-

-

-

Decongestants

CNS- Insomnia

-

✓

✓

-

-

Monoamine oxidase inhibitors
(MAOIs)
SSRIs

CNS- Insomnia

-

✓

✓

-

-

CNS- Insomnia

-

✓

-

-

-

Antipsychotics (except aripiprazole,
quetiapine, clozapine)
Metoclopramide

CNS- Parkinson Disease

-

-

✓

✓

✓

CNS- Parkinson Disease

-

-

✓

✓

✓

Prochlorperazine

CNS- Parkinson Disease

-

-

-

✓

✓

Promethazine

CNS- Parkinson Disease

-

-

-

✓

✓

Tacrine

CNS- Parkinson Disease

-

-

✓

-

-

Barbiturates

Cognitive Impairment

-

-

✓

-

-

Anticholinergics

Cognitive Impairment

-

-

✓

-

-

Antispasmodics

Cognitive Impairment

-

-

✓

-

-

Muscle relaxants

Cognitive Impairment

-

-

✓

-

-

Dextroamphetamine

Cognitive Impairment

-

-

✓

-

-

Methylphenidate

Cognitive Impairment

-

-

✓

-

-

Methamphetamine

Cognitive Impairment

-

-

✓

-

-

Pemolin

Cognitive Impairment

-

-

✓

-

-

Beta Blockers

COPD

-

✓

-

-

-

Sedative hypnotics

COPD

-

✓

-

-

-

Chlordiazepoxide

COPD

-

-

✓

-

-

Chlordiazepoxide-amitriptyline

COPD

-

-

✓

-

-

Clidinium-chlordiazepoxide

COPD

-

-

✓

-

-

Diazepam

COPD

-

-

✓

-

-

Quazepam

COPD

-

-

✓

-

-

Halazepam

COPD

-

-

✓

-

-
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Beers Drug

Disease/Syndrome

Chlorazepate

COPD

Propranolol

COPD

Long-term benzodiazepine

1991

1997

2003

2012

2015

-

-

✓

-

-

-

-

✓

-

-

Depression

-

-

✓

-

-

Methyldopa

Depression

-

-

✓

-

-

Reserpine

Depression

-

-

✓

-

-

Guanethidine

Depression

-

-

✓

-

-

Beta Blockers

Diabetes

-

✓

-

-

-

Corticosteroids

Diabetes

-

✓

-

-

-

Darifenacin

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Fesoterodine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Oxybutynin (oral)

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Solifenacin

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Tolterodine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Trospium

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Diltiazem

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Verapamil

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Brompheniramine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Carbinoxamine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Chlorpheniramine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Clemastine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Cyproheptadine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Dexbrompheniramine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Dexchlorpheniramine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Diphenhydramine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Doxylamine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Hydroxyzine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Promethazine

Gastrointestinal- Chronic constipation

-

-

-

✓

Triprolidine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Anticholinergics

Gastrointestinal- Chronic constipation

-

✓

✓

-

-

Calcium channel blockers

Gastrointestinal- Chronic constipation

-

-

✓

-

-

Nartcotic drugs

Gastrointestinal- Chronic constipation

-

✓

-

-

-

Amitriptyline hydrochloride

Gastrointestinal- Chronic constipation

-

✓

✓

-

-

Doxepin hydrochloride

Gastrointestinal- Chronic constipation

-

✓

✓

-

-

Imipramine hydrochloride

Gastrointestinal- Chronic constipation

-

✓

✓

-

-

Antipsychotics

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Belladonna alkaloids

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Clidinium-chlordiazepoxide

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Dicyclomine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Hyoscyamine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Propantheline

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Scopolamine

Gastrointestinal- Chronic constipation

-

✓

-

-

-
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Disease/Syndrome

Amitriptyline

Gastrointestinal- Chronic constipation

2003

2012

2015

-

-

✓

-

Clomipramine

Gastrointestinal- Chronic constipation

-

-

-

-

✓

-

Doxepin

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Imipramine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Trimipramine

Gastrointestinal- Chronic constipation

-

-

-

✓

-

Aspirin (>325 md/g)

-

✓

✓

✓

✓

-

✓

✓

✓

✓

-

✓

-

-

-

-

-

-

✓

✓

-

-

-

✓

-

Estrogen oral & transdermal
(excludes intravaginal estrogen)
Doxazosin

Gastrointestinal- history of gastric/duodenal
ulcers
Gastrointestinal- history of gastric/duodenal
ulcers
Gastrointestinal- history of gastric/duodenal
ulcers
Kidney & urinary tract- chronic kidney disease
stage IV or less
Kidney & urinary tract- chronic kidney disease
stage IV or less
Kidney & urinary tract- urinary incontinence in
women
Kidney & urinary tract- urinary incontinence

-

-

-

✓

✓

-

✓

✓

✓

✓

Prazosin

Kidney & urinary tract- urinary incontinence

-

✓

✓

✓

✓

Terazosin

Kidney & urinary tract- urinary incontinence

-

✓

✓

✓

✓

Amitriptyline hydrochloride

Kidney & urinary tract- stress incontinence

-

-

✓

-

-

Doxepin hydrochloride

Kidney & urinary tract- stress incontinence

-

-

✓

-

-

Imipramine hydrochloride

Kidney & urinary tract- stress incontinence

-

-

✓

-

-

Long-acting benzodiazepine drugs

Kidney & urinary tract- stress incontinence

-

-

✓

-

-

Anticholinergics except
Antimuscarinics
Inhaled anticholinergic agents

-

-

-

✓

✓

-

-

-

✓

-

-

-

✓

-

-

-

-

✓

-

-

-

-

✓

-

-

-

-

✓

-

-

-

-

✓

-

-

-

-

✓

-

-

-

-

✓

-

-

-

-

✓

-

-

Dextroamphetamine

Kidney & urinary tract- lower urinary tract
symptoms, benign prostatic hyperplasia
Kidney & urinary tract- lower urinary tract
symptoms, benign prostatic hyperplasia
Kidney & urinary tract- bladder outflow
obstruction
Kidney & urinary tract- bladder outflow
obstruction
Kidney & urinary tract- bladder outflow
obstruction
Kidney & urinary tract- bladder outflow
obstruction
Kidney & urinary tract- bladder outflow
obstruction
Kidney & urinary tract- bladder outflow
obstruction
Kidney & urinary tract- bladder outflow
obstruction
Kidney & urinary tract- bladder outflow
obstruction
Malnutrition/Anorexia

-

-

✓

-

-

Methylphenidate

Malnutrition/Anorexia

-

-

✓

-

-

Methamphetamine

Malnutrition/Anorexia

-

-

✓

-

-

Pemolin

Malnutrition/Anorexia

-

-

✓

-

-

Fluoxetine

Malnutrition/Anorexia

-

-

✓

-

-

Olanzapine

Obesity

-

-

✓

-

-

Fluoxetine

SIADH/hyponatremia

-

-

✓

-

-

Citalopram

SIADH/hyponatremia

-

-

✓

-

-

Non-Cox-2 selective NSAIDs
Potassium supplements
NSAIDs (non-Cox & COXselective, oral & parenteral)
Triamterene

Anticholinergics and antihistamines
Gastrointestinal antispasmodics
Muscle relaxants
Oxybutynin
Flavoxate
Antidepressants
Decongestants
Tolterodine

1991

1997
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Beers Drug

Disease/Syndrome

Fluvoxamine

SIADH/hyponatremia

Paroxetine

SIADH/hyponatremia

Sertraline

1991

1997

2003

2012

2015

-

-

✓

-

-

-

-

✓

-

-

SIADH/hyponatremia

-

-

✓

-

-

Beta Blockers

Syncope or Falls

-

✓

-

-

-

Long-acting benzodiazepine drugs

Syncope or Falls

-

✓

-

-

-

Short- to intermediate
benzodiazepine drugs
Amitriptyline hydrochloride

Syncope or Falls

-

-

✓

-

-

Syncope or Falls

-

-

✓

-

-

Doxepin hydrochloride

Syncope or Falls

-

-

✓

-

-

Imipramine hydrochloride

Syncope or Falls

-

-

✓

-

-
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Appendix L. PIMs to be used with caution in older adults represented in 2012 and
2015 Beers Criteria
Beers Drug
Aspirin for primary prevention of cardiac events
Dabigatran
Prasugrel
Antipsychotics
Diuretics
Carbamazepine
Carboplatin
Cyclophosphamide
Cisplatin
Mirtazapine
Oxcarbazepine
Serotonin norepinephrine reuptake inhibitor
(SNRIs)
Selective serotonin reuptake inhibitor (SSRIs)
Tricyclic antidepressants (TCAs)
Vincristine
Vasodilators

1991
-

1997
-

2003
-

2012
✓
✓
✓
✓
✓
✓
✓
✓
✓

2015
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓

-

-

-

✓
✓
✓
✓

✓
✓
✓
✓
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Appendix M. Comprehensive list of variables included in the final dataset

#
147
3
41
40
43
42
123
45
44
47
46
49
48
51
50
53
52
55
54
57
56
59
58
61
60
63
62
65
64
151
102
15
67
66
69
68
71
70
23
13
14

Variable List
Variable
Label
ADMS
# of hospital admissions
AGE
Age of Patient
Alpha_Agonist_Central_Dys
Beers Criteria Medication (Rx Days)
Alpha_Agonist_Central_Rx
Beers Criteria Medication (# Rx)
Alpha_Blocker_Dys
Beers Criteria Medication (Rx Days)
Alpha_Blocker_Rx
Beers Criteria Medication (# Rx)
Ambu
Frailty measure indicator
Antiarrhythmic_Dys
Beers Criteria Medication (Rx Days)
Antiarrhythmic_Rx
Beers Criteria Medication (# Rx)
Antiemetics_Dys
Beers Criteria Medication (Rx Days)
Antiemetics_Rx
Beers Criteria Medication (# Rx)
Antihistamine_1st_Gen_Dys
Beers Criteria Medication (Rx Days)
Antihistamine_1st_Gen_Rx
Beers Criteria Medication (# Rx)
Antihypertensive_Dys
Beers Criteria Medication (Rx Days)
Antihypertensive_Rx
Beers Criteria Medication (# Rx)
Antiinfective_Dys
Beers Criteria Medication (Rx Days)
Antiinfective_Rx
Beers Criteria Medication (# Rx)
Antiparkinson_agent_Dys
Beers Criteria Medication (Rx Days)
Antiparkinson_agent_Rx
Beers Criteria Medication (# Rx)
Antipsychotics_FirstGen_Dys
Beers Criteria Medication (Rx Days)
Antipsychotics_FirstGen_Rx
Beers Criteria Medication (# Rx)
Antipsychotics_SecondGen_Dys
Beers Criteria Medication (Rx Days)
Antipsychotics_SecondGen_Rx
Beers Criteria Medication (# Rx)
Antispasmodic_Dys
Beers Criteria Medication (Rx Days)
Antispasmodic_Rx
Beers Criteria Medication (# Rx)
Antithrombotic_Dys
Beers Criteria Medication (Rx Days)
Antithrombotic_Rx
Beers Criteria Medication (# Rx)
Anxiolytic_Dys
Beers Criteria Medication (Rx Days)
Anxiolytic_Rx
Beers Criteria Medication (# Rx)
AnyADM
Any hospital admission
AnyBeers
Use of any Beers Criteria Medication
Asthma
Elixhauser Comorbidity Indicator
Barbiturates_Dys
Beers Criteria Medication (Rx Days)
Barbiturates_Rx
Beers Criteria Medication (# Rx)
Benzodiazepines_Long_Acting_Dys Beers Criteria Medication (Rx Days)
Benzodiazepines_Long_Acting_Rx Beers Criteria Medication (# Rx)
Benzodiazepines_Short_Acting_Dys Beers Criteria Medication (Rx Days)
Benzodiazepines_Short_Acting_Rx Beers Criteria Medication (# Rx)
CF
Elixhauser Comorbidity Indicator
CHF
Elixhauser Comorbidity Indicator
COPD
Elixhauser Comorbidity Indicator
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#
17
33
9
11
12
146
19
20
73
72
16
5
1
29
75
74
129
126
137
135
136
125
77
76
121
21
22
124
79
78
127
34
37
99
98
2
28
6
128
81
80
83
82
85

Variable
CRF
Carditis
CharlsScore
ConductHeart
ConductHeartB
Days
Diab
DiabComp
Diuretic_Dys
Diuretic_Rx
Divert
EGEOLOC
ENROLID
Epil
Ergoloid_Dys
Ergoloid_Rx
Female
FrailCat
FrailCat_0
FrailCat_1
FrailCat_2
FrailScore
Gut_motility_stimulator_Dys
Gut_motility_stimulator_Rx
HHBed
HIV
Hep
HomeO2
Hormones_Dys
Hormones_Rx
HospitalAdm
Hyp
LateStroke
Laxative_Dys
Laxative_Rx
MEMDAYS
MS
MSA
Male
NSAIDs_Dys
NSAIDs_Rx
Narcotic_Dys
Narcotic_Rx
NonCOX_NSAIDs_Dys

Label
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Charlson Comorbidity Score
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Days in hospital
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Elixhauser Comorbidity Indicator
Geographic Location Employee
Patient ID
Elixhauser Comorbidity Indicator
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Gender of Patient
Frailty measure
Frailty measure (robust)
Frailty measure (pre-frail)
Frailty measure (frail)
Frailty Score
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Frailty measure indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Frailty measure indicator
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Hospital admission
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Member Days
Elixhauser Comorbidity Indicator
Metropolitan Statistical Area
Gender of Patient
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Beers Criteria Medication (Rx Days)
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#
84
87
86
89
88
30
39
27
101
100
10
18
7
130
131
132
133
134
4
35
38
26
25
24
91
90
148

Variable
NonCOX_NSAIDs_Rx
Nonbarbiturate_sedative_hypn_Dys
Nonbarbiturate_sedative_hypn_Rx
Nonbenzodiazepine_sedative_Dys
Nonbenzodiazepine_sedative_Rx
Otitis
Paral
Parkin
Phenothiazines_Dys
Phenothiazines_Rx
PulmHeart
RA
REGION
Region_1
Region_2
Region_3
Region_4
Region_5
SEX
SLE
SUlcer
Scizo
Senile
Sicle
Skeletal_muscle_relaxants_Dys
Skeletal_muscle_relaxants_Rx
Studycost

93
92
145
144
143
95
94
32
97
96
31
138
140
141
142
150

Sulfonylureas_Dys
Sulfonylureas_Rx
SumIP13
SumOP13
SumRx13
Tertiary_TCAs_Dys
Tertiary_TCAs_Rx
Valve
Vasodilator_Dys
Vasodilator_Rx
Vertigo
_LEVEL_
_Lps
_MATCHWGT_
_MatchID
adms_0

Label
Beers Criteria Medication (# Rx)
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Region
Northeast
North Central
South
West
Unknown
Gender of Patient
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Elixhauser Comorbidity Indicator
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Total Cost
(SumRx13+SumOP13+SumIP13)
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Sum of inpatient visit costs
Sum of outpatient visit costs
Sum of prescription drug costs
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Elixhauser Comorbidity Indicator
Beers Criteria Medication (Rx Days)
Beers Criteria Medication (# Rx)
Elixhauser Comorbidity Indicator
Response Value
Logit of Propensity Score
Matched obs ATT weight
Matched ID number
Hospital admission

221
#
115
103
118
107
104
149
106
120
111
108
109
105
112
113
139
110
114
117
116
119

Variable
arthritis
bladder
braininj
cancer
coagulopathy
days_0
dementia
diabetes
diffwalk
heartfail
lipid
paraplegic
pd
podiatry
pscore
psychiatric
rehab
sepsis
skinulcer
weakness

Label
Frailty measure indicator
Charlson Comorbidity Score variable
Charlson Comorbidity Score variable
Charlson Comorbidity Score variable
Charlson Comorbidity Score variable
Days in hospital
Charlson Comorbidity Score variable
Charlson Comorbidity Score variable
Frailty measure indicator
Charlson Comorbidity Score variable
Charlson Comorbidity Score variable
Charlson Comorbidity Score variable
Charlson Comorbidity Score variable
Frailty measure indicator
Estimated Probability
Charlson Comorbidity Score variable
Frailty measure indicator
Charlson Comorbidity Score variable
Charlson Comorbidity Score variable
Frailty measure indicator

